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Abstract 
 
Stroke is the single largest cause of disability and second highest cause of death 
globally. It is estimated that 10 million people a year are affected by stroke in the 
United Kingdom (UK). Of the 130,000 annual new stroke occurrences in the UK, one 
third will go on to have a further stroke. Recurrent stroke is more likely to be fatal 
than first stroke and survivors are more likely to be left with major disability. Many 
stroke patients do not adhere to secondary prevention strategies due to complex 
reasons, including lack of appreciation of their high risk of a secondary 
cardiovascular event. Long-term secondary prevention remains a desired goal in the 
management of stroke survivors, however, studies have shown that current 
strategies are not routinely and universally working. Hypothesis: Raising awareness 
of secondary stroke risk may improve stroke survivor’s adherence to secondary 
prevention strategies after stroke. Results: A survey of the general public (n=1019) 
and a population-based study of over 600 stroke survivors found that knowledge 
about Blood Pressure (BP) and stroke risk factors was poor in high risk populations. 
Only 55% of stroke survivors were able to cite any well-known vascular risk factors. 
However, those who were appropriately risk-aware significantly improved their health 
behaviour post-stroke by consuming less alcohol (P<0.001), less salt (P=0.05) and 
eating a healthy diet (P=0.02). Further, In a Randomised Controlled Trial setting an 
intervention to increase risk awareness was successful in increasing awareness 
(P=0.04) and resulted in a significant increase in knowledge of stroke sub-type (95% 
CI 0.72-0.677, P<0.001), risk factor control of systolic BP (95% CI 12.1-10.4, 
P=0.01) and increased the number of healthy lifestyle behaviour changes made at 
follow-up (P<0.001). Conclusions: Increasing risk awareness is potentially an 
important mechanism to improve health behaviour following stroke and may improve 
risk factor control as part of secondary stroke prevention.  
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1.1 Cerebrovascular disease 
Stroke is the 2nd leading cause of death globally (WHO 2011) and the single largest 
cause of disability in the UK (Stroke Association 2010).  Nationally, stroke is 
responsible for 9% of all deaths in men and 13% in women (National Audit Office 
(NAO) 2005). Stroke can be defined as a clinical syndrome consisting of a rapidly 
developing neurological deficit and persisting for 24 hours, or leading to death, in the 
absence of other diseases that could explain the symptoms (Hatano 1976). Of the 
130,000 annual stroke occurrences in the UK, one third is likely to go on to have a 
further stroke. Recurrent stroke is more likely to be fatal than first stroke and 
survivors are more likely to be left with major disability (Rothwell 2007). Stroke 
recurs in up to 20% of patients often within the first year and within the first 90 days 
following a Transient Ischaemic Attack (TIA) (Talelli & Greenwood 2008, Bushnell et 
al 2009, Feasby & Barnett 2007).  
Cerebrovascular (CV) disease is part of a family of atherothrombotic diseases 
including peripheral arterial disease (PAD) and coronary artery disease (CAD)  and 
ischaemic heart disease (IHD).The term ‘cardiovascular disease’ (CVD) is used to 
describe this family of vascular diseases. CVD’s are responsible for more than 17 
million deaths per year worldwide (WHO 2011). Cardiovascular Diseases (CVDs) are 
the number one cause of death globally and more people die annually from CVDs 
than from any other cause. An estimated 17.1 million people died from CVDs in 
2004, representing 29% of all global deaths (WHO 2011). Of these deaths, an 
estimated 7.2 million were due to coronary heart disease and 5.7 million were due to 
stroke. Ischaemic stroke caused by atherosclerotic plaque or cardio-embolic 
thrombus is the most common stroke subtype, accounting for 85% of first events, 
while haemorrhagic causes (primary intracerebral haemorrhage) account for 15% of 
all strokes (Pendlebury et al 2009) .  
By 2030, almost 23.6 million people will die from CVDs globally, mainly from heart 
disease and stroke. These are projected to remain the single leading causes of 
death (WHO 2011).  Stroke currently costs the National Health Service (NHS) 
approximately £7 billion per year with direct and indirect costs (NAO 2005) and 
affects the wider economy by £1.8 billion. Stroke patients occupy 20% of all acute 
hospital beds. One third of stroke patients are likely to remain dependent on others 
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for all aspects of care, therefore the burden on informal caregivers is vast and the 
loss of earnings for individuals and their families can be catastrophic.   
1.2 The National Stroke Strategy 
The Department of Health (DH) have recognised the importance of developing better 
services for stroke patients by including specific milestones, targets and actions in 
The National Service Framework for Older People (NSF Standard-5) in 2001 (DH 
2001). The National Stroke Strategy was more recently launched in 2007 (DH 2007) 
and followed on from the NSF for older people to modernise services and deliver the 
latest treatments for stroke, with specific disease reduction targets to reduce the 
death rate from stroke, coronary heart disease and related diseases in people under 
the age of 75 years by at least 40% by the year 2010. This target has been achieved 
but the strategy continues to set a clear direction for the development of stroke 
services in England up to 2017 (DH 2011). 
The Stroke Strategy was developed in conjunction with stakeholders from stroke 
charities, health professionals within the NHS, social care professionals and stroke 
survivors and their families. The strategy includes campaigns to improve stroke 
awareness in the general populations, for example, the F.A.S.T (Face-Arm-Speech-
Time) campaign was launched in 2009 and includes strong imagery to highlight the 
visible signs and symptoms of stroke (DH 2009). As part of the Stroke Strategy 
smaller networks were set up within the NHS with the objective to bring together 
clinicians, health professionals and managers from all the organisations in order to 
work together to improve local services for patients. England has been divided into 
28 stroke network regions and London is divided into 5 networks. 
There are clear guidelines set out for the diagnosis and management of acute stroke 
in the UK, as well as guidance on secondary prevention measures in the National 
Clinical Guidelines for Stroke (RCP 2008) and the National Institute of Clinical 
Excellence (NICE 2008) stroke guidance documents. For secondary stroke 
prevention general recommendations suggest each patient should have an 
individualised, comprehensive strategy for stroke prevention and it should be 
implemented as soon as possible after the stroke/TIA and continue in the long term 
(RCP 2008). The guidelines suggest some detail regarding when information should 
be given to patients’ e.g. 
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 Given first in hospital setting 
 Reinforced at every opportunity by all health professionals involved in 
patient care 
 Provided in an appropriate format for the patient, taking into account both 
their stroke specific impairments and their personal situation. 
The guidelines state that patients should have their risk factors reviewed and 
monitored regularly, at a minimum, on a yearly basis (RCP 2008). It is useful for all 
health professionals involved in stroke patient care to have clear guidance that is 
evidence based for equity of care across the country and to reinforce secondary 
prevention measures to patients. Risk factors for vascular disease include 
hypertension, diabetes, smoking, Atrial Fibrillation (AF), hypercholesterolaemia, 
obesity, physical inactivity and poor diet. The British Heart Foundation (2003) also 
identified 9 key risk factors for CVD; smoking, poor diet, physical inactivity, 
hypertension, obesity, diabetes, psychosocial aspects, alcohol, high cholesterol. 
However, modification of reversible risk factors can reduce morbidity and mortality 
and improve survival and longevity (Chaudhry et al 2008).  
Despite the clear evidence for risk factor management (Chaudhry 2008, Rothwell 
2007), many stroke patients do not adhere to secondary prevention strategies due to 
complex reasons, including their lack of appreciation of their high future secondary 
cardiovascular (myocardial/stroke) event rate. Long-term secondary prevention 
remains a desired goal in the management of stroke survivors. However, studies 
have shown that current strategies are not routinely and universally working, with 
cholesterol remaining high, many patients still smoking and others remaining obese 
at 1 year (Qureshi 2001). The importance of investigating patient perceptions of their 
health beliefs is becoming more recognised as the key to understanding their 
decision–making behaviours and coping processes (Cooper 2007). 
1.3 Cardiovascular disease as a global issue 
Over 80% of the world’s deaths from cardiovascular diseases occur in low to middle 
income countries (WHO 2011). People in low to middle income countries are more 
exposed to risk factors leading to vascular diseases and other non-communicable 
diseases and they are also less exposed to prevention strategies and treatments 
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than people in high income countries. Also people in low-middle income countries 
have less access to effective, equitable health care to treat the vascular diseases 
and as a result, die younger from the diseases. At a macro-economic level vascular 
disease places a heavy burden on the economies of the low-middle income 
countries, more so because people die younger and in their most productive years. 
Heart disease, stroke and diabetes are estimated to reduce the Gross Domestic 
Product (GDP) between 1-5% in low-middle income countries experiencing rapid 
economic growth as many die prematurely (WHO 2011). It is estimated over the next 
10 years (2006-2015) China will lose $558 billion in foregone national income due to 
the combination of heart disease, stroke and diabetes (WHO 2011).  
The largest increase in number of deaths from CVDs will occur in the South-East 
Asia Region (WHO 2011). However, stroke death rates have been falling in the US, 
from 1996-2006 stroke death rates fell 33.5% (Lloyd-Jones et al 2010). This is 
undoubtedly due to improvements in health care and medical technologies, however, 
it has been suggested (Pennant et al 2010) that variations in the incidence of CVD 
related illness in the UK are caused by geographical, ethnic and social disparities 
and death rates are three times higher among lower socioeconomic groups than 
among more affluent groups. Bunker (2001) suggests that elimination of inequalities 
in healthcare could increase life expectancy of the most disadvantaged groups by up 
to 9 years. However, medical advances in the west are responsible for a rise in the 
ageing population and a higher prevalence of older people living with chronic 
diseases including cardiovascular disease (Yusuf 2000). Prevalence of stroke is 
reducing in the West due to improved care and advances in risk factor management, 
however, the ageing population brings with it increasing incidence of stroke, 
therefore the challenge remains to optimise secondary prevention in patients with 
vascular diseases. NICE (2010) estimate the cost of treating disease that could be 
prevented through lifestyle or behaviour modification represents a considerable 
burden on Western budgets and this is one of the reasons why there has been an 
increase in government led initiatives to improve public health. 
1.4 Worldwide styles of public health 
Different countries have different ways to influence the health behaviours of their 
individual populations, often affected by the political regimens of the country at a 
certain time. Some have a dogmatic, command fashioned approach to public health 
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and others allow a more communicative and democratic approach. Health education 
in China has been characterised by centrally led, top-down messages and methods. 
This is exemplified by the Patriotic Health Campaign, (PHCC) established in the 
1950’s and is still operating to some extent today (Wang 2000). Through this 
campaign the Chinese population were told what they should and shouldn’t do in 
order to improve health. As part of the PHCC campaign the government declared 
‘war’ on the ‘four devils – flies, mosquitos, mice and sparrows’. The people were 
instructed to clean their homes, schools and workplaces and were instructed to 
practice personal hygiene techniques daily. The PHCC committee organised 
inspections to check implementation of these actions. This campaign continued 
throughout the 1960’s and 1970’s in China as the dominant form of health promotion. 
The main outcome of the campaign was the control of serious infectious diseases 
e.g. cholera, malaria and plague. However, Wang (2000) argues that health 
education in China has to evolve to respond to social and political changes over the 
years. Both WHO and Unicef have heavily influenced health promotion in China 
during the last two decades, with the introduction of 2-way communication, however, 
Wang (2000) suggests health messages continue to be limited to narrow spectrums 
of commands and inspections. More recently China faces new challenges in health 
care due to pollution and newer infectious diseases such as HIV and sexually 
transmitted diseases, despite this, mortality due to chronic disease and cancer have 
become the leading cause of death in the overall population (WHO 2011) and Wang 
(2000) suggests health education programmes aimed at increasing critical health 
understanding need to be developed and involve more than simple transmission of 
health information commands to the masses. 
In England, during the 1960’s and 1970’s health promotion campaigns focussed on 
promoting healthy lifestyles to prevent non-communicative diseases. The early 
campaigns focussed on the transmission of information based on the simplistic 
relationship between communication and behaviour change (Nutbeam 2000). 
However, over time it became apparent that simple transmission of information failed 
to account for social and economic differences in the population. The expected 
outcomes of the campaigns were not successfully achieved in all aspects of society. 
It became clear that only socially and economically affluent members of society were 
reacting to the messages. It was assumed these groups had higher educational and 
literacy levels and personal skills to receive health messages communicated through 
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traditional media routes. The introduction of school based health education 
programmes in the 1980’s considerably strengthened health promotion messages 
and started the development of new theories to improve the national approach to 
health promotion messages to influence of behaviour.  
Most industrialised countries aim to influence their populations with information about 
disease risk and prevention, although this isn’t always particularly effective. Canada, 
however, is reporting success in terms of hypertension management, in contrast to 
other industrialised nations (McAlister et al 2011). Canada has among the lowest 
mean levels of systolic BP around the World, researchers suggest these findings 
may go some way to explaining the greater-than-expected reduction in 
cardiovascular mortality seen in Canada during the last decade. The main difference 
seems to be that Canada is the only country in the world that annually updates its 
hypertension guidelines, this results in continuous publicity, unlike countries that 
update guidelines every 5 years, with 6 months of high level publicity which declines 
to relatively nothing for the following 4 and a half years. They suggest the annual 
updates ensure concomitant continuing education programmes for health 
professionals in particular. From 1992-2009 prevalence remained at 21% for the 
population, however, hypertension control improved for the country as a whole by 
13.2% to 64.6%, improvement in awareness 56.9% to 82.5% and treatment of 
hypertensives from 34.6% to 79% (McAllister et al 2011). This success in control 
may be in part, down to the improvement in awareness of hypertension management 
in both the public and in health professionals. 
1.5 Vascular disease: evidence from clinical trials  
Atherothrombosis, ischaemic heart disease (IHD), CVD  and PAD are all associated 
with the main cause of mortality on a world-wide scale and are predicted to be the 
leading cause of death world-wide by 2020 (Bhatt & Steg 2007). In the Health 
Survey for England (DH 2003) in 2003 the prevalence of IHD (angina and heart 
attack) was 6.4% in men and 4.1% in women and with stroke added, the 
cardiovascular (CV) disease prevalence was 7.9% and 5.8%, respectively. The 
National clinical guidelines for stroke (RCP 2008) suggest the risk for further stroke 
is highest early after stroke or TIA, 10% within the first week, 20% first month rising 
up to 30-43% over the next 5 years. It is now widely recognised that patients who 
survive a stroke or Transient Ischaemic Attack (TIA) are at a relatively high risk for 
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subsequent vascular events, including recurrent stroke, myocardial infarction (MI) 
and death from vascular causes, (Touze et al 2005, Hackam & Spence 2007) 
reflecting the shared common risk factors and pathological mechanisms (Adams et 
al 2003). 
The CAPRIE (1996) (Clopidogrel versus Aspirin in patients at risk of Ischaemic 
events) study showed that approximately one quarter of the medium risk individuals 
had multi-vascular disease and in 1 in 30 individuals CVD, IHD and PAD were all 
present. People with symptomatic atherosclerosis in 1 vascular bed are at a higher 
risk of subsequent events in other beds (Barnett et al 2007). Therefore, patients who 
suffer a stroke are at a high risk of going on to suffer another stroke or heart attack, 
with a 10 year risk of 42.8% (Jenkinson 2007). These reports have been supported 
by the findings from the REACH (REduction of Atherothrombosis for Continued 
Health) registry which evaluated the long term risk of atherothrombotic events in an 
at risk population. REACH has already demonstrated that a significant proportion of 
people with PAD, CVD or IHD will have disease in more than 1 vascular location. In 
1 year follow-up 8.29% of patients with CVD went on to have a further vascular event 
while CV event rates increased significantly with the number of symptomatic 
locations (p=0.0043) (Morrell and Kassianos 2007). 40% of patients with CVD 
demonstrated multi-vascular involvement with many of these affected beds being 
clinically silent yet ultimately exposing patients to increasing risk profiles with each 
bed involved. However, fewer than 20% of patients with cardiovascular disease are 
reaching their target lipid levels (Chaudhry et al 2008) despite clear 
recommendations that implementation and adherence to secondary risk reduction 
strategies are important for reducing the risk of recurrent stroke.     
Steg et al (2007) performed a large international study of stable or high at-risk 
populations with established atherosclerosis receiving contemporary risk reduction 
therapies. The 1 year event rates were high and accrued almost linearly over time 
and the hard event rates for CV death, MI or stroke increased markedly within the 
number of symptomatic arterial disease locations. Despite receiving evidence-based 
preventative drug therapy, this vascular stable population experienced a 4.7% yearly 
rate of hard events (Steg et al 2007). During the 1 year follow-up approximately 1-in-
7 patients with established arterial disease experienced either a hard CV event or 
required hospitalisation for an atherothrombotic event. Patients with established 
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arterial disease experienced 2-3 times higher event rates than patients with multiple 
risk factors only. These data support the need for increased awareness among 
physicians and patients alike, of the amount of cross-risk that is related to the 
overlap between the various locations of atherosclerosis. 
1.6 Pathophysiology of atherosclerosis 
Atherosclerosis develops early on as a protective response to various insults on the 
arterial endothelium and smooth muscle cells.  Over time the initial lesion of a ‘fatty 
streak’ and aggregation of lipid-rich macrophages, advances with excessive 
inflammatory fibro-proliferation and remodelling of the vessel wall.  The resulting 
complex accumulation of atherosclerotic plaque is covered by a dense cap of 
connective tissue and smooth muscle cells overlying a lipid necrotic core (Ross 
1993).  As these plaques increase in size and complexity, further luminal narrowing 
and arterial stenosis limits the flow of blood to the surrounding tissues.  
Consequently, a perfusion imbalance between oxygen supply and demand exists, 
forming the underlying pathogenesis of cerebral and cardiac ischaemia.  The 
ultimate rupture or erosion of an unstable vulnerable plaque gives rise to thrombus 
formation, or distant embolism of particles, precipitating complete occlusion of a 
vessel, activation of the ischaemic cascade, cell death and an acute cardiovascular 
event (Ogata 2011, Poddar et al 2010).   
1.7 Stroke recurrence 
The cumulative risk of stroke recurrence varies greatly up to 10 years. Studies have 
shown considerable variation in the estimation of risk of stroke recurrence in both 
early years and the long term (19% in Manhattan to 32% in Perth). Accurate 
identification of the time at which patients are at the greatest risk of stroke 
recurrence is important for risk factor modification and secondary prevention 
measures. However, a systematic review and meta-analysis by Mohan et al (2011) 
also demonstrated wide variations in recurrence across all studies at different time 
points (figure 1.1). 
Figure 1.1 shows the estimates of risk of stroke recurrence across all the included 
studies (Mohan et al 2011).The risk of stroke recurrence was reported to range from 
1.1% in South London, UK (Mohan et al 2009) to 15% in Oxfordshire, UK (Coull et al 
2004) by 1 month, from 7.0% in Lisbon, Portugal (Salgado et al 1996) to 20.6% in 
Nanjing, China (Xu et al 2007) by 1 year and from 16.2% in South London, UK 
 23 
(Mohan et al 2009) to 35.3% in Hisayama, Japan (Hata et al 2005) by 5 years; and 
from 14% in Rome, Italy (Prencipe et al 1998) to 51.3% in Hisayama, Japan (Hata et 
al 2005) by 10 years after initial stroke. Mohan et al (2011) suggest genuine 
differences in populations, temporal changes in stroke management and secondary 
prevention may be important factors which contribute to the disparity in stroke 
recurrence rates. Also the definition of stroke recurrence may also be a contributing 
factor towards the variations and some studies include TIA as a first event while 
others do not. However, it is important to note rates of recurrence are substantial 
even at their lowest and they increase proportionally over time in all studies. 
1.8  Secondary stroke prevention 
Secondary stroke prevention offers a unique opportunity to decrease stroke rates 
and mitigate the devastating consequences of this disease. Advances in medical 
treatments have played a large role in reducing secondary stroke rates. Randomised 
controlled trials (RCTs) have clearly shown the benefits of secondary prevention with 
antithrombotic and antihypertensive therapies in patients with ischaemic stroke 
(Diener 2004, Eccles 1998). The Anti-platelet trialist’s collaboration demonstrated a 
23% risk reduction in important vascular events through the use of prophylactic 
antiplatelet agents among patients who had had a previous stroke (Antiplatelet 
Trialists 1994). It is well recognised that reduction in systolic BP by as little as 
10mmHg can reduce the risk of stroke by approximately 23% (Asplund et al 2009) 
and Statins to reduce serum cholesterol have been shown to effectively reduce 
secondary stroke by as much as 25% (SPARCL 2009) as well as possible reductions 
in stroke severity (Goldstein et al 2009). It is also recognised that glycaemic control 
is shown to reduce the occurrence of microvascular complications and is 
recommended in multiple guidelines for secondary stroke prevention (Sacco et al 
2006). In addition to drug treatments, lifestyle behaviour changes have also been 
shown to reduce stroke risk, such as smoking cessation in smokers which has a 
20% increased risk (Cole 2011). 
Secondary prevention strategies should be implemented early, monitored frequently 
and maintained long-term after a stroke (Ovbiagele et al 2004). However, Hillen et al 
(2000) concluded in their population based study of antithrombotic and 
antihypertensive management 3 months after ischaemic stroke that secondary 
prevention appears to be inadequate. They found high rates of non-treatment among 
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457 patients with ischaemic stroke who were appropriate for treatment 3 months 
following the event. It was identified that 24.4% of patients suitable for antiplatelet 
therapy did not receive it, however, it remains unclear whether the reason for this lies 
at the door of the acute Trust for failure to communicate the need for preventive 
therapy, the GP for the discontinuation of treatments or the patient for non-
adherence. This is disappointing as cardiovascular and stroke risk factor 
management has been made a national and international priority for some years 
now, despite this studies have shown treatment remains suboptimal (Hillen et al 
2000). 
1.9 Risk 
There are many inconsistent and ambiguous meanings attached to the term “risk”, 
this has led to widespread confusion and many different approaches to risk 
management in different fields (Hubbard 2009). The Oxford English Dictionary 
(2011) online definition of risk is “(exposure to) the possibility of loss, injury or other 
adverse or unwelcome circumstance; a chance or situation involving such a 
possibility”. Risk is also seen as the potential that a chosen action or activity 
(including the choice of inaction) will lead to a loss or undesirable outcome. The 
notion implies that having a choice can have an influence on the outcome. Potential 
losses themselves have been called “risks” and almost any human endeavour 
carries some risk, but some are more risky than others. The International 
Organization for Standardization (ISO 2002) Guide 73 definition of ‘risk’ is the ‘effect 
of uncertainty on objectives’. In this definition, uncertainties include events which 
may or may not happen and uncertainties caused by a lack of information or 
ambiguity. Another definition is that risks are future problems that can be avoided or 
mitigated, rather than current ones that must be immediately addressed (Hubbard 
2009). Occupational Health and Safety Advisory Services (OHSAS 2007) defines 
risk as the product of the probability of a hazard resulting in an adverse event. 
Hanson (2007) goes on to suggest the word ‘risk’ refers rather vaguely to situations 
in which it is possible but not certain that some undesirable event will occur. Hubbard 
(2007) gives us five variations where the term risk can be used to describe the 
possibility of an event or action: 
1. Risk = the unwanted event which may or may not occur. 
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An example of the usage is: “Lung cancer is one of the major risks that affect 
smokers”. 
2. Risk = the cause of an unwanted event which may or may not occur. 
 
An example of the usage is: “Smoking is by far the most important health risk 
in industrialised countries”. (The unwanted event is a disease caused by 
smoking). Both 1 and 2 are qualitative senses of risk, the word also has 
quantitative senses. 
3. Risk = the probability of an unwanted event which may or may not occur. 
An example of the usage is: “The risk that a smoker’s life is shortened by a 
smoking related disease is approx. 50%”. 
4. Risk = the statistical expectation value of an unwanted event which             
 may or may not occur. 
 
5. Risk = the fact that a decision is made under conditions of known probabilities 
(“decision under risk” as opposed to “decision under uncertainty”) (Hubbard 
2007). 
 
The expectation value of a possible negative event is the product of its probability 
and some measure of its severity, for example, it is common to use the number of 
people killed to measure of the severity of an accident. With this measure of severity, 
the “risk” associated with a potential accident is equal to the statistically expected 
number of deaths and Hubbard (2007) suggests that other measures of severity give 
rise to other measures of risk (Hubbard 2007). 
Although expectation values to estimate a potential outcome have been calculated 
since the 17th century, the use of the term “risk” in this sense is relatively new. It was 
introduced into risk analysis in the influential Reactor Safety Study WASH-1400, 
(Rasmussen et al 1975) which is now obsolete.  
Financial risk is often defined as the unexpected variability of returns and includes 
both potential worse-than-expected as well as better-than-expected returns. 
However, in information security, risk is defined as ‘the potential that a given threat 
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will exploit vulnerabilities of an asset or group of assets and thereby cause harm to 
the organisation. The mathematical formulations of risk describe the notion of risk as 
a statistical model of the expected value of some outcome seen as undesirable. This 
combines the probabilities of various possible events and some assessment of the 
corresponding harm in a single value. In a formula that can be used in a simple case 
of binary possibility, risk is; Risk = (probability of the accident happening) X 
(expected loss in case of the accident) (Tapeiro C 2004) 
It has been suggested that fear can be used as an intuitive risk assessment. De 
Becker (1997) suggests people rely on their fear and hesitation to keep them out of 
the most profoundly unknown circumstances and that ‘true fear is a gift’ as it is the 
survival signal that sounds in the presence of danger. It has also been suggested 
that risk could be the way we collectively measure and share ‘true fear’ where there 
is a fusion of rational doubt, irrational fear and a set of biases based on our prior 
experiences. Recognising and respecting the irrational influences on human decision 
making may do much to reduce disasters caused by naïve risk assessments that 
pretend to rationality but in fact merely fuse shared biases together (De Becker 
1997). Leventhal’s work started in the 1970’s looking at how ‘fear’ messages in acute 
situations may lead people to taking health promoting actions such as wearing seat-
belts or quitting smoking (Leventhal 1997, cited by Hale et al 2007). The changes in 
law requiring drivers and their passengers to wear seatbelts was what ultimately 
changed behaviour in the 70’s, however the campaigning messages from that period 
used strong imagery to portray the message. Nevertheless changing the law would 
have significantly reinforced the behaviour change and now it is second nature to 
secure a seatbelt when getting into a car. 
Slovic (1993) introduces trust as an important aspect of the risk perception problem. 
This has become so during recent years as trust has been pointed out as important 
in risk management in industry and the distrust which is linked to risk perception and 
political activism. Slovic (1993) suggests trust is important in all forms of human 
social interaction and offers lack of trust is an underlying factor of the controversies 
surrounding technological hazards. Slovic (1993) cites Starr (1985) who pointed out 
the public’s lack of concern about risks of tigers in urban zoos as evidence that the 
acceptance of risk lies strongly in the confidence held in the risk management. This 
is a key message for health professionals, as patients who have confidence and trust 
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in the risk information provider may gain a greater understanding of the risk 
information being delivered and be more likely to undertake risk modifications 
suggested by the risk manager in this case. 
Risk in personal health can be reduced by primary prevention action that may 
decrease early causes of illness or by secondary prevention actions after a person 
has been identified as having measureable clinical signs and symptoms recognised 
as risk factors for a certain disease. Tertiary prevention reduces the negative impact 
of an already established disease by restoring function and reducing disease related 
complications (Hubbard 2007).  Insurance is a risk-reducing investment in which the 
buyer pays a small fixed amount to be protected from a potential large loss. 
Gambling is a risk-increasing investment, wherein money on hand is risked for a 
possible large return, but with the possibility of losing it all. Purchasing a lottery ticket 
is a very risky investment with a high chance of no return and a small chance of a 
very high return. In contrast, putting money in a bank at a defined rate of interest is a 
risk-averse action that gives a guaranteed return of a small gain and precludes other 
investments with possibly higher gain (Hubbard 2007). 
In his seminal work ‘Risk, Uncertainty, and Profit,’ Knight (1921) established the 
distinction between risk and uncertainty: 
“ ... Uncertainty must be taken in a sense radically distinct from the familiar notion of 
Risk, from which it has never been properly separated. The term "risk," as loosely 
used in everyday speech and in economic discussion, really covers two things 
which, functionally at least, in their causal relations to the phenomena of economic 
organization, are categorically different. ... The essential fact is that "risk" means in 
some cases a quantity susceptible of measurement, while at other times it is 
something distinctly not of this character; and there are far-reaching and crucial 
differences in the bearings of the phenomenon depending on which of the two is 
really present and operating. ... It will appear that a measurable uncertainty, or "risk" 
proper, as we shall use the term, is so far different from an immeasurable one that it 
is not in effect an uncertainty at all. We ... accordingly restrict the term "uncertainty" 
to cases of the non-quantitative type….” 
Thus, Knightian uncertainty is immeasurable and not possible to calculate, while in 
the Knightian ‘sense' risk is measurable. 
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Risk carries many different meanings and there are many formal methods to assess 
or measure risk. Some quantitative definitions of risk are well-grounded in statistical 
theory and lead to statistical estimates, but some are more subjective and in many 
cases a critical factor is in human decision making. 
1.10 Communicating risk 
Medical advances have made it possible to identify high and low risk populations for 
various diseases, however, communicating risk to patients has its challenges as the 
concept of risk has so many theoretical definitions and means different things to 
different people.  It has been suggested that the particular effects of risk information 
on patient behaviour are relatively unknown and it is unknown if perceptions can be 
altered or translated into specific actions.  A systematic review (Edwards et al 2000) 
of 82 studies identified that risk communication interventions may be most effective 
when including individual risk estimates rather than general risk information. 
Edwards et al (2000) found that patients appeared to be more amenable to make 
behaviour changes with risk estimates given during a discussion between the health 
professional and patient rather than attending screening sessions. 
1.11 Risk perception 
The study of risk perception arose out of the observation that experts and lay people 
often disagreed about how risky various technologies and natural hazards were. The 
mid 1960’s saw the rapid rise of nuclear technologies, however, despite this 
successful scientific advancement, public perception shifted against this new 
technology. Fears of both longitudinal dangers to the environment as well as 
immediate disasters creating radioactive wastelands turned the public against this 
new technology. The scientific and governmental communities asked why public 
perception was against the use of nuclear energy when all of the scientific experts 
were declaring how safe it really was. The need to identify what factors influenced 
public opinion and perception was important for the future of this industry and has 
therefore influenced the growing field of research into risk and risk perception. 
Psychometric research identified a broad domain of characteristics of risk perception 
that may be condensed into 3 factors in a high factor order which are; 1) the degree 
to which a risk is understood, 2) the degree to which it evokes a feeling of dread, 3) 
the number of people exposed to the risk. A dread elicits visceral feelings of terror, 
uncontrollable, catastrophe, inequality and uncontrolled. All unknown risk is new and 
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unknown to science. The more a person dreads an activity or occurrence, the higher 
its’ perceived risk and the more that person wants the risk reduced (Slovic et al 
1987). In health, certainly the concept of the more a person dreads the recurrence of 
an unpleasant or painful experience such as a myocardial infarction (MI) the more 
they want to avoid that experience again is a useful parody to use for improving 
adherence to secondary prevention strategies, however if the experience was 
painless, which stroke often is, then the elicited perception of dread is non-existent 
and may be less useful, however that is not to say that the experience of suffering a 
stroke is not something that a person might fear or dread recurrence of but they 
might not be as aware of the experience in the absence of pain. 
Risk perception in stroke has been studied and Dearborn et al (2009) investigated 
the perception of risk and knowledge of risk factors in women at high risk for stroke.  
They suggest risk perception is a key element in understanding how persons 
become motivated to change health behaviours. Despite being at a high risk for 
stroke, the women in this study perceived their risk to be the same as their low risk 
peers. They also found that stroke knowledge of risk factors or warning signs did not 
predict perception of risk. 
To reduce stroke risk, it has been suggested that perception of risk is a parameter 
that is separate from stroke knowledge and presence of personal risk factors but 
may be useful in predicting the likelihood of initiating a behaviour change in high risk 
patients (Dearborn et al 2009). In secondary stroke prevention risk perception could 
be affected by the patient’s experience of their first stroke and their dread of 
recurrence as suggested by Slovic et al (1987) could be useful for health 
professionals to discuss during consultation to increase patients understanding of 
the possibility of recurrence of their stroke. However, the challenge of how to 
communicate risk to patients remains high. In the British Family Heart Study 
(Wonderling et al 1996) people were more likely to cite smoking and family history of 
heart disease as important risk factors than hypertension and cholesterol (Marteau et 
al 1995). Here, a message of risk has been conveyed but the levels of risk are 
proportioned inaccurately towards smoking and family history rather than towards 
hypertension which carries a much higher risk for vascular events. The Social 
Amplification of Risk Framework (SARF) (Kasperson et al 1988), combines research 
in psychology, sociology, anthropology and communications theory. SARF outlines 
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how communications of risk events pass from the sender through intermediate 
stations to a receiver and in the process which serve to amplify or attenuate 
perceptions of risk. Amplifications occur at two stages: in the transfer of information 
about the risk and in the response mechanisms of society or the target population 
(Kasperson et al 1988). All links in the communication chain such as individuals, 
groups and media contain filters through which information is sorted and understood. 
The theory attempts to explain the process by which risks are amplified, receiving 
public attention or attuned, receiving less public attention. The theory may be used to 
compare responses from different groups in a single event or analyse the same risk 
issue in multiple events. In a single risk event some groups may amplify their 
perception of risks while other groups may attune or decrease their perception of 
risks. The main theory of SARF states that risk events interact with individual 
psychological, social and other cultural factors in ways that either increase or 
decrease populations perceptions of risk. Therefore when developing public or 
population based health messages all aspects of culture, society and personal 
psychological perceptions should be taken into account, so a single message will not 
necessarily reach every member of the population you seek to reach. Therefore, for 
stroke risk perception there is an argument for specific individual messages to 
influence risk perception and behaviour positively. 
Townend et al (2006) found that although their stroke population were found to fear 
recurrent stroke and reported ‘worrying about ‘having another’, their belief in causal 
controllability remained low even up to 9 months post stroke and indicated less than 
moderate confidence in their ability to prevent a recurrence. This suggests a 
population-wide perception that stroke recurrence is uncontrollable and influenced 
more by personal beliefs or experiences than risk factor control or confidence in 
health professionals to treat risk factors. Townend et al (2006) highlight patient 
interpretation of the suddenness of the onset of the stroke syndrome as a reaction of 
‘why now? Their participants asked advice on what things they should or shouldn’t 
do to avoid overexertion, possibly as a way of explaining the suddenness of onset 
they looked for strenuous or stressful situations which have recently occurred. 
Medical and lifestyle risk factors can only explain how risk and damage builds up 
over time and don’t explain to patients the reason for suddenness of the onset at one 
particular time in their life. Townend et al (2006) found their participants expressed a 
fatalistic approach to stroke prevention. They believed ‘nothing could stop’ a 
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recurrence, which highlights a decreased sense of control but may also suggest a 
lack of faith in medical professional interventions to prevent recurrence. Further 
research is needed to identify psychologically sophisticated interventions to reduce 
fear recurrence and improve adherence to medical treatments and recommended 
behaviour change. 
Social scientists have theorized about the concept of ‘risk management’ in a number 
of different ways, including risk management as a tool for controlling future 
uncertainty (Giddens 1991, Beck 1992 cited by Redfern 2008) as a means of 
categorizing individuals in to social groups (Eichar 1989) for allocating responsibility 
and apportioning blame (Lupton 1995) and as a mechanism for surveillance and 
socio-political control (Armstrong 1995). However in the context of stroke secondary 
prevention, we have taken risk management to mean a specific clinical construct 
defined in recent health policy for older people and stroke management (Department 
of Health 2001, Royal College of Physicians 2008) that is, the design of strategies to 
prevent future strokes. In this context ‘risk’ refers both to risk factors (characteristics 
of the individual patient’s body or behaviour making them risky) and the probability of 
having a subsequent stroke.  
1.12 Risk assessment 
The Framingham study has been used for 30 years to produce ‘health risk appraisal’ 
systems to predict primary and subsequent risk of IHD and stroke. The risk appraisal 
models have proven to be useful to clinicians in understanding the multi-factorial 
nature of IHD in particular (D’Agostino et al 2000). It is, however, well known that the 
study is limited by being based mainly on a predominantly European population. 
Notwithstanding this limitation, the length of the study provides us with the most 
comprehensive overview of the effects of CV disease available to date. Conversely, 
the strengths of the MOnica Risk, Genetics, Archiving and Monograph (MORGAM) 
(Asplund et al 2009) study are that it includes a very large number of population-
based cohorts of both men and women across Europe and that it includes both fatal 
and nonfatal strokes with individual validation of the diagnosis in the majority of 
stroke events. With more than 3100 stroke events, MORGAM is, by far, the largest 
prospective stroke study performed. There are many reasons why stroke risk factors 
would have varying impact in different populations, whether they are defined by sex, 
age, or geography. In addition to genetic variations, the burden of socioeconomic 
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risk factors in whole populations or subsets may well interact with classical 
cardiovascular risk factors to modify the risk of stroke (Asplund et al 2009). 
D’Agostino et al (2000) and Wolfe et al (1991) used the Framingham study risk 
models to identify cross-risk for IHD, stroke and diabetes. They found the models to 
be useful tools to gain a better understanding of the relationship between risk factors 
and the occurrences of CVD events in subjects who are free of CVD, as well as 
individuals who have had a prior event or are at particularly high risk of an event 
(D’Agostino et al 2000). 
The Joint British Society guidelines suggest that all adults from 40 years onwards, 
who have no history of CVD or diabetes, and who are not already on treatment for 
BP or lipids, should be considered for an opportunistic comprehensive CVD risk 
assessment in primary care (JBS 2005). Younger adults (<40 years) with a family 
history of premature atherosclerotic disease should also have their CV risk factors 
measured. Risk assessment should include ethnicity, smoking habit history, family 
history of CVD, and measurements of weight, waist circumference, BP, non-fasting 
lipids (total cholesterol and HDL cholesterol), and non-fasting glucose. Those not 
found at this comprehensive CV risk assessment to be at high total CVD risk based 
on the Joint British Societies’ charts (JBS 2005), or started for other reasons on drug 
therapy to lower BP, lipids, or glucose, should have their risk assessment repeated, 
ideally within 5 years. Under the age of 40 years the 10 year total CVD risk will 
usually be low but the risk in the coming years, assuming risk factors do not change, 
can be tracked forward to older age groups. Over the age of 70 years CVD risk is 
usually > 20% over 10 years, especially for men, but they suggest that total CVD risk 
should still be formally estimated. However, this will underestimate the true total CVD 
risk of a person older than 70 years. For people with established atherosclerotic 
cardiovascular disease, hypertension with target organ damage, familial 
dyslipidaemias such as familial hypercholesterolaemia, or diabetes, formal risk 
estimation is not necessary as all these people are at high total CVD risk and their 
risk factors should be treated. 
1.13 Risk associated with vascular disease in a high risk population 
Comprehensive approaches to the control of vascular diseases have resulted in a 
60% decline in mortality rates over a 25-year period (WHO 2002). At least four-fifths 
of recurrent vascular events in patients with CV diseases might be prevented by the 
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application of a comprehensive, multi-factorial approach as suggested by Hackam & 
Spence (2007). Following a comprehensive literature review (Hackam & Spence 
2007) to identify randomized controlled trials reporting on the efficacy of secondary 
prevention strategies, strategies were combined on a multiplicative scale and 
cumulative risk reduction were computed over a 5 year interval. They concluded the 
combination of 5 proven strategies applied to survivors of an initial stroke or TIA 
including, dietary modification, exercise, aspirin, statin and antihypertensive agent 
could result in an 80% risk reduction with a number needed to treat of ~5. This 
finding is influential and highlights the effectiveness of treatments for secondary 
stroke prevention. However, compliance with treatment is usually substantially lower 
in routine clinical practice than in closely monitored and motivated trial populations 
and it is still up to the healthcare professional to educate the patient in a way that 
helps them to understand the level of risk and the need for lifestyle and medical 
modifications (Rothwell 2007).  
Van Wijk et al (2005) looked at the long-term determinants of survival and risk of 
vascular events following TIA or minor ischaemic stroke and found that 
approximately 10 years after a first event 54% of the participants had experienced at 
least 1 new vascular event. They found that the risk of a vascular event was highest 
shortly after the ischaemic event and reached its lowest point at about 3 years and 
then gradually rose again afterwards. One explanation they gave for the gradual rise 
of increased risk after the 3 year period was the possible decline in drug compliance 
and from the reduced attention to lifestyle factors in follow-up. In light of the 
substantial risk of recurrence of subsequent ischaemic events and advances in 
therapeutic treatments which have demonstrated to be effective for secondary 
prevention, Vickrey et al (2002) suggest that further research should be performed to 
look at assessment and care patterns for secondary prevention to determine whether 
there are gaps between actual care and the evidence based recommendations. This 
could be useful in light of the study by Qureshi et al (2001), who reported in 1252 
survivors of MI and stroke from the National Health and Nutrition Examination 
Survey 3, that only 35% of hypertensives were controlled. Blood glucose in diabetes 
was controlled in only about 50% and cholesterol was poorly controlled in 46%. 
About 18% of individuals were also still smoking cigarettes. 
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1.14 Established stroke risk factors  
Stroke risk factors can be divided into modifiable and non-modifiable. Non-modifiable 
risk factors are those that cannot be influenced by environment or behaviour change, 
such as age, gender and ethnicity. Modifiable risk factors are those that are thought 
to be influenced by medications or a change in behaviour such as diet, exercise or 
smoking cessation. 
Hypertension, Diabetes Mellitus (DM), Atrial Fibrillation (AF) and high cholesterol are 
the highest ranking medically controllable risk factors for stroke whereas smoking, 
alcohol consumption and obesity rank as the most important lifestyle risk factors 
(Andersen et al 2010). The mechanisms for risk factors for vascular diseases lead to 
the activation of the renin-angiotensin system and oxidative stress. This leads to 
elevated asymmetric dimethylarginine (ADMA), low-grade inflammation and 
dyslipidaemia which are all common pathophysiological mechanisms that play a role 
in this association with vascular disease (Schiffrin et al 2007).  
AF, hypertension and obesity are more common in women, where DM and previous 
Myocardial Infarction (MI) are more often found in men (Reeves et al 2008). Stroke 
risk factors are most commonly found in men before the age of 70-80 years after 
which the gender differences equalize, except for hypertension and AF which 
continue to be relatively more prevalent in women (Andersen et al 2010). However, 
one reason for this could be due to ‘mortality displacement’, which is a decrease in 
the prevalence of a risk factor in a population due to excess mortality of the people 
within that population with that specific risk factor. An example of this would be a 
decrease in the prevalence of hypertension in men over the age of 70-80 years due 
to the excess mortality of men with hypertension in that population (Andersen et al 
2010). 
1.14.1 Transient Ischaemic Attack (TIA) 
TIA is a known risk factor for stroke (Purroy et al 2007) and stroke recurrence after 
the initial event. Stroke recurrence studies which included TIA as a first event (Coull 
et al 2004), showed a substantially higher stroke recurrence at 30 days than those 
studies which excluded TIA (Mohan et al 2011). Timing is an important factor in 
predicting subsequent risk for cerebrovascular events following TIA. When 
combining previous TIA and stroke, there is an increased risk that goes up over time, 
a cumulative risk of almost 25% for a subsequent stroke 3 years after a TIA or a 
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stroke When examining separate studies of post-TIA and post-stroke outcomes, it 
has been suggested that in the first 30 days the risk for stroke is similar: 4% to 8% 
for the risk of stroke after TIA and 3% to 10% for the risk of recurrent stroke after 
stroke (Sacco 2004). Johnston et al (2007) have more recently suggested patients 
with TIA are generally unstable, with recent studies showing that between 4–20% will 
have a stroke within 90 days after a TIA, half within the first 2 days. The differential 
risk between TIA and stroke is suggested to be small and does not take into account 
such aspects as controlling for other risk factors. Sacco (2004) infers people with TIA 
may have less severe disease, less hypertension, and less co-morbidity compared 
with stroke patients, which makes it slightly less likely for them to progress to stroke 
than for stroke patients to have a recurrence.  
1.14.2 Age and silent brain infarction 
Age is the highest non-modifiable risk factor for stroke. The risk of stroke increases 
each year by 9% in men and 10% in women (Asplund et al 2009). Life expectancy is 
longer for women (Heron et al 2009) and women are older than men at stroke onset 
(Petrea et al 2009). However, risk factors which affect the elderly more may 
therefore have a higher impact on women and stroke causality than men (Andersen 
et al 2010). The prevalence of hypertension, DM and MI have been found to 
decrease in the elderly (>70-80years), however, this could be due again to mortality 
displacement in the populations with these risk factors.  
Common risk factors for cardiovascular disease undergo rapid changes in frequency 
and distribution with advancing age. Diabetes may be one of the most important risk 
factors that continue to have a consistent relationship with the risk of 
thromboembolic stroke throughout life. Attention to the risk of an embolic event due 
to atrial fibrillation is also critical because of the large increases in stroke incidence 
that can be attributed to this condition (Wolf et al 1991, Curb et al 1996).  The 
Honolulu Heart Program (Hakim et al 1999) reports physically active lifestyles in 
older middle age seem to be protective against stroke, and current findings suggest 
that this effect extends to the elderly population. Cigarette smoking has also long 
been known to promote thrombo-embolic and haemorrhagic events, and although it 
becomes a less common habit with advancing age, its effects on haemorrhagic 
events persist (Kurth et al 2003). 
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Silent brain infarctions (SBI) are parenchymal brain lesions seen on imaging (CT or 
MRI) characteristically associated with no clinical signs and symptoms 
corresponding to stroke (Masuda et al 2001). SBI is an independent risk factor for 
stroke (Vermeer et al 2003). SBI’s are known to be associated with a vascular origin 
and are reportedly seen frequently in asymptomatic elderly people (Longstreth et al 
1996, Howard et al 1998, Vermeer et al 2002). The Framingham cohort were 
investigated and showed a prevalence of 10.7% SBI on MR imaging in stroke free, 
community dwelling participants in mid-life (Das et al 2008). Several studies have 
examined the incidence of SBI and its relation to risk factors for stroke. Two recent 
studies (Vermeer et al 2003 and Bernick et al 2001) both found that risk of stroke 
increased 2-3 fold in the presence of silent brain infarctions on MRI in an elderly 
population. Vermeer et al (2003) stated an absolute risk of stroke within 4 years was 
11.7% for participants with SBI compared to 2.3% for those without SBI. The majority 
of these studies demonstrated that age and hypertension, strongly and 
independently correlated with SBI which would highlight an association with 
cerebrovascular disease.  
1.14.3 Hypertension 
Hypertension is the most common treatable or modifiable risk factor for stroke (Volpe 
et al 2006, Bosworth et al, 2006).  Individuals with pre-hypertensive levels of Blood 
Pressure (BP), as defined by 120/80 to 139/89 mmHg, also have an increased risk of 
developing vascular disease and stroke compared with those with optimal BP 
<120/80 mmHg. The highest association for hypertension is among African and 
Caribbean people, those with diabetes mellitus and those with a high BMI 
(Kshirsagar et al 2007).  
A Meta-analysis of 147 randomised controlled trials demonstrated a 41% reduction 
of stroke by blood pressure lowering (Law et al 2009). By as little as a 10mmHg 
reduction in systolic blood pressure as much as a 28% reduction in the risk of 
recurrent stroke can be achieved (Rodgers et al 1996). Other Meta-analyses of 
randomised controlled trials confirm an approximate 30%-40% risk reduction in 
stroke with BP lowering (Yusuf et al 2000, Lawes et al 2004).  It has been estimated 
that nearly half (45%) of all strokes in patients who are on treatment for hypertension 
could be attributed to poorly controlled hypertension (Li et al 2005). Recent studies 
have shown that patients and public are aware of the link between hypertension and 
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stroke but do not appreciate the consequences of uncontrolled hypertension (Volpe 
and Dedhiya, 2006), however it has been suggested that patients who recognize 
their increased risk for stroke are more likely to engage in stroke prevention 
practices than those who do not (Samsa et al 1997). Volpe and Dedhiya (2006) 
found that the public and hypertensive patients alike did not consider hypertension 
as a serious health problem and only a third of the respondents in their study knew 
that hypertension could be asymptomatic. 
It has been estimated that for the population as whole worldwide, 75% of strokes 
occur in 90% of individuals with a blood pressure greater than 155/95 (MacMahon 
and Rogers 1994). In a population based study, Oliveria et al (2005) found that 
hypertensive patients had a  general understanding of ’hypertension’ but were less 
knowledgeable about specific factors related to their condition and specifically their 
own level of BP control. There is no standardized tool available to assess knowledge 
or awareness of hypertension (Oliveria et al 2005). Cohort studies have indicated 
that, in the Asia Pacific region as well as in North America and Western Europe, 
each 10 mmHg lower systolic BP is associated with a decrease in risk of stroke of 
approximately one third in subjects aged 60-79 years (Lawes et al 2004). The 
association is continuous down to levels of at least 115/75 mmHg and is consistent 
across sexes, regions, and stroke subtypes and for fatal and nonfatal events. The 
proportional association is age dependent but is still strong and positive in those 
aged 80 years. Data from randomized controlled trials, in which mean age at event 
was approximately 70 years, indicate that a 10 mmHg reduction in systolic BP is 
associated with a reduction in risk of stroke of approximately one third. Per mmHg 
systolic BP reduction, the relative benefits for stroke appear similar between agents, 
by baseline BP levels, and whether or not individuals have a past history of CVD. 
There is, however, evidence of greater benefit with a larger BP reduction. 
Epidemiologically expected benefits of BP lowering for stroke risk reduction are 
broadly consistent across a range of different population subgroups with greater 
benefits from larger BP reductions. The MORGAM project (Asplund et al 2009) 
investigated the relative risk for stroke by Age, Sex and population based in 18 
European populations and identified for each 10mmHg increase in BP, the risk of 
stroke increased by 23-29%. The Perindopril Protection Against Recurrent Stroke 
Study (PROGRESS) (2001) was designed to test the effects of BP-lowering 
regimens in 6105 patients with stroke or TIA within a 5 year period. The intervention 
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involved single (ACE1) or combination (ACE1 plus diuretic) therapy in both 
hypertensive (>160 mmHg systolic or >90 mmHg diastolic) and non-hypertensive 
patients with stroke or TIA. The combination therapy resulted in a 43% (95% CI, 30-
54) reduction in the risk of recurrent stroke and a 40% (95% CI, 29-49) reduction in 
risk of major vascular events (PROGRESS 2001). 
There is also debate regarding BP control in the elderly. Beckett et al (2008) 
reported on a retrospective cohort analysis of elderly patients over 80years of whom 
84.5% were taking antihypertensive medication which showed a shorter survival for 
those patients with a systolic BP below 140mmHg, even after adjustment for known 
predictors of death (Oates et al 2007). They reported that the 36% reduction in the 
risk of stroke may be offset by the possible adverse effects of treatment of 
hypertension in this very elderly population. However, the HYVET (Hypertension in 
the Very Elderly Trial) study sought to provide some clarity and found evidence that 
antihypertensive treatment with Indapamide (sustained release), with or without 
perindopril in the very elderly e.g. persons over 80 years of age or older, aimed to 
achieve a target blood pressure of 150/80 mm Hg is in fact beneficial and is 
associated with reduced risks of death from stroke, death from any cause and heart 
failure (Beckett et al 2008). 
1.14.4 Diabetes 
The impact of diabetes on stroke is an important factor due to the increasing 
incidence of diabetes globally (Air & Kissela 2007). Diabetes Mellitus (DM) is 
estimated to affect 3.7% of the UK population (Diabetes UK 2007). DM remains an 
independent risk factor for systemic atherosclerosis and increases the risk of 
Atherothrombosis via detrimental effects on the vessel wall (Chi & Jaff 2008). The 
Framingham study found a 2.5-fold incidence of ischaemic stroke in diabetic men 
(Kannel et al 1983). More recently DM was one of two independently associated risk 
factors for recurrent stroke in the Oxfordshire Stroke Project with 9.17% of recurrent 
strokes attributable to DM (Hillen et al 2003). It has been suggested diabetics are as 
much as 2.9 times more likely than non-diabetics to have a stroke for reasons that 
diabetes appears to amplify high risk, non-modifiable risk factors for stroke (Air & 
Kissela 2007).  DM is more associated with small vessel disease than large vessel 
disease, Tuttolomondo et al (2008) found the prevalence of lacunar stroke sub-types 
was highest in hypertensive and diabetic patients. Surprisingly, Touze et al (2005) 
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found no correlation between diabetes mellitus prevalence at baseline and risk of MI 
during follow-up and suggested the link between diabetes mellitus and small vessel 
disease as a possible explanation for this. The association between diabetes and 
small vessel disease does appear to carry a lower risk of MI during follow-up (Diener 
et al 2004).  The association between diabetes and stroke is undoubtedly related to 
the pathologic changes observed in the brain vessels. It has however, been 
suggested that the changes in a diabetic brain differ from non-diabetics due to 
diabetic angiopathy rather than atherosclerotic angiopathy. Therefore further 
research needs to be performed to understand if established treatments need to be 
reviewed further for diabetic patients at risk of stroke or other vascular diseases. 
Giorda et al (2007) found during 4 year follow-up of over 4,000 patients with 
diabetes, 296 stroke events. In patients with no history of CV disease the age-
standardised incidence of stroke was 5.5 in men and 6.3 in women, this went up to 
13.7 in men and 10.8 in women with a history of CV disease. They identified age and 
history of stroke as the main predictors of stroke in diabetes. The Greater Cincinnati-
Northern Kentucky Stroke Study (GCNKSS) (Kissela et al 2005) found the risk for 
ischaemic stroke in white diabetics was higher at every age-group compared with 
non-diabetic patients. Both these studies identify diabetic patients of any age with a 
previous stroke have a high risk of recurrent vascular events and should be treated 
aggressively with secondary prevention therapies. 
1.14.5 Hyperlipidaemia 
Hyperlipidaemia is a well-established risk factor for CV disease (Heart Protection 
Study 2002). It initiates atherosclerosis by disturbing the normal homeostatic function 
of the endothelium and vascular wall (Kinlay et al 2001). Raised Low Density Lipid 
(LDL) levels in the plasma increase the rate of delivery and retention of LDL in the 
arterial wall, this leads to reactive oxygen species depleting antioxidants to oxidize 
fatty acids on the LDL surface transforming it to oxidized LDL particles. Oxidized LDL 
will activate the overlying endothelial cells, the combination will go on to inhibit the 
production of nitric oxide and rapidly convert the available nitric oxide to the inactive 
metabolite. This drop in nitric oxide causes detrimental effects on the vascular wall 
and in turn causes recruitment of inflammatory cells and leads to atherosclerotic 
lesions (Kinlay et al 2001). A large amount of data has been collected to support the 
use of statin therapy to reduce CV risk and several recent meta-analyses assessing 
the risk reduction on statin therapy have shown that statin therapy provides high 
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levels of protection for all-cause mortality and non-haemorrhagic strokes and other 
vascular diseases such as CKD and CAD (Pedersen et al 1998, O’Regan et al 2008, 
Strippoli et al 2008, Gould et al 2007). Statins both reduce levels of low density lipids 
and increase levels of high density lipids which have been shown to decrease the 
risk of stroke during follow-up (Asplund et al 2009). As well as producing a potent 
low density lipid-lowering effect, Statins also contain anti-inflammatory, 
antithrombotic and vaso-active effects which might act as a neuro-protector, leading 
to possible reductions in stroke severity (Goldstein et al 2009). The Medical 
Research Council (MRC) and British Heart Foundation (BHF) identified a relative risk 
reduction of 25% for an endpoint of stroke in the Heart Protection Study (HPS) but 
found no significant reduction in stroke risk in patients with existing cerebrovascular 
disease (Collins et al 2004). Over 4.9 years (576 subjects) results from the SPARCL 
(Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive 
Reduction in Cholesterol Levels) trial showed reductions in fatal, severe, moderate 
and mild outcomes using the Modified Rankin Scale (MRS) measure of disability. 
Primary endpoint of time to first fatal or non-fatal stroke was increased by 16% in the 
intervention group which received Atorvastatin 80mgs (Amarenco et al 2009). 
1.14.6 Smoking 
Up to one quarter of all strokes are attributable to cigarette smoking, which 
independently increases the relative risk of stroke about three-fold (Hankey & 
Warlow 1999). The mechanisms for tobacco smoke exposure increasing stroke risk 
are numerous as the smoke contains over 4000 different harmful chemicals. The 
chemicals promote the development of free radicals that induce vascular endothelial 
dysfunction and inflammation which can lead to the development of atherosclerotic 
processes (Cole 2011). Smoking in itself reduces the life expectancy of the average 
smoker by 14 years (Cole 2011). A 20% risk of stroke is directly associated with 
smoking and while both the general public and global healthcare systems are aware 
of the risk associated with smoking, the prevalence of tobacco use over the last 25 
years remains largely unchanged (Cole 2011). The risk is dependent upon the 
amount of cigarettes smoked (Cole 2011, Hajat et al 2004). Risk is equally high in 
both male and female smokers but it declines considerably and rapidly after smoking 
cessation, thus supporting a causal relationship. Studies performed across varying 
ethnicities and populations demonstrate a highly consistent association between 
smoking and ischaemic stroke risk, with current smokers having a 2-4 fold increased 
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risk of ischaemic stroke compared with lifelong non-smokers or individuals who have 
stopped smoking >10 years (Shah & Cole 2010). Interestingly in ethnicity studies of 
stroke patients (Hajat et al 2004) UK Whites are more likely to smoke than UK Black 
African and UK Black Caribbean populations. It has been suggested that smoking 
introduces a very high risk of stroke in young and middle aged individuals (Andersen 
et al 2010) in particular and therefore are a population where information for 
prevention should be targeted. 
1.14.7  Heart disease 
Coronary artery disease (CAD) is an independent risk factor for stroke (Wolf et al 
1992). In the Framingham study CAD increased the possibility of stroke events 
independent of other well-known cardiovascular risk factors (Kannel et al 1983). The 
incidence of stroke at 10 years follow-up in acute myocardial infarction (AMI) patients 
was 19.5% and 29.3% for men and women respectively (Wolf et al 1996). One third 
of patients with ischaemic stroke already have clinical manifestations of CAD, such 
as angina or a past myocardial infarction (MI) (Sandercock et al 1989). 
A meta-analysis to identify the incidence of stroke after MI found 21.4 strokes 
occurred per 1000 MI at 1 year (Witt 2006).  Conversely, there is an average annual 
incidence of 1% for MI after TIA (Burns 2011) and a 2.2% annual risk has been 
shown through meta-analysis for MI after stroke/TIA (Touze et al 2005).  Following 
an acute ischaemic stroke, although there is a high short-term risk of recurrent 
stroke, the leading cause of mortality is CAD (Vickrey et al 2002, Touze et al 2005, 
Adams et al 2003, Dhamoon 2006).  It is probable that those with an established 
previous history of Ischaemic Heart Disease (IHD) will account for the majority of 
subsequent coronary events following stroke, with known cardiac disease at entry in 
around a quarter of all stroke patients ( Adams 2003).   
There is a risk of ‘silent’ and asymptomatic IHD in the presence of TIA and stroke 
(Adams et al 2003). Rokey et al (1984) and Di Pasquale et al (1986) both showed 
abnormal myocardial imaging and asymptomatic IHD in 41% and 28% of their study 
populations, respectively. Subtypes of ischaemic stroke related to underlying 
atherosclerosis such as carotid, vertebral or intracranial stenosis, are associated with 
a higher risk of IHD than non-atherosclerotic subtypes of stroke (Adams et al 2003, 
Rothwell et al 2005).  
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A systematic review and meta-analysis of the risk of MI and vascular death after TIA 
and ischaemic stroke showed that after a stroke or TIA the risk of MI and non-stroke 
vascular death are each 2% per annum (Touze et al 2005). Other smaller studies 
suggested that between 25-60% of stroke patients without any clinical evidence of 
IHD may have (silent) myocardial ischemia on non-invasive tests (Adams et al 
2003). While atherosclerosis may explain 20-40% of stroke, strokes related to 
atherosclerosis are at a higher risk of MI or non-stroke death than other patients 
(Touze et al 2005).  
1.14.8 Carotid artery stenosis 
Several other but smaller studies suggest that patients with carotid stenosis have a 
high prevalence of IHD (Urbinati et al 1992, Sconocchini et al 1997). Sconocchini et 
al (1997) evaluated 133 patients with asymptomatic and symptomatic significant 
(>50%) carotid stenosis for the presence of IHD using stress-exercise 
electrocardiography (SE). The study demonstrated that 25% of patients with no 
history or IHD had latent myocardial ischemia. They concluded that screening with 
SE was easy, inexpensive and safe and would allow early detection of those patients 
who need more active treatments.    
Patients with identified carotid, vertebral or intracranial atherosclerosis may therefore 
be at highest risk of MI or non-stroke death and may be a group which would benefit 
from CV investigation on diagnosis of atherosclerosis in a single bed.  
1.14.9 Atrial fibrillation 
Atrial Fibrillation (AF) is responsible for at least 15-20% of all stroke in the United 
States (US) (Lloyd-Jones et al 2010) and is the most common cardiac rhythm 
disorder and a major risk factor for ischaemic stroke (Ogawa et al 2011). The 
prevalence of AF increases significantly in the elderly, affecting approx 9-14% of the 
population of over 80 year olds in North America and Western Europe (Feinberg et al 
1995, Ninios et al 2010). 
AF causes stroke due to the increased coagulation activity in the left atrium of the 
heart. Patients with paroxysmal AF are at an increased risk even during the sinus 
rhythm period (Koretsune Y 2009). A risk reduction of up to 50% can be achieved in 
stroke patients with non-rheumatic AF through the use of anticoagulation therapy 
(European AF Trial study group 1993) and Warfarin has for years been the drug of 
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choice to treat AF. Its use has seen a reduction in the risk of stroke in patients by up 
to 68% (Ezekowitz et al 2009). However, due to the complexities of taking and 
monitoring the drug, therapeutic range is achieved in less than two-thirds of patients 
(Matchar et al 2002). New oral anticoagulants such as Dabigatran require less 
monitoring and may provide a better alternative to Warfarin. Dabigatran is 
administered orally at fixed doses, has a rapid onset of action, predictable 
pharmacokinetics and minimal food/drug interactions (Mavrakanas and Bounameaux 
2011). By adopting new oral anticoagulants the process may improve through 
simplification and the numbers of patients achieving a therapeutic anticoagulant 
range may increase and therefore stroke incidence may be positively affected. 
1.14.10 Metabolic syndrome and Obesity 
The Metabolic Syndrome is characterised by a number of vascular risk factors such 
as, elevated BP, high blood glucose, obesity and hyperlipidaemia. Boden-Albala et al 
(2008) performed a study looking at the association between the metabolic 
syndrome and stroke. The study was part of the Northern Manhattan Study and 3298 
stroke-free community residents were prospectively followed up for a mean of 6.4 
years. The metabolic syndrome was defined according to the National Cholesterol 
Education Program (NCEP) Adult Treatment Panel III guidelines (ATP III update 
2004). The study showed that more than 44% of the cohort had the metabolic 
syndrome (48% of women vs. 38% of men, P=0.0001), which was more prevalent 
among Hispanics (50%) than whites (39%) or blacks (37%). The metabolic 
syndrome was associated with increased risk of stroke (HR=1.5; 95% CI, 1.1 to 2.2) 
and vascular events (HR=1.6; 95% CI, 1.3 to 2.0) after adjustment for socio-
demographic and risk factors. The effect of the metabolic syndrome on stroke risk 
was greater among women (HR=2.0; 95% CI, 1.3 to 3.1) than men (HR=1.1; 95% CI, 
0.6 to 1.9) and among Hispanics (HR=2.0; 95% CI, 1.2 to 3.4) compared with blacks 
and whites. The estimates suggest that elimination of the metabolic syndrome would 
result in a 19% reduction in overall stroke, a 30% reduction of stroke in women and a 
35% reduction of stroke in Hispanics.   
However, there is still debate about the metabolic syndrome as an independent risk 
factor for CVD with the absolute CV risk of the metabolic syndrome not necessarily 
higher than those of its individual components (Qiao et al 2007). The prevalence of 
the metabolic syndrome varies according to definition, ethnicity and gender (Qiao et 
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al 2007). Subjects with the metabolic syndrome are at increased vascular risk but 
whether it is a useful CV risk marker above and beyond the risk associated with its 
individual components remains uncertain. 
Obesity is defined as a body mass index (BMI) of >30kg/m2. Worldwide obesity has 
more than doubled since 1980. In 2008, 1.5 billion adults, 20 and older, were 
overweight. Of these over 200 million men and nearly 300 million women were 
obese. 65% of the world's population live in countries where overweight and obesity 
kills more people than underweight. In the US, 63% of men and 55% of women are 
considered overweight and 30% of the population are considered obese (Kurth 
2002). It does not look as though the problem is improving as nearly 43 million 
children under the age of five were overweight in 2010 (WHO 2011). Obesity is 
preventable and is independently associated with increased stroke risk. There is also 
an association between obesity and risk of cardiovascular disease in middle aged 
individuals (Kurth et al 2002, Janssen et al 2007). Obesity is strongly associated with 
major stroke risk factors including hypertension, diabetes and hyperlipidaemia, 
however some studies have shown increasing BMI is associated with a steady 
increase in ischaemic stroke, independent of any other risk factors (Kurth et al 2002).  
Wilson et al (2002) found overweight and obesity categories were highly related to 
risk of hypertension in both men and women. The incidence of new diabetes was 
increased in overweight men and obese persons of both sexes. Interestingly approx. 
21% of diabetes in men in this study (Wilson et al 2002) was attributable to 
overweight and obesity but only 3% in women. This may be a contributing factor 
towards the high incidence of stroke in men, however, Wilson et al (2002) could find 
no reason for the weaker relations in women. They summarize, overweight and 
obesity are associated with an increased risk for the development of cardiovascular 
risk factors and CVD itself. However, the risk may be reversible as the MORGAM 
project (Asplund et al 2009) identified 1 unit of Body Mass Index (BMI) increased the 
risk of stroke in men by 2%, therefore even a moderate reduction in BMI may 
alternatively reduce stroke risk. 
1.14.11 Alcohol 
There is widespread alcohol consumption in the general population. It is suggested 
that 44% of adults over the age of 18 years consume 12 or more alcoholic drinks per 
year in the US. Studies have reported conflicting results regarding the risk of stroke 
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and alcohol consumption over the past twenty years. However, Reynolds et al (2003) 
performed a meta-analysis of 19 cohort studies to identify the risk association 
between alcohol and stroke. The meta-analysis showed that consumption of more 
than 60g of alcohol per day was associated with an increased risk of total stroke 
(1.64%), ischaemic stroke (1.69%) and haemorrhagic stroke (2.18%). These results 
show that heavy alcohol consumption increases the relative risk of stroke whereas 
light to moderate consumption may provide a protective element against total and 
ischemic stroke. Several studies describe a j-shaped association between alcohol 
and ischaemic stroke (Djousse et al 2002, Hillborn et al 1999, Berger et al 1999). 
Reducing alcohol consumption in heavy drinkers should be an important approach to 
stroke prevention in the general population (Reynolds et al 2003), however, health 
professionals should think carefully how best to share this information with patients 
at high risk of first or second stroke in order to ensure the most accurate information 
is relayed regarding the potential for misunderstanding the benefits of moderate 
drinking compared with the harm caused by consuming large amounts of alcohol. 
1.14.12 Ethnicity 
Understanding ethnic differences in stroke is a crucial element of understanding the 
aetiology of stroke (Sacco et al 2001). The incidence of stroke in black populations is 
approximately twice as high in the United States (US) black and United Kingdom 
(UK) black populations compared with the local white populations. The population 
attributable risk depends on both the prevalence and risk associated with each risk 
factor. Certain populations have a higher prevalence of physiological risk factors for 
ischaemic stroke. The South London Stroke Register (Hajat et al 2004) identified 
hypertension as significantly associated with stroke, in keeping with other studies 
(Sacco et al 2001), however, Ethnic differences were demonstrated in the population 
attributable risk with values of 38% for white, 46% for black Caribbean, and 59% for 
black African subjects. Black African subjects have been shown to have the highest 
prevalence of hypertension regardless of their geographical location (Sacco et al 
2001, Hajat et al 2004). However, an interesting finding in the South London Stroke 
Register is the population attributable risk from smoking was less in black Caribbean 
and black African groups compared with the European group, and for DM the risk 
was 2-fold greater in the black Caribbean population compared with the black African 
and white groups (Hajat et al 2004). However, both coronary artery disease and AF 
are more common in White populations (Lynch et al 1999, Wolf et al 1996). These 
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findings go a great deal further to highlighting the need to inform and educate stroke 
patients at least individually if not with ethnicity specific risk factor advice. 
Different ethnic populations also have different lifestyle behaviours. UK black stroke 
patients have been shown to behave differently to white stroke patients with a lower 
prevalence of smoking and heavy alcohol intake (Hajat et al 2001). This is an 
important finding for the development and implementation of stroke prevention 
programmes. 
Stroke prevention relies heavily on the treatment of risk factors in all high risk 
groups. Studies to understand ethnic differences in stroke risk are key to preventing 
stroke in different populations who have higher or lower prevalence of different 
behaviours or physiological markers for stroke risk. Prevention programmes 
specifically designed and implemented to ethnic groups may be helpful for both 
physiological and behaviour risk factor management. 
In the UK according to the 2001 census 92% of the UK population is White, 4% 
Asian or Asian British, 2% Black or Black British and 1.5% Mixed. The UK census 
classified ethnicity into 16 groups. Bhopal (2007) discusses the tensions which 
highlight the range of approaches and challenges in responding to ethnic disparities 
in the UK. Race and ethnicity are important variables in health care management 
and noteworthy in stroke prevention as risk is increased in different ethnic 
populations. Healthcare for ethnic minority groups has been found to be inferior 
compared to white Europeans in a range of diseases including stroke (Bourke et al 
2006). It has been suggested that Physicians advice and behaviour may vary 
depending on perceived patient attributes (Smedley et al 2002), also ethnic minority 
groups have reported lower levels of trust and satisfaction with their providers in 
physicians, health plans and hospitals in general (Morales et al 2001, Collins et al 
2002, Hunt et al 2005, Shi et al 2005). Cultural diversity programmes for training 
health care professionals have been shown to improve patient outcomes including 
compliance but as yet there are no UK requirements for inclusion in professional 
training except for psychiatry (Bentley et al 2008). 
The Health Survey for England (HSE) (2003) showed that BME groups have 
generally worse health than the overall population. Evidence suggests poorer socio-
economic status of BME groups is the main factor driving ethnic health inequalities 
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(Parliamentary Office of Science and Technology (POST) 2007). Bhopal (2007) 
challenges us to achieve better health for ethnic minority populations. The 
Department of Health have published several documents and targets to improve 
health inequalities focussing on socio-economic status but not specifically for BME 
groups. The HSE (2003) also showed that BME groups as a whole were more likely 
to report ill-health and that ill-health starts at a younger age among BME groups 
compare to white British. Some BME groups experience worse health than others, 
surveys commonly show that Pakistani, Bangladeshi and Black-Caribbean people 
report the poorest health, however, Chinese people report better health than white-
British. BME groups are known to have higher rates of vascular disease than white-
British but lower rates of cancer (POST 2007). 
1.14.13 Health inequalities targets 
The NHS Plan (2000) committed to two national Public Service Agreement (PSA) 
targets to reduce health inequalities, which were set up in February 2001: 
• To reduce by at least 10% the gap between the fifth of local authorities with the 
worst health and deprivation indicators and the population as a whole, by 2010. 
• To reduce by at least 10% the gap in infant mortality between routine and 
manual groups and the population as a whole, by 2010. 
Since then, a number of local authorities have agreed health inequalities targets as 
part of their Local Area Agreements. In some cases, the targets attract financial 
incentives through the reward element initiative. Local authorities, their partners and 
communities have been encouraged to collaborate on delivery in the hope of 
ensuring greater accountability for meeting the targets. Nonetheless, evidence 
shows that health inequalities remain at large and POST (2007) suggest the biggest 
ethnic variation for health in the UK is seen in the elderly ethnic minority groups.  
Chin et al (2007) suggest health disparities originate from societal factors such as 
poverty and unequal educational opportunities, which continue to be a challenge for 
all western countries. They also reported on the published annual Disparities Report 
by The Agency for Healthcare, Research and Quality to provide a national overview 
of disparities in the US. The 2006 report documents that racial and ethnic minorities 
continue to receive poorer quality of care as compared to whites in 22 essential 
quality of care measures. Specifically, Hispanics receive poorer quality of care as 
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compared to non-Hispanic whites in 77% of these measures, African Americans 
73%, American Indians and Alaska Natives 41%, and Asian Pacific Islanders 32% 
(US Department of health and human services 2006).  
As global movement increases its momentum still further, the challenge in health 
care is to be aware of individual ethnic biological differences which affect health as 
well as the cultural and religious influences which affect behaviour. Socio-economic 
status is an important factor, however as health professionals, information and 
education is key to providing all members of society with the opportunity to 
participate in their health care through improved health literacy and knowledge. 
1.14.14 Physical inactivity 
Numerous studies have shown that low physical fitness is an independent predictor 
of death from cardiovascular disease among healthy, middle-aged men and women 
(Wenger 1996, Elsawy & Higgins 2010). Recent findings continue to provide 
evidence of the overwhelming benefit of physical activity on stroke prevention. One 
of the more important findings from Sacco et al (2001) study was the elevated 
Etiological Factor (EF) (estimates the proportion of strokes attributable to a specific 
risk factor) for physical inactivity found in all 3 race-ethnic groups (Europeans, Blacks 
and Hispanic Caribbean’s) indicating physical inactivity is an important risk factor for 
all ethnic groups and populations. It has however, been argued that subjects who 
report a lack of physical activity may have an undiagnosed or subclinical condition 
that prevents such activity and that physically fit subjects may adopt other health-
promoting habits. However, Lee et al (2003) identified in a meta-analysis of 23 
studies (18 cohort and 5 Case-controls) looking at  physical activity and stroke, that 
demonstrated highly active individuals had a  25% lower stroke risk or mortality 
compared with inactive or unfit individuals. By decreasing the risk burden of physical 
inactivity stroke risk among all race-ethnic groups could be substantially altered 
(Sacco et al 2001). Physical activity, although seen as a lifestyle behaviour, can 
have an impact on physiological stroke risk factors as it lowers BP and weight, 
improves glucose tolerance and can enhance overall cardiovascular health (Lee et al 
2003).  Disability after stroke can be substantial and neurological deficits can affect 
patient’s ability to initiate and tolerate exercise. This provides a challenge to health 
professionals, patients and carers to establish safe and effective physical activities 
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after stroke to aid recovery and reduce the risk of further stroke and CV disease 
(Sacco et al 2006). 
1.14.15 Renal artery disease 
Impaired renal function is a strong independent predictor of cardiovascular mortality 
and morbidity in the absence of any previous history (Elsayad et al 2007, Townsend 
2008). Traditional risk factors seem to account for much but not all of this excess 
risk. There is a significant burden of CVD risk factors among patients with chronic 
kidney disease (CKD) and these patients are more likely to be treated for 
hypertension, elevated low density lipoprotein cholesterol (LDL-C) levels, and 
diabetes, but rates of control of risk factors are uniformly low in those with and 
without CKD (Parikh et al 2006). However, their predisposition to CV disease 
persists even after adjustment for this overabundance of standard risk factors. Early 
detection of CKD can not only slow the progression to end-stage renal disease but 
also identify risk factors for stroke and CV disease (Hostetter 2004). 
Impaired renal function is measured by low Glomerular Filtration Rate (GFR) which 
has also been shown to be associated with markers of cerebral small vessel disease 
on MRI (Ikram et al 2008). The population based study of a large sample of elderly 
people (>60 years) from the Rotterdam Scan Study (Ikram et al 2006), showed that 
compared with those with normal kidney performance persons with reduced renal 
function had a smaller brain volume, smaller deep white matter volume and more 
white matter lesions and that these findings were independent of CV risk factors. 
GFR may be an easy and readily measureable indicator of cerebral small vessel 
disease in patients with kidney problems. Understanding the interplay of vascular 
disease between the kidney and the brain may hold the promise of identifying novel 
strategies to reduce the risk of damage to either organ (Seliger et al 2008). 
Cystatin C is a serum protein that is filtered out of the blood by the kidneys and 
serves as a measure of kidney function. Cystatin C is produced steadily by all types 
of nucleated cells in the body. Deo et al (2008) performed a study for the Health, 
Ageing and Body composition study, to evaluate whether impaired kidney function 
predicted the risk of fatal CV disease independent of prevalent and incident CV 
events. Higher Cystatin-C concentrations were significantly associated with CV 
disease (Deo et al 2008). Although end-stage renal disease substantially increases 
the risks of death and CV disease (Seliger et al 2003), the effects of less severe 
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kidney dysfunction on these outcomes are less well defined (Go et al 2004, Mann et 
al 2001). The HOPE study aimed to determine whether mild renal insufficiency 
increased CV risk and whether ramipril, an angiotensin converting enzyme inhibitor, 
decreased that risk. 980 patients with mild renal insufficiency measured by an 
increased serum Creatinine (>1.4 mg/dL; 124 µmol/) and 8307 patients with normal 
renal function were investigated for a primary outcome measure of CV death, MI or 
stroke. The cumulative incidence of the primary outcome was higher in patients with 
renal insufficiency than those without. Ramipril reduced the incidence of the primary 
outcome in patients with and without renal insufficiency. The study showed that 
patients with pre-existing vascular disease or diabetes combined with an additional 
CV risk factor and mild renal insufficiency had a significantly increased risk for 
subsequent CV events (Mann et al 2001) but importantly, this risk was reversible. 
Shlipak et al (2002) concluded through a study aimed to determine the prevalence of 
elevated risk through serum Creatinine levels (>1.4 mg/dL; 124 µmol in women and 
>1.5 mg/dL; 133 µmol/L in men) that renal insufficiency is a marker for elevated CVD 
risk in elderly (>65 years age) adults. Older individuals demonstrated more 
significant differences in hypertension prevalence, treatment and control. The 
prevalence of hypertension was significantly higher among those with compared with 
those without CKD. These differences were more evident among older individuals, 
consistent with previously published data demonstrating lower rates of blood 
pressure (BP) control among older individuals with mild to moderate CKD (Parikh et 
al 2006). Poor kidney function is also highly prevalent in the elderly population 
together with more widespread small vessel disease in the brain (Ikram et al 2008). 
Whether CV disease is a risk factor for the progression or development of worsening 
kidney disease was studied by Elsayed et al (2007). This study looked at 13,826 
individuals, used an increase in serum Creatinine level and a reduced estimated 
GFR (eGFR) as markers of a kidney function decline. They concluded that CV 
disease is indeed independently associated with kidney function decline and the 
development of CKD. This is an important finding which reiterates the importance of 
the need to be aware of the interconnectors between diseases and the independent 
impact one has on the other. Peripheral Artery Disease (PAD) has also been shown 
to have a high prevalence in patients with renal insufficiency (O’Hare et al 2004). 
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Both the kidney and brain are low resistance end-organs and are exposed to high-
volume blood flow (Schiffrin et al 2007). The similarities in the vascular supply to 
these organs could be useful as vascular disease in one organ may inform us about 
vascular disease in the other (Seliger et al 2008). Prevention and treatment of CVD 
are major considerations in the management of individuals with CKD. Less is known 
regarding the CVD risk factor burden among individuals with earlier stages of CKD, 
many of whom are not necessarily treated for CKD or do not manifest clinical CVD. 
However, relatively minor renal abnormalities such as a slightly reduced GFR or 
micro albuminuria, but even within normal ranges, may be associated with increased 
risk of vascular events (Schiffrin et al 2007). Moderate CKD is an independent risk 
factor for CV disease, suggesting a need to better understand CV risk factor burden 
and rates of risk factor treatment and control in this group. 
The limitation with evaluation studies of the prevalence of renal disease in 
association with CV disease is that different studies appear to use different markers 
for  diagnosis of renal disease, with some using GFR, some Cystatin C and others 
serum Creatinine levels. However, all these measures are well defined biochemical 
markers of reduced kidney function but nevertheless this possibly blurs the 
association between renal disease and CV disease risk, as each marker used for 
renal disease may have an alternative independent influence on atherosclerotic 
events.  
1.14.16 Peripheral artery disease (PAD) 
PAD is defined by atherosclerotic obstruction of the abdominal aorta and arteries to 
the legs that reduces arterial flow during exercise and/or at rest (Chi & Jaff 2008). 
Approximately one third of patients with PAD have typical claudication defined as 
pain in one or both legs on walking, primarily affecting the calves, that does not go 
away with continued walking and is relieved by rest. In patients with claudication, the 
severity of the condition increases slowly with 25% have worsening claudication, and 
5% undergo an amputation within 5 years. Less than 5 -10% of patients have critical 
leg ischaemia (ischaemic pain in the distal foot, ischemic ulceration or gangrene), 
but their risk of limb loss is substantial (Hiatt 2001). Only ~10-30% of patients with 
PAD present with classic symptoms of intermittent claudication (Chi & Jaff 2008). 
This may be a reason for its under-diagnosis and clinicians reliant on a classic 
history of claudication could miss the majority of cases (Hirsch et al 2001).  
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This is of concern as patients with PAD, even in the absence of a history of MI or 
ischaemic stroke, have approximately the same relative risk of death from CV 
causes as patients with a history of IHD or CVD (Hiatt WR 2001). The age-adjusted 
prevalence of PAD is approximately 12%, and the disorder affects men and women 
equally. Patients with PAD are usually regarded as a group that is at particularly high 
risk of cardiac ischaemic events, yet PAD is commonly both under-diagnosed and 
undertreated (Steg et al 2007).  
Vickrey et al (2002) found that the PAD cohort in their study of secondary ischaemic 
events among persons with atherosclerotic vascular disease experienced the highest 
case fatality or proportion of secondary events that were fatal stroke, fatal MI and 
other vascular deaths. The REACH registry findings support these findings with PAD 
patients experiencing the highest rates of CV death and major CV events due to an 
atherothrombotic event (Steg et al 2007). However, Janes et al (2008) performed a  
multivariate analysis that showed compared to patients with IHD, patients with PAD 
had decreased use of antiplatelet agents, statins and ACE inhibitors and during 
hospital admission, treatment was significantly less likely to be initiated in patients 
with PAD. This is a significant discovery and should raise awareness to health 
professionals of the importance of treating patients with PAD as aggressively as they 
would a patient with CAD. 
The Ankle Brachial Index (ABI) may be the most reliable detector of PAD (Chi & Jaff 
2008) in high risk patients. It compares systolic BP in the dorsarlis pedis and/or 
posterior tibial arteries of the lower limbs to that of the brachial artery with the use of 
a hand-held Doppler device (Chi & Jaff 2008). As this is the simplest, most 
inexpensive, reliable and reproducible method of identifying PAD it may be used on 
patients with a history of CV disease and stroke, to easily identify if there is 
atherosclerosis in another vascular bed resulting in a further increase in the risk of 
vascular disease. The Scandinavian Simvastatin Survival Study (Pedersen et al 
1998) revealed that the use of simvastatin reduced episodes of new or worsening 
intermittent claudication providing evidence that if treated with CV disease risk factor 
management strategies, PAD patients can have a positive outcome. The Heart 
Protection Study (HPS 2002)  went on to conclude that simvastatin not only reduced 
the risk of a first event being suffered by a person but also reduced the risks of 
subsequent events for many types of high risk patients including those with PAD .  
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1.14.17 Retinal artery disease 
A study to determine if hypertensive retinopathy (HTR) is an indicator of silent brain 
infarction (SBI) in asymptomatic hypertensive subjects using MRI and retinal 
photography has been undertaken (Kwon et al 2007). 14% of subjects had the 
presence of HTR and, following multivariate analysis, age (OR, 1.07; 95% CI, 1.03 - 
1.10) and HTR (OR, 2.01 for grade 1; OR, 3.03 for grade 2) were the independent 
indicators for the presence of SBI. The higher the grade of HTR, the more prevalent 
the presence of SBI than in persons with normal retina (by linear association test, 
p=0.001).  
Mitchell et al (2005) performed a study investigating retinal micro vascular signs as a 
potential risk of stroke and stroke mortality. The purpose of this study was to assess 
the relation of retinal micro vascular signs and incident stroke and stroke mortality in 
an older population. The authors took retinal photographs on baseline participants 
(3,654 patients aged 49+ years) of the Blue Mountains Eye Study from 1992 to 1994 
(Ivers et al 1999). They assessed the presence of retinopathy (micro aneurysms, 
retinal haemorrhages) in participants without diabetes and retinal arteriolar signs in 
all participants using standardized grading protocols. Incident stroke, TIA and CVD 
deaths (combined stroke events) were identified at follow-up examinations during 
1997 - 1999. During a 7-year period they reported 859 participants died, 97 (11.3%) 
of which died of CVD causes. Of survivors, 24 had confirmed incident of stroke, and 
11 had incident TIA. Combined stroke events were more frequent in participants with 
retinopathy (5.7%), with moderate-severe arteriovenous nicking (4.2%), or with focal 
arteriolar narrowing (7.2%) compared with those without (1.9%). After controlling for 
age, sex, systolic BP, smoking, and self-rated health, retinopathy was significantly 
associated with combined stroke events (relative risk (RR) 1.7, 95% CI 1.0 to 2.8) in 
persons without diabetes. This association was stronger in those without severe 
hypertension (RR 2.7, CI 1.2 to 6.2) or in persons with 2 or more retinal micro 
vascular signs (RR 2.7, CI 1.5 to 5.2). Generalized or focal arteriolar narrowing or 
arteriovenous nicking was not independently associated with combined stroke 
events after multivariate adjustment. They concluded that in older Australians without 
diabetes, retinopathy signs predict stroke or stroke-related death independent of 
traditional stroke risk factors (Mitchell et al 2005). 
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Mead et al (2002) performed a comparison study of risk factors in patients with 
transient and prolonged eye and brain ischemic events. It was the largest study to 
date to compare risk factors in ischaemic stroke, cerebral TIA, retinal artery 
occlusion (RAO) and amaurosis fugax. The results showed that severe ipsilateral 
carotid stenosis was more common in eye than brain events and atrial fibrillation was 
more common in brain than eye events. Atrial fibrillation was more often associated 
with prolonged stroke and RAO than transient cerebral TIA and amaurosis fugax 
symptoms. These data suggest that brain and eye events reflect distinct patterns of 
vascular disease and risk factors that probably have relevance to the 
pathophysiology of the event and its prognosis. They suggest focusing management 
of subgroups of patients with different cerebrovascular ischemic symptoms to target 
stroke prevention more effectively. 
1.14.18 Retinal vein disease 
Patients with retinal vein occlusions (RVO) are at increased risk of CV disease 
(Martin SC et al 2002). The risk of future CV disease was determined by this group 
using the Framingham algorithm and the risk estimated to guide decision about 
preventative treatment for CV disease in this patient group. The study concluded that 
RVO is a presenting complaint in a group of patients at increased risk of CV disease. 
They agreed that long-term follow up data demonstrates an increased risk of 
mortality from CV disease in patients with RVO. For patients presenting with RVO, 
this may be the first indication of developing atherosclerosis and could be used as an 
early indicator and initiation of treatment may be helpful at this time.  
1.14.19 Patent foramen ovale (PFO) 
PFO is a persistence of an embryonic defect in the inter-arterial septum (Sacco et al 
2006). The prevalence of PFO in the general populations is high at approx. 25%, 
however, it is approximately doubled in the presence of ischaemic stroke patients 
(Kent & Thaler 2010). This has been generally attributed to paradoxical embolism 
and many physicians recommend closure to prevent recurrence. However, there has 
been much debate regarding the importance of PFO closure in relation to stroke 
recurrence and prevention. Kent and Thaler (2010) have gone some way to provide 
further evidence that PFO is indeed an important risk factor for stroke after the initial 
event, however, the benefit of closure remains in questions. In the PFO in 
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cryptogenic stroke study (PICSS), PFO was found in 39% of patients between the 
ages of 30-85 years (Homma et al 2002). 
1.15 Genetics of stroke 
Genetics as a cause of stroke are thought to arise as a consequence of polygenic or 
multifactorial influences whereby multiple genes each exert a small influence or risk 
on phenotype, with individuals showing different combinations of genetic and 
environmental influences (Bevan and Markus 2004). Understanding the genetic 
contributions to ischaemic stroke is important to explain the minority cases of stroke 
that occur in the absence of established risk factors (Bentley et al 2010) but they 
may also go some way to explain why some people are more susceptible to vascular 
disease and stroke than others despite similar risk factors and environmental 
influences. Bentley et al (2010) suggest there are a growing number of studies 
reporting positive genetic associations with stroke. They performed a comprehensive 
meta-analysis (Bentley et al 2010) of the causal relationship of susceptibility genes 
to ischaemic stroke and found positive gene associations. From a total of 37,481 
identified ischaemic stroke cases, they identified six candidate genetic 
polymorphisms reliably associated with ischaemic stroke (Factor V Leiden, ACE 
(Angiotensin Converting Enzyme), MTHFR (Methylenetetrahydrofolate reductase), 
Prothrombin, PAI-1 (Plasminogen activator inhibitor), Glycoprotein-III). However, 
whilst the effect size of each of the positive gene associations was small (odd ratios 
of 1.11 to 1.60), the overall contribution that genetic factors make towards stroke is 
likely to be relatively large given the frequency of these risk variants in the general 
population (from 3 to 45% each). The sum of the population attributable risks across 
all the gene associations identified in the Meta analysis was 30% (Bentley et al 
2010).  
 
Ischaemic stroke involves a series of pathophysiological processes often occurring 
over many years, and each may be influenced by a number of different genes.  
When referring to stroke, a distinction must be made between isolated stroke in 
which there are no additional physical characteristics and conditions in which stroke 
is just one feature of a multi system disorder. CADASIL (cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy), is the only 
form of isolated stroke to display familial patterns of inheritance in which the 
responsible gene has been identified (Kalaria et al 2002). The presence of this 
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appears to confer an increased risk of ischaemic stroke, and specifically of cardio-
embolic and large vessel stroke subtypes (Gretarsdottir et al 2003). The gene 
identified was phosphodiesterase 4D (PDE4D), which is a regulator of cyclic AMP 
levels (Houslay et al 2003) and is proposed to control the level of smooth muscle 
proliferation and immune function in vessels, which leads to the proliferation of 
atherosclerosis and ultimately an increase in ischaemic stroke risk. 
1.16 Health behaviour 
For patients with multiple vascular risk factors, lifestyle and behaviour change is one 
way to reduce risk, however risk factor reduction by addressing lifestyle has been 
shown to be poorly implemented, with discussion of lifestyle recorded in only 37% of 
consultations in the Royal College of Physicians sentinel audit for stroke (RCP 
2004).  It is well documented that patients with chronic diseases inconsistently 
adhere to secondary prevention advice and strategies (Hillen et al 2000, Mouradian 
et al 2002, Horne et al 2009). Gilham and Endacott (2010) go as far as to suggest 
there is little stroke-specific evidence to inform the effectiveness of lifestyle change 
to modify stroke risk factors after first stroke. However, improving adherence to 
medications does have the potential to have a major impact on cardiovascular 
disease prevention (Silcock & Standage 2007). In order to understand how to 
improve patient adherence to secondary prevention strategies it is important to 
understand more about why patients make decisions to adhere or non-adhere or 
why they chose not to undertake a lifestyle modification which may have the 
potential to reduce their risk of recurrent  stroke and vascular events. 
Several theories of behaviour change were developed in the 1980’s as more 
sophisticated health promotion programmes were being considered beyond the 
simplistic transmission of information which failed to succeed beyond affluent, higher 
socio-economic sections of the populations (Nutbeam 2000).  These programmes 
focused on developing personal and social skills required to make positive health 
behaviour choices. Examples of theories of behaviour change include, the theory of 
planned behaviour (Azjen and Fishbein 1980), social learning theory (Bandura 1986) 
and updated versions of the health belief model (Lewin 1951 cited by Kritsonis 2004, 
Becker et al 1974,Glanz 2002). Such theories were developed to go some way to 
explain the complex relationships between knowledge, beliefs and perceived ‘norms’ 
and provide guidance on how to develop educational programmes to promote 
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behavioural change in a set of given circumstances. Few theories have been used to 
specifically study stroke survivors, however, recently the Cerebrovascular Attitudes 
and Beliefs Scale (CABS) was designed using the Health Belief Model (HBM) as a 
framework to understand stroke survivors’ perceptions of their risk of future stroke 
(Sullivan and Waugh 2007). CABS is still in its’ developmental stage and was 
therefore not used as a measure of stroke-related health behaviour in this thesis, 
however, following further development and validity testing, the tool will be extremely 
useful in the development of interventions for stroke prevention in the future. Despite 
this progress in stroke, interventions which have relied primarily on communication 
and education have mostly failed to achieve substantial results in terms of closing 
the gap in health status between different social and economic groups in society 
(Nutbeam 2000). Other mechanisms used in chronic illnesses include patient self-
efficacy, intention to comply with treatment advice, attitudes and motivation. Theories 
of reasoned action and planned behaviour have also been used to explain variations 
in medication adherence such as the Beliefs about Medicines questionnaire (Horne 
et al 1999) which assesses patient’s beliefs about the necessity of prescribed 
medications for controlling their illness and their concerns about the potential 
adverse consequences of taking them. 
Subjective risk factor perception is an important component of the motivation to 
change unhealthy life-styles. As far back at the 1970’s there was clear evidence that 
demographic variables such as socioeconomic status, gender, ethnicity and age 
affects the extent to which people adopt preventive health behaviours (Rosenstock 
1974). However, it also became clear that health education and financed services 
were not enough to change health behaviours alone and there was another aspect of 
human psychological behaviour which affected a patient’s likelihood to undertake 
preventive action and follow medical advice (Sheeran and Abraham 2003). Lewin 
(1951) described the idea of ‘valence’, that is the rendering of a behaviour as more 
or less attractive. This lead to the idea that the likelihood of experiencing a health 
problem, the severity of the consequences of that problem and the perceived 
benefits of health behaviour in combination with its potential costs could be key 
beliefs guiding health behaviour (Lewin 1951).   
The HBM is a useful framework for understanding the relationships between health 
beliefs and health behaviour. The model fundamentally focuses on two aspects of 
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individuals representations of health and health behaviour, threat perception and 
behaviour evaluation (Sheeran and Abraham 2003). Threat perception depends 
upon two beliefs, perceived susceptibility to illness or health breakdown and 
anticipated severity of the consequences of such illness. Behaviour evaluation 
consists of two distinct sets of beliefs, those concerning the benefits of 
recommended health behaviour and those concerning the costs or barriers to 
enacting the behaviour. The perception of these consequences of behaviour is 
relevant to stroke survivors and may affect their motivation to change lifestyles or 
adhere to potentially large additions to current medication levels. The model takes 
individual perceptions and modifying factors and is able to predict likelihood of action 
(Glanz et al 2002). The HBM (Glanz et al 2002) focuses on attitudes and beliefs of 
individuals based on the understanding that a person will take a health-related action 
from core assumptions, if that person; (1) feels that a negative health condition can 
be avoided, (2) has a positive expectation that by taking a recommended action, 
he/she will avoid a negative health condition and (3) believes that he/she can 
successfully take a recommended health action (i.e. s/he can physically take the 
medication or take physical activity). In order to change, patients need to understand 
the consequences of the disease and also their behaviours, in order to initiate the 
suggested change.  The HBM suggests ‘risk perception’ is a key element to 
understanding how a person becomes motivated to change their behaviour (Glanz et 
al 2008). Prochaska and Velicer’s (1997) Transtheoretical model of health behaviour 
change was developed to measure a person’s ‘readiness to change’ and used six 
stages, 1) pre contemplation (no intention to change), 2) contemplation (thinking 
about making a change), 3) preparation (intending to make a change in the 
immediate future 4) action (changing the health behaviour), 5) maintenance (working 
to prevent a relapse back into unhealthy or risky behaviour and 6) termination ( zero 
temptation and 100% self-efficacy). The Transtheoretical model uses stages of 
change to integrate processes and principles of change from different theories of 
intervention. The model, originally used in smoking cessation rapidly expanded to 
apply to a broad range of health and mental health behaviours (Prochaska & Velicer 
1997). Both models have been integral to the development of studies exploring 
human behaviour. The HBM is used within this thesis for the development of 
questions and both theories were used during the development and communication 
of the intervention in the RCT. 
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The theory of planned behaviour was developed from the theory of reasoned action 
(Ajzen & Fishbein 1975) which is based upon the relationship between attitudes and 
behaviour and the principle of compatibility (Ajzen 1988). The main theory is based 
upon the assertion that each attitude and behaviour has four elements, an action, 
target, context and time. It is thought that the attitudes and behaviour will be most 
positive when both are measured at the same time in conjunction with the four 
elements. Hence any particular behaviour consists of (a) an action or behaviour, (b) 
performed on or toward a target, (c) in a context, (d) at a time or occasion. For 
example, a person concerned about oral hygiene (a) brushes (b) their teeth (c) in the 
bathroom (d) every morning after breakfast. This example illustrates how behaviour 
can be aggregated over a range of occasions. In the study of health behaviours it is 
the repeat performance of a single behaviour that is useful in predicting future 
behaviours (Ajzen 1988). The theory was developed further by adding to the model 
the concept of perceived behavioural control, which is the individuals perception of 
the extent to which performance of a behaviour is easy or difficult (Connor & Sparks 
2003). This theory would be useful in identifying beliefs and values of health that 
might be influential in changing attitudes towards secondary prevention which may 
result in improved adherence to strategies, however there has been criticism that 
communication strategies alone are ineffective in changing attitudes (Connor & 
Sparks 2003). However the theory gives a greater understanding of how clearly 
defining an action or behaviour may be useful in changing behaviours in the long-
term. Both models have been used to study behaviours in patients with chronic 
diseases such as diabetes, heart disease and hypertension, however none have 
been used to specifically predict stroke survivor’s behaviours (Rhodes et al 2005). 
Some researchers believe it is possible to improve risk perception in the general 
public through the provision of information and through awareness campaigns 
(Kraywinkel et al 2007). However, the stroke population is complex and may require 
a more targeted strategy to improve their risk perceptions and adherence. Patient-
centred strategies may lead to the identification of better tools to improve adherence 
(Schedlbauer et al 2007, Silcock & Standage 2007) while randomized controlled 
trials have shown specific health behaviour modification interventions can be 
successful, such as advice to give up smoking (Law et al 1995) and healthy eating in 
nurse-led CVD follow-up programmes (Wood et al 2008). However, it remains 
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unclear what aspects of the programmes influence behaviour besides the added 
contact with a health professional. 
However, other studies have shown brief interventions have little impact on risk 
factor control and do not appear to have any long-term benefit (McManus et al 
2009), however in the short term it has been suggested that patients feel more 
satisfied with the information provided to them about stroke disease, risk factors and 
who to contact in the event of problems, therefore at the very least there is evidence 
of an improvement in patient experience. Specifically targeted programmes may be 
beneficial to the stroke population if they are individually designed. Some studies 
(Sudlow et al 1997, Hillen et al 2003, Van Wijk et al 2005) have shown some 
association between smoking cessation and specific socio-demographic 
characteristics of stroke survivors such as younger age and males. However, 
Sienkiewicz-Jarosz (2009) investigated the relationship between degrees of nicotine 
dependence and smoking abstinence 3 months after ischaemic stroke in order to 
explore predictors for smoking abstinence after stroke. This study suggests 
dependent smokers have greater difficulty quitting smoking due to more withdrawal 
symptoms and stronger nicotine cravings. This is an important factor in identifying 
specific prevention programmes for individuals, ensuring physiological assistance is 
provided for those who we can predict will struggle to make behaviour changes more 
than others. 
Notwithstanding these successes, studies to examine if improvements have been 
made to long-term management of chronic vascular diseases such as coronary heart 
disease, diabetes and hypertension with the formal introduction of pay-for-
performance targets have shown no improvement in blood pressure, blood glucose 
or cholesterol control (Crawley et al 2009). Indeed, even improved patient knowledge 
has failed to guarantee higher levels of adherence supporting the opposite view that 
poor knowledge does not necessarily lead to low adherence (Silcock and Standage 
2007). Studies investigating interventions to improve adherence have been unable to 
identify advantages in any one type of intervention (Schedlbauer et al 2004, Horne et 
al 2005). The provision of medically accurate information may improve knowledge 
but may not improve mood or perceived health status and therefore the patient’s own 
perspectives about stroke and their recovery. Preliminary studies of additional risk 
factor advice provision have produced disappointing results for lifestyle change 
 61 
following stroke (Townend et al 2006). It is therefore an important consideration to 
include individuals’ prior personal experience, beliefs, fears and perceptions prior to 
developing an intervention if it is to be successful for long term behavioural change. 
1.17 Illness perceptions and beliefs 
It is becoming increasingly recognised that a person’s perception of illness can affect 
how they react to change lifestyles and adhere to treatment prevention strategies to 
reduce the risk of recurrence of their illness. However, it is still not understood how 
best healthcare professionals can measure or influence perception to improve 
patients adherence to secondary prevention. The illness perception questionnaire 
(IPQ) (Weinman1996) is a theoretically derived measure comprising five scales to 
assess the cognitive representation of illness. The five scales assess, identity – the 
symptoms the patient associates with the illness, cause – personal ideas about the 
aetiology of the illness, time-line – the perceived duration of the illness, 
consequences – expected effects and outcome and cure control- how one controls 
or recovers from the illness (Weinman et al 1996). Understanding patients’ 
representations of their illness may be a useful tool to understanding the 
psychological impact of the illness and may help to influence behaviour change 
following stroke. The IPQ can be used as a framework and amended to include 
items which are specific to a particular illness or patient population which makes it a 
useful tool to study the stroke population.  In cardiac rehabilitation studies it has 
been shown that socio-demographic variables and beliefs about illness are related to 
the non-attendance at the programmes rather than medical variables (Cooper et al 
2007). Patients who were older, with lower incomes or who were more likely to deny 
the severity of their condition or believed they had little or low personal control over 
the cause of their heart condition were less likely to attend (Cooper et al 2007). It is 
reasonable then to suggest that what patients believe about their treatment and 
illness may strongly influence their adherence to the rehabilitation or prevention 
programmes designed for them.  
The health belief model and theory of planned behaviour are the two psychological 
theories which have been frequently used as the frameworks to examine health 
beliefs in the context of compliance (Ross et al 2004). Sullivan and Waugh (2007) 
used the health belief model as a framework to develop the CABS measure of stroke 
related health beliefs. It measures survivor’s beliefs and attitudes about their 
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susceptibility to future stroke, the perceived seriousness of stroke and likely benefits 
and barriers associated with undertaking behaviours to reduce stroke risk. Most 
participants in this small study (n=42) changed at least some behaviours post stoke 
to reduce their stroke risk which may be an indication that measuring perception 
inadvertently increases awareness and perception of risk, which in turn increases the 
likelihood of behaviour change taking place. Ross et al (2004) theorise that health 
beliefs not only predict compliance but that they may be more consistent in doing so 
than demographic variables which can vary widely. They propose that health beliefs 
mediate the relationship between demographic variables such as age and gender 
and compliance. Age, gender and other characteristics of a population may lead 
patients to have different health beliefs. It is also important to consider how receiving 
low risk information may affect a patient’s behaviour (Cooper 2007). Patients who 
receive information that their risk of future stroke or heart disease is low may 
negatively alter their behaviour falsely believing they have a lower than ‘normal’ risk 
for recurrence. 
1.18 Adherence 
Adherence is defined as the extent to which the patient’s behaviour matches the 
recommendations agreed with a prescriber (Horne et al 2005).  It assumes that there 
is a partnership between the patient and provider and that the patient is not simply a 
passive participant (Bushnell et al 2009) However, adherence is the result of a 
complex set of perceptions, attitudes, cognitive abilities, intentions and behaviours 
(O’Carroll et al 2010). Adherence to secondary prevention measures has been 
shown to reduce the risk of future vascular events, (Husted 2009, Horne 2005, 
Chaudhry & McDermott 2008) is associated with lower mortality and suboptimal 
adherence can reduce any positive effects from secondary prevention medications 
and strategies (Albert  2008). Despite this, non-adherence has been reported in over 
40% of patients taking maintenance therapies for such chronic diseases such as 
inflammatory bowel disease (Horne et al 2008) and several studies have identified 
poor adherence rates for antithrombotics, lipid lowering, antihypertensives and 
smoking cessation in stroke populations (Mouradian et al 2002, Hillen et al 2000). 
Nevertheless, the appropriate use of medication is key to the self-management of 
most chronic illnesses (Horne & Weinman 1999) and can significantly reduce the risk 
of secondary stroke (Husted 2009, Chaudhry & McDermott 2008, Rothwell 2007). 
The Duke Databank for Cardiovascular disease identified patients between 1995-
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2002 who self-reported use of Aspirin, β-Blockers, lipid lowering medications and a 
combination of all three drugs in patients with CAD (Newby et al 2006). The rates of 
self-reported use were reported as, Aspirin 71%, β-Blocker 46%, lipid lowering 
medications 44% and a combination of all three in only 21%. In this study they 
identified a lower adjusted mortality was associated with consistent use of the 
medications, however, they were unable to differentiate between patient non-
adherence and physician non-prescribing as the main cause of the low levels of self-
reported adherence (Newby et al 2006). Self-reported adherence to medications is 
often suboptimal (O’Carroll et al 2010) and is associated with elevated mortality 
(Albert 2008). 
Most non-adherence reports relate to negative attitudes to treatment (Phatak et al 
2006, Kane et al 2006, Horne et al 1999) and to the way in which patients judge their 
personal need for on-going medications (Horne et al 2008). Improving adherence to 
medications has the potential to have a major impact on cardiovascular disease 
prevention (Silcock & Standage 2007). The most current Cochrane systematic 
review of interventions to improve adherence to medications for chronic diseases 
concluded that “current methods to improve adherence for chronic health problems 
are mostly complex and not very effective so the full benefits of treatment cannot be 
realised” (Haynes et al 2008). They suggest high priority should be given to 
fundamental and applied research to assist patients to follow medications 
prescriptions for long-term medical disorders (Haynes et al 2008). 
Approaches that are physician focused and patient centred, such as frequent follow-
up and better education of patients about cardiovascular disease have been 
suggested (Chaudhry & McDermott 2009) as ways of improving adherence 
particularly in the management of hyperlipidaemia. More specifically, closer 
monitoring and greater attention is required by clinicians and a better understanding 
of the disease is required by patients (Chaudhry & McDermott 2009). However there 
is also evidence that many physicians fail to adhere to guidelines for treatment of 
patients with atherosclerosis (Husted 2009).  Potential reasons for this have been 
budget restrictions and access to treatments or concerns regarding excess bleeding 
particularly for anti-platelet treatment in the elderly population (Husted 2009). 
Patient’s perceptions about their need for medication may vary according to their 
underlying health beliefs and this is particularly so for asymptomatic conditions such 
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as hypertension and hyperlipidaemia (Horne et al 2005). Adherence figures for 
statins suggest that fewer than 50% of patients were still taking lipid-lowering therapy 
at 6 months after initiation (Jacobson 2004) and it’s been estimated between 30-50% 
of patients with hypertension regularly take their anti-hypertensive medications 
(Stephenson 1999, cited by O’Carroll et al 2010). Such long-term therapies for 
asymptomatic conditions, as well as the number of medicines taken are particularly 
associated with a lower adherence (Husted 2009).  
1.18.1 Measuring adherence 
Several measurement frameworks have been devised to measure patients’ 
adherence to medications in particular (Horne et al 1999), including the Beliefs about 
Medicines Questionnaire (BMQ) (Horne & Weinman 1999) and the Medication 
Adherence Report Scale (MARS-5) (Horne et al 2008). Horne et al (1997) initially 
proposed a theoretical framework to explain how beliefs may influence patients’ 
decision making about medication taking. The framework suggests adherence 
decisions are influenced by a cost-benefit assessment in which personal beliefs 
about the necessity of the medication for maintaining or improving health are 
balanced by the patient against concerns about the potential adverse effects of 
taking it (Horne & Weinman 1999). Several studies have highlighted the difficulties in 
measuring adherence e.g. the incidence of non-adherence to aspirin therapy may be 
underestimated by physicians (Shantsila and Lip 2008, Husted 2009). Measuring 
biochemical markers of inhibition of platelet aggregation (Husted 2009) in patients 
prescribed aspirin is one suggested technique to measure adherence but this is only 
relevant to a single aspect of identifying adherence compared with the totality of 
secondary preventative strategies. Measures used to assess medication adherence 
can be varied, however, the gold standard assessment of medication concordance is 
by electronic counting or pill-counting methods (Dunbar-Jacob et al 1996). 
Self-reporting by patients to measure adherence is a useful method but it has been 
argued that self-reported compliance is not accurate enough to justify its use. 
However, studies that have compared different types of measurement have found it 
useful (Choo et al 1999 & Di Matteo et al 2002). One author went as far as to 
suggest that self-reporting should be used in all studies of compliance (Choo et al 
1999). It is certainly the most economical and practical measure of adherence open 
to health professionals (Ross et al 2004) and may be a useful tool if used in 
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conjunction with more empirical measures. However, it is important to recognise the 
limitations of self-reporting as it is subject to self-presentational and recall biases. It 
has also been suggested patients may overestimate the extent of their adherence in 
an attempt to “please the doctor” or believe that admitting to non-adherence may 
result in adverse judgement or penalties (Horne & Weinman 1999) or may affect 
their ongoing care. 
1.18.2 Barriers to adherence 
The concept of ‘unintentional non-adherence’ has been described in chronic 
conditions (Horne et al 2008) and  stroke survivors (Silcock & Standage 2007) when 
patients are prevented from adhering to risk reduction strategies due to limitations 
caused by their stroke syndrome, such as physical or cognitive problems (Horne et 
al 2008, Silcock & Standage 2007). This is particularly problematic for all stroke 
patients however those with mild cognitive problems are at risk also as they tend to 
receive less support compared to those with severe cognitive problems. 
Muscle pain and pain interference with daily activities has been associated with non-
adherence to statin therapy (Chaudhry and McDermott 2008). The muscle-related 
symptoms or myopathies are adverse side-effects of statins and the fear of such has 
prompted some patients to discontinue medications. It is thought the myopathy may 
be related in part to statin inhibition of the endogenous synthesis of coenzyme Q10 
which is considered an essential cofactor for mitochondrial energy production 
(Chaudhry & McDermott 2008). Studies investigating patients with chronic diseases 
have suggested severity of illness, addictive behaviours such as smoking and 
alcohol use and the presence of psychosocial factors such as depression are also 
related to poor adherence (Osterberg and Blaschke 2005, Wu et al 2008). These 
factors are themselves common in stroke patients and may be a reason for high 
rates of non-adherence in this population.  
Recent evidence also implicates ethnic origin as a determinant of the type and level 
of health care received, suggesting that inequalities exist as a function of ethnic or 
social background. Very few studies have attempted to address this question. 
Pandian et al (2005) reported that awareness of stroke risk factors among high-risk 
individuals in India was poor and did not differ significantly from those respondents 
who had no risk factors at all. Moreover, even the medical profession underestimates 
risk with regard to ethnic minorities (Bourke et al 2006). Work from our group has 
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shown that such minorities are less likely to receive appropriate care following stroke 
compared to their white Caucasian counterparts (Bourke et al 2006), a similar finding 
was replicated by Jacobs et al (2006) in stroke and by Baljaran et al (1991) in heart 
disease. Teaching and training health professionals about risk and health care needs 
of ethnic minorities are severely lacking nationwide (Bentley et al 2008). 
1.18.3 Suggestions to improve adherence 
Benner et al (2004) found that patients who received a follow-up visit and a serum 
cholesterol test were 45% more likely to be adherent to statin medications than those 
who did not. In a recent population-based study 2 cohorts of patients were identified: 
those prescribed a statin and who were followed-up with subsequent cholesterol 
testing and upward titration of statin therapy to reach their target as necessary, and 
the second cohort who were prescribed the statin without any further follow-up (Wei 
et al 2007). Adherence to the statin in the patients with follow-up was found to be 
significantly better than those without. This suggests there is a clinical benefit to 
following these patients up and the health benefits in stroke/cardiac event prevention 
would outweigh costs incurred through clinical investigation and follow-up. Reviewing 
a patient’s medications list at each outpatient appointment can be time consuming 
but necessary to ensure medications are being taken (Chaudhry & McDermott 2008) 
and gives patients an opportunity to discuss any concerns regarding their 
medications with a health professional.  
Studies investigating interventions to improve adherence have been unable to 
identify advantages in any one type of intervention (Schedlbauer et al 2004, Horne et 
al 2005). The provision of medically accurate information may improve knowledge 
but may not improve mood or perceived health status and therefore the patient’s own 
perspectives about stroke and their recovery. Preliminary studies of additional risk 
factor advice provision have produced disappointing results for lifestyle change 
following stroke (Townend et al 2006). Studies have shown that patient education 
alone may not be sufficient to promote health behaviour change (Sullivan & Waugh 
2007). Knowledgeable patients do not always change their behaviour. Indeed, even 
improved patient knowledge has failed to guarantee higher levels of adherence 
supporting the opposite view that poor knowledge does not necessarily lead to low 
adherence (Silcock and Standage 2007). These studies show conflicting ideas 
relating to education and knowledge and their influence on adherence, suggesting 
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the possibility that knowledge itself has little impact on what makes humans behave 
in the healthiest way. However, in clinical practice it would be negligent to abstain 
from providing information regarding disease management and risk factor 
awareness, however, it might be useful for health professionals to be aware that 
information alone may not make a patient change their behaviour to reduce their risk 
or control their symptoms. 
1.18.4 Understanding risk as a means of improving adherence 
It is important for patients to have an understanding of their risk of future vascular 
events in order to improve adherence to therapeutic and life-style modifications in all 
ethnic groups (Samsa et al 1997, Muller-Nordhorn et al 2006, Dearborn & 
McCullough 2009). A lack of knowledge and understanding of risk of future events 
may affect attitudes to behaviour change following stroke. Social scientists argue 
that any behavioural change first requires understanding of the disease (Dearborn & 
McCullough 2009) e.g. educating and motivating patients to understand the benefits 
and risks of statin therapy may be an important step for ensuring the benefits of 
management cited in clinical trials are translated to the general population (Pearson 
& Kopin 2003).  In two studies of smokers’ perceptions of their chances of getting 
lung cancer, although in both studies the smokers rated their chances higher than 
non-smokers, they rated their own chances as only about average and in one study 
44% considered that smoking caused cancer but only for those whose daily 
consumption was higher than their own. This could be an indication of poor risk 
perception of lung disease in the presence of smoking and suggests unrealistic 
optimism regarding chances of getting a smoking related illness in this population 
(Repucci et al 2007 and Perett-Watel et al 2007). 
Although most studies have focussed on the general public, Samsa et al (1997) 
looked at the knowledge of risk of stroke among patients at increased risk and 
showed that only 42% of patients with a history of previous stroke were aware of 
their future stroke risk and as few as 27% recalled being informed of any risk by their 
physician. In 2001, Qureshi reported that only 35% of hypertensives were 
appropriately controlled and 50% of diabetics had adequate blood glucose control. 
Cholesterol was poorly controlled in 46% and 18% of individuals were still smoking 
cigarettes after their first stroke. This was supported by Crosquelois and 
Bogousslavsky (2006) who at 3 month follow up concluded that cerebrovascular risk 
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factor control was not optimal. They concluded that this may be related to poor 
patient awareness and knowledge and highlighted that older patients and patients 
who had made an excellent recovery were at particular risk of poor awareness and 
adherence to risk modifications.  
Samsa et al (1997) reported that respondents most likely to be aware of their stroke 
risk were younger as were those who reported their current health status as poor. 
Indeed, one year post stroke Redfern et al (2000) found 27% of patients still smoked 
(mostly young, white males), 36% were obese and 4% drank excessively. However, 
half of those who still smoked at 3 months had reduced the amount they smoked, 
suggesting that they were willing to change their risk factors but might have needed 
further support to give up completely. Sappok et al (2001) found that higher age, 
more severe neurological deficit on admission and a cardio-embolic cause were 
associated with better long-term compliance, however it is important to add that older 
age and severe neurological deficit suggest a need for more direct care which 
indicates further assistance is given with medication taking and lifestyle choices. 
Women and younger patients (< 75years) with heart failure are known to be less 
adherent than men and older people (Granger et al 2009). Conversely, Lip et al 
(2002) performed a study looking at ethnic differences in patient perceptions of AF 
and anticoagulation therapy found only 63% of patients aware of their cardiac 
condition, with South Asians and African Caribbean’s significantly less aware of AF 
compared to their European  counterparts (p<0.001). Worryingly, in this study 61% 
felt that AF was not a ‘serious’ condition and only 52% associated it as the reason for 
commencement on warfarin therapy.  
Dearborn and McCullough (2009) in a study of women at high risk of stroke found 
that they were often unable to identify their health condition as a risk factor for stroke 
and their risk perception was low. Women who were high-risk still perceived their risk 
to be the same as their peers. This continued lack of perceived risk and lack of 
knowledge of risk factors has considerable consequences for health professionals 
working with first time stroke survivors to ensure high risk individuals adhere to 
stroke prevention strategies.   
Vascular disease is a real risk to health in a huge population and patients with a 
history of vascular disease are at risk of further vascular events. Patients with stroke 
are at a particularly high risk of further stroke but secondary prevention strategies 
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can reduce that risk. However, despite studies to investigate stroke behaviours and 
theories which have identified strategies to study patient risk reduction behaviours, 
adherence to secondary prevention strategies in stroke patients is still 
disappointingly low and ineffective.  
1.19 Health literacy 
Adherence is influenced by low health literacy among patients (Colledge et al 2008). 
The WHO definition of health literacy is “the cognitive and social skills which 
determine the motivation and ability of individuals to gain access to understand and 
use information in ways which promote and maintain good health” (WHO 1998). 
Nutbeam (2000) describes 3 types of health literacy; 
Basic – implies a fundamental understanding of a health problem and the ability 
to comply with prescribed action to remedy the problem 
Functional – involves more advanced knowledge and skills to function in 
everyday society and the ability to seek out information in order to respond to 
changing needs. 
Critical – advanced level of health literacy implies a significant level of 
knowledge, personal skills and confidence to manage ones health and the ability 
to take action to change the determinants of health in the environment. 
Basic health literacy should be the aim for all members of society and ideally patients 
with chronic conditions should be supported to have critical health literacy in order to 
make the decisions needed for them to participate in their long-term health 
management. 
Health literacy is also defined as “the degree to which individuals have the capacity 
to obtain, process and understand basic health information and services for 
appropriate health decisions” by Healthy People 2010 (National Centre for Health 
Statistics 2010). Health illiteracy has been made a government priority in the US as 
reportedly 90 million Americans struggle to understand basic health information 
(Kirsch et al 1993). This is a major obstacle to providing high quality care, as long-
term and chronic diseases require self-management skills and the ability to negotiate 
complex treatments and health services. The British government identified their 
commitment to improving health literacy in the ‘saving lives: our healthier nation’ 
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policy (DH 1999). The policy identified a range of social determinants of health and 
inequalities in health with the identification and connection between educational 
status, literacy and health.  A health literate individual is likely to have sufficient 
knowledge and skills to handle the information demands of the health system, 
communicate with health professionals, make appropriate use of health services, 
and contribute to optimizing the management of their own disorders. Patients with 
good health literacy skills can also act as advisers and mentors for other patients 
with long-term diseases and thus help spread best practice and improve disease 
management. However, rates of non-compliance may be as high as 50% in chronic 
conditions (Ross et al 2004 & Dunbar-Jacob et al 2001). Non-adherence in chronic 
disease has been associated with misunderstanding of the condition, perceived 
improvement in health, worsening in health, general disapproval of medications and 
concern over side-effects (Dunbar-Jacob et al 2004 & Svensson et al 2000). 
Hypertensive patients are clearly an example of a chronic disease population at high 
risk of non-adherence as they generally have no symptoms and therefore may 
perceive no benefit in feelings of well-being associated with their medication and 
side-effects from medications for a condition which is asymptomatic may be 
unacceptable to some of these patients (Ross et al 2004). 
To patients, adherence may suggest the relief of symptoms and to providers more 
increasingly it may suggest the achievement of therapeutic goals and targets 
(Kennedy 2000), however adherence is not restricted to the act of taking 
medications, it is also related to the patient actively making changes in their lifestyle 
and behaviours such as smoking cessation, nutrition, and activities as well as 
attending medical appointments and making changes in response to new diagnosis 
and changes in their condition. 
1.20 Conclusions 
This thesis aims to go some way to increasing the body of knowledge to 
understanding risk awareness as a tool to improve secondary stroke prevention. An 
initial systematic review and meta-analysis was performed in order to gain a 
thorough understanding of risk of stroke in the presence of vascular disease. A 
systematic approach was taken to the literature review and search strategies were 
used when searching databases such as PubMed, Google scholar, Embase and 
Medline. Search terms such as ‘risk awareness in secondary prevention’, ‘stroke 
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prevention’, ‘stroke risk factors’ and ‘recurrence’, ‘adherence’, ‘health literacy’ and 
‘risk perception’ were all used to identify the literature. The literature identified in the 
review was used as a basis of information gathering and informed the general 
framework for the studies within this thesis.  
Several theoretical frameworks were identified in order to inform questions for a 
population based study (chapter 3) to understand knowledge of stroke, signs and 
symptoms, behaviours and risk perceptions in a high risk stroke survivor population. 
The Health Belief Model and The Illness Perceptions Questionnaire (IPQ) were the 
main theoretical frameworks used and modified for the development of the sections 
investigating patient perceptions of the causes, consequences and timelines of their 
condition.  
Chapter 4 describes a survey study of the general public population regarding their 
understanding of Blood Pressure. The participants were asked about their 
knowledge of blood pressure in order to understand whether awareness of BP 
affects control of BP in the healthy and hypertensive populations. Finally the 
knowledge gained from the previous studies described in chapters 1-4 informed a 
randomised controlled trial (RCT) aimed to identify if increased awareness of risk 
improves adherence to secondary prevention strategies and impacts on risk factor 
control as part of secondary stroke prevention.  
The literature used throughout this work has identified risk perception theories and 
adherence measures such as HBM, IPQ, BMQ, however, these measurement 
frameworks have not been used specifically in the RCT, and they informed the 
general direction of the work. Specific medication adherence to cardiovascular 
secondary prevention medication was not measured as part of the RCT and 
therefore the BMQ (Horne et al 1999) was not used, however the theoretical 
framework behind the measurement tool was useful in understanding the 
relationship between health beliefs and health behaviour. The literature surrounding 
health literacy, adherence and the perception of medicine beliefs questionnaire was 
useful in the development of the intervention for the RCT to understand how to 
influence patients’ behaviours and how best the researcher could communicate the 
intervention to the participant. In summarising the findings of the RCT the theoretical 
frameworks were useful during discussions surrounding human behaviour.   
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1.21 Chapter 1: Tables and Figures 
Figure 1.1: Risk of Stroke recurrence (Mohan et al 2011) 
 
Figure 1.1 shows the estimates of risk of stroke recurrence across all the included 
studies (Mohan et al 2011). The risk of stroke recurrence was reported to range from 
1.1% in South London, UK (Mohan et al 2009) to 15% in Oxfordshire, UK (Coull et al 
2004) by 1 month, from 7.0% in Lisbon, Portugal (Salgado et al 1996) to 20.6% in 
Nanjing, China (Xu et al 2007) by 1 year and from 16.2% in South London, UK 
(Mohan et al 2009) to 35.3% in Hisayama, Japan (Hata et al 2005) by 5 years; and 
from 14% in Rome, Italy (Prencipe et al 1998) to 51.3% in Hisayama, Japan (Hata et 
al 2005) by 10 years after initial stroke.  
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Chapter two: Silent brain infarction in the presence 
of systemic vascular disease: a systematic review 
and meta-analysis 
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2.1 Introduction 
It is now recognised that systemic vascular disease is part of a larger family of 
atherothrombotic diseases which are predicted to be the leading cause of death 
worldwide by 2020 (WHO 2011) However, despite receiving contemporary evidence-
based preventative drug therapy, patients with established arterial disease and those 
with multiple risk factors for atherothrombosis both experience high cardiovascular 
(CV) event rates (Steg et al 2007) and are at a high risk of secondary stroke. People 
with symptomatic atherosclerosis in 1 vascular bed are at a higher risk of 
subsequent events in other beds, e.g. patients who suffer a stroke are at a high risk 
of going on to suffer a coronary event, with a 10 year CV event risk of 42.8% 
(Barnett et al 2007). These findings support the need for increased awareness 
among physicians and patients for the amount of vascular cross-risk that is related to 
the overlap between the various beds of atherothrombosis.  
Stroke is the second most common manifestation of atherothrombotic vascular 
disease after coronary artery disease (Fuster and Moreno 2005). There is a need to 
identify and understand the risk factors and vascular disease risk markers for silent 
brain infarction, so that stratification of risk of an individual patient or population can 
be established (Gallego et al 2005). The aim of this study is to identify the 
prevalence of asymptomatic brain ischaemia in the presence of vascular disease in 
other locations to add to the field of knowledge. To highlight the importance of 
investigating and treating other vascular diseases in the presence of silent or 
asymptomatic cerebrovascular disease, this review will investigate studies which 
have identified the presence of silent brain infarction in the presence of coronary 
artery disease (CAD), peripheral vascular disease (PAD) and in acute ischaemic 
stroke. A number of studies have investigated and evaluated the relationship 
between stroke and MI, supporting the positive predictors for either event, yet shows 
varying results on the rate of subsequent cardiovascular events (Lichtman et al 2009 
and Witt et al 2006).  A previous meta-analysis synthesising the incidence of stroke 
after MI found 21.4 strokes occurred per 1000 MI at 1 year (Witt et al 2006).  
Conversely, there is an average annual incidence of 1% for MI after TIA (Burns et al 
2011), and a 2.2% annual risk has been shown through meta-analysis for MI after 
stroke/TIA (Touze et al 2005).  
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Ischaemic stroke occurs predominantly as the result of a complex accumulation of 
atherosclerotic plaque which ultimately results in an atherothrombotic occlusion of 
the large or small vessels, followed secondly by cardio embolic stroke and less 
frequently by venous thrombosis or hypo-perfusion. Coronary artery disease (CAD) 
encompasses both ischaemic heart disease (IHD) and acute coronary syndromes 
including ST or non-ST elevation myocardial infarction (MI) or unstable angina. This 
is usually due to ischaemia from vulnerable plaque or coronary thrombosis and less 
frequently embolism (Anderson et al 2011) 
Silent brain infarction (SBI) is an independent risk factor for stroke (Vermeer et al 
2003) and if risk of SBI in other vascular diseases can be established also, then 
appropriate assessment and therapeutic treatments could be initiated to reduce the 
incidence of stroke in this high risk population. SBI’s are known to be associated with 
a vascular origin and are reportedly seen frequently in asymptomatic elderly people 
(Longstreth et al 1996, Howard et al 1998, Vermeer et al 2002). Those with SBI are 
generally considered to be a high-risk group for clinical stroke. Several studies have 
examined the incidence of SBI and its relation to risk factors for stroke. Two recent 
studies (Vermeer et al 2003 and Bernick et al 2001) both found that risk of stroke 
increased 2-3 fold in the presence of SBI’s on MRI in an elderly population. Vermeer 
et al (2003) stated an absolute risk of stroke within 4 years was 11.7% for 
participants with SBI compared to 2.3% for those without SBI. The majority of these 
studies (Vermeer et al 2003) demonstrated that age and hypertension, strongly and 
independently correlated with SBI’s which would highlight an association with 
cerebrovascular disease as both age and hypertension are the largest modifiable 
risk factors for stroke.  Patients with stroke caused by atherosclerotic disease of the 
large artery have a higher risk than those with stroke caused by small vessel disease 
(Hara et al 1994). 
2.1.1 Silent brain infarction 
Silent brain infarcts by definition are asymptomatic and frequently go unnoticed, 
however the presence of silent infarcts can as much as double the risk of 
subsequent stroke. Vermeer et al (2007) suggest future studies should investigate 
whether screening and treating high risk patients can effectively reduce the risk of 
further infarcts and stroke.  
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Most SBI’s observed in acute stroke patients are small and deep (Ong et al 2009). 
Bokura (2008) found SBI to be the most significant independent risk factor for clinical 
stroke onset in a prospective cohort study. SBI was found in 380 of 2684 participants 
(14%). 102 subjects went on to have a clinical stroke (3.8%) during the follow-up 
period which suggests an increased risk of clinical stroke in patients with SBI. The 
Rotterdam scan study (Vermeer 2002), identified a prevalence of 20% of SBI in a 
normal healthy population aged 60-90 years. The prospective Rotterdam scan study 
showed that the presence of silent infarcts more than doubled the risk of dementia. 
Risk factors for SBI are considered to be comparable to those for stroke. The 
presence of SBI in stroke patients is associated with increasing age, hypertension, 
cigarette smoking, internal carotid artery stenosis and atrial fibrillation (Corea et al 
2001). 
The objectives of the study by Giele et al (2004) were to investigate the prevalence 
of silent infarcts in a high–risk population of patients with clinically manifest vascular 
diseases (coronary artery disease, peripheral vascular disease, abdominal aortic 
aneurysm (AAA) and to investigate its determinants. In this study patients with silent 
infarcts were older and more often had hypertension. Silent infarcts were found in 
17% (51) of the 308 patients included in the study (mean age 58.4 years). Giele 
(2004) concluded that patients with manifest vascular disease especially AAA, are at 
risk of silent infarcts at a younger age and identified significant risk factors for the 
presence of silent infarcts were age, hypertension, systolic and diastolic BP, AAA, 
elevated creatinine, renal failure, elevated homocysteine and increased Intimal 
Medial Thickness (IMT). 
The Rotterdam scan study (Vermeer et al 2002) showed of 1077 patients, 24% had 
1 or more infarcts on MRI, of these, 217 (20%) had only silent infarcts, 26 (2.4%) had 
symptomatic infarcts and 16 (1.5%) had both. The majority of silent brain infarcts are 
lacunar infarcts found in the basal ganglia, one third of the patients with symptomatic 
infarcts had cortical lesions.  Kobayashi et al (1997) go on to suggest a strong 
association of SBI with hypertension and suggests the underlying mechanism to be 
small vessel vasculopathy.  This study showed that subjects with SBI showed 
significant association for clinical subcortical stroke, hypertension, age, diabetes, 
alcohol habits and retinal artery sclerosis were significant and independent risk 
factors. Annual incidence of clinical stroke was higher in the subjects with SBI than in 
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those without focal lesions (10.1% versus 0.77%). Vermeer et al (2007) performed a 
systematic review of the frequency, causes and consequences of MRI-defined SBI’s. 
They examined 105 original papers which described the frequency, risk factors and 
consequences of silent brain infarcts detected on MRI imaging in a variety of adult 
populations.  
The Northern Manhattan Study (Prabhakaran et al 2008) found SBI prevalence 
increased with age (<65years: 9.7%, 65-75years: 16.4%, >75years: 26.1%), was 
increased among men (21.3% in men, 15.2% in women) and was increased 
amongst blacks (24% Vs 18.1 in Europeans and 15.8 in Hispanics). They concluded 
age, male sex and hypertension were independently associated with SBI.  
Hypertensive and Diabetic small vessel disease are thought to be the main causes 
of most infarcts which are found within the basal ganglia (Vermeer 2007). These 
Lacunar infarcts are small infarcts occurring in the deeper parts of the brain (Basal 
Ganglia, Thalamus, Brain stem). They are caused by occlusion of the deep 
penetrating branches of major cerebral arteries (Vermeer 2007). The association 
with hypertension and diabetes is due to severe atherosclerosis of the small vessels, 
known as small vessel disease. In hypertension and diabetes, these vessels become 
thickened, and the normal components of their walls are replaced by a 
homogeneous substance composed of collagen and other proteins (Agamanolis and 
Adams 2011). In hypertension, it is caused by endothelial injury and leakage of 
plasma proteins in and around vessels, in diabetes, it has to do with glycation of 
proteins and diffuse basement membrane thickening.  The overall effects are 
narrowing of the lumen and tortuosity, which lengthens the distance blood has to 
travel to perfuse its targets. Ischaemia resulting from these processes, causes small 
infarcts (lacunar infarcts) and diffuse loss of tissue density in the white matter 
(Agamanolis and Adams 2011). 
2.1.2 Silent brain infarction in healthy populations 
SBI have been found in healthy populations also and have been detected in 20% of 
healthy elderly populations and up to 50% in specific patient populations. The 
Rotterdam scan study (Vermeer et al 2002) found a prevalence of 20% of SBI in a 
normal, healthy population aged between 60-90years. The prevalence was strongly 
affected by age (Giele et al 2004) and increased from 8% in the participants aged 
60-64 years to 35% in the oldest group (85-90years). The Framingham offspring 
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cohort were investigated for SBI with no history of stroke or TIA and 10.7% had at 
least 1 SBI which were largely located in the basal ganglia (52%) (Das et al 2008). A 
population based autopsy series found that nearly 13% of asymptomatic subjects 
had pathological evidence of SBI (Shinkawa et al 1995). There is therefore, a need 
to identify and understand  risk factors and vascular disease risk markers for SBI, so 
that the stratification of risk of an individual patient or in a specific population can be 
established, appropriate cerebrovascular assessments conducted and appropriate 
therapeutic interventions initiated (Gallego J et al 2005). 
To detect silent infarcts, MR images were made in 308 participants of the Second 
Manifestations of ARTerial disease (SMART) study (mean age, 58 years) without 
prior stroke or transient ischemic attack (Giele et al 2004). These are patients 
referred because of atherosclerotic vascular disease. Silent infarcts were found in 51 
patients (17%). Most infarcts (62%) were located in white matter, 20% in the basal 
ganglia, 14% in the brain stem and cerebellum, and 4% in the cortical area. 
Categorical determinants for presence of silent infarct(s) that remained (borderline) 
significant after adjustment for age were hypertension (odds ratio [OR]=2.2; 95% CI, 
1.2 to 4.2), abdominal aortic aneurysm (OR=2.4; 95% CI, 0.9 to 6.4), severe renal 
failure (OR=7.3; 95% CI, 2.1 to 25.2), and hyperhomocysteinaemia (OR=2.6; 95% 
CI, 1.1 to 5.9).  
2.1.3 Impact on outcome in stroke patients 
Silent brain infarctions are thought to be associated with a higher mortality, however 
no significant difference in mortality has been found between two groups with and 
without SBI (p=0.26) (Ong et al 2009). Mortality has been shown to be related to the 
subtype of stroke and is higher in patients with cardio embolic and large artery 
atherosclerosis as opposed to reports that most SBI are small and located in small 
arteries in the subcortical areas. Ong et al (2009) found SBI did not influence 
functional or vital outcomes among acute stroke patients and outcome has not been 
affected in patients with and without SBI at 2 year follow-up (Corea et al 2000 and 
Minn et al 2005). 
2.1.4 Silent brain infarction in the presence of acute ischaemic stroke 
Silent brain infarction is a common finding in asymptomatic elderly populations 
(Vermeer et al 2002), however, the frequency of SBI found in patients with first 
ischemic stroke has been previously reported with large variations between 10-40% 
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(Brainin et al 1992, Chodosh et al 1988, Herderschel 1992 et al and Ricci et al 
1993). However, little is known about it as an independent risk associated with 
recurrent stroke or indeed its impact on stroke outcome in stroke survivors. Ong et al 
(2009) performed a study to evaluate the prevalence, risk factor and impact of SBI 
on the outcome of stroke patients. The frequency of SBI in the presence of first ever 
ischemic stroke or TIA was 20%.  This study confirmed the majority of SBI to be 
small and deep. They also identified age, hypertension, diabetes mellitus, 
hypercholesterolaemia, hypertriglyceridaemia, alcohol use, smoking habits and AF 
did not significantly differ between patients with or without SBI. The mortality rate 
was higher in the patients without SBI than those with. The study concluded that 
first-ever stroke patients with SBI should be considered at a high risk for recurrent 
stroke.  
2.1.5 Silent brain infarction in the presence of coronary artery disease 
Vascular disease is a systemic, diffuse condition involving the coronary and 
peripheral arteries and is the most common cause of death and disability worldwide 
Fuster and Moreno 2005). Ikram et al (2008), showed that both clinical and 
subclinical cerebrovascular disease have been shown to be closely associated with 
each other and share similar risk factors, silent Myocardial Infarction and silent brain 
infarction present in patients with dementia. Kurl et al (2003) performed a study 
investigating the association of exercise-induced silent ST-segment depression with 
the risk of stroke and cardiovascular diseases in men and found that silent 
myocardial ischaemia is an important indicator of increased risk of stroke. Men with 
silent ischaemia during exercise had a 2.2 fold increased risk of stroke and a 3.5 fold 
increased risk of cardiovascular death compared with men without silent ischaemia. 
Prosser et al (2007) suggested that in the first 3 months after acute stroke 2-6% of 
patients die from cardiac causes. They found that from 846 patients with ischaemic 
stroke, 35 (4.1%) died from cardiac causes and 161 (19%) suffered at least one 
serious cardiac adverse event (SCAE). 
It is well known that coronary artery disease and cerebrovascular disease (CVD) 
coexist and have similar risk factors. One third of patients with ischaemic stroke 
already have clinical manifestation of CAD such as angina or a history of ischaemic 
heart disease or myocardial infarction (Sandercock et al 1989). Alternatively CAD 
and ischaemic heart disease are well known as independent risk factors for 
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cerebrovascular disease (Pardo et al 1998). Patients with a history of ischaemic 
heart disease or coronary atherosclerosis have a higher risk for silent brain infarction 
than those who don’t (Tanaka et al 1993). CAD is the most common manifestation of 
atherothrombosis (Fuster and Moreno 2005) and therefore patients with CAD may 
have  increased risk of SBI, resulting in increased (2-3 fold) risk of stroke. This 
review identified studies which looked at populations with symptomatic coronary 
artery disease and investigated the relationship between CAD and the presence of 
SBI on either CT or MRI imaging.  Giele et al (2004) concluded that patients with 
manifest vascular disease are at risk of SBI at a younger age and Hoshide et al 
(2001) performed a study to clarify differences in the progression and characteristics 
of SBI in patients with CAD. They concluded SBI were more advanced in patient with 
multi-vessel CAD than in patients with hypertension alone. Coronary atherosclerosis 
was independently associated with SBI in these patients (Hoshide et al 2001). 
2.1.6 Silent brain infarction in the presence of peripheral artery disease 
Peripheral artery disease (PAD) is a common manifestation of arthrosclerosis 
affecting an estimated 27 million people in Europe and North America (Berger et al 
2009). PAD is associated with increased risk of cardiovascular events due to CAD 
and CVD. There is a 20-60% increased risk of MI, a two-six fold increased risk of 
cardiovascular death and a 40% increased risk of stroke in patients with PAD (Hirsch 
et al 2006). Antiplatelet therapy reduces the risk of MI, stroke and vascular death in 
patients with PAD (Cacoub et al 2005).The prevalence of PAD has increased from 
0.5% in 1970 to 3.6% in 2002 (Fuster and Moreno 2005). The outcome in the 
CHARISMA study (Berger et al 2009) for patients with asymptomatic or symptomatic 
PAD showed the overall rate of cardiovascular death, MI or stroke was 8.2% 
compared to 6.8% in patients without PAD during mean follow up of 27.6 months 
(Bhatt et al 2007). 
This systematic review and meta-analysis has been undertaken to identify the 
prevalence of silent brain infarction in the presence of acute ischaemic stroke, heart 
disease and peripheral artery disease, in order to attempt define the associated risk 
of future vascular events in the presence of silent brain infarction. The method of 
identifying and combining specific results from studies of SBI in the presence of 
systemic vascular diseases aims to summarize the existing evidence available from 
previous studies performed. 
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2.2 Aims and Objectives 
1. To perform a comprehensive systematic review of silent brain infarction in the 
presence of acute ischaemic stroke, coronary artery disease and peripheral 
artery disease as the 3 main aspects of vascular disease 
2. Summarize the existing evidence from previous studies performed. 
3. To undertake a meta-analysis and identify the prevalence of SBI in order to 
define the associated risk of future vascular events. 
2.3 Methodology  
Data Sources Studies dating from 1988-January 1st 2011 were identified through 
searches in PubMed, Google scholar, Embase and Medline. The following search 
terms were used in each search engine: “silent brain infarction in stroke” and/or 
“asymptomatic stroke and cerebral infarction” and/or  “silent cerebral infarction in 
stroke” and then separate searches were performed looking specifically at terms 
linking silent brain infarction with other vascular diseases locations, such as: “silent 
brain infarction in peripheral vascular disease”,  “silent brain infarction in coronary 
artery disease” and “silent brain infarction in vascular disease”.  The retrieved 
studies were examined thoroughly to assess their appropriateness for inclusion in 
the study. The references of all identified publications were manually reviewed for 
additional studies and the PUBMED ‘relevant articles’ function was used to ensure 
comprehensive use of this database. 
2.3.1 Meta-analysis 
Meta-analysis is the combination of results from multiple independent studies. The 
earliest specific example of meta-analysis as a tool to inform clinical practice was by 
Karl Pearson in 1904 when he looked at the effectiveness of Typhoid vaccines. 
There has always been a need and a desire for medical and clinical evidence to 
inform practice, however, evidence based research has increased more so in recent 
years and the use of meta-analysis has grown enormously (Sutton 2007). It is now 
been identified as the most cited type of research paper found in journals 
(Patsopoulos et al 2005). The process of systematic review which is usually 
undertaken in most studies does to some extent reduce bias due to selective 
inclusion of studies for analysis. Meta-analyses are generally undertaken for a 
variety of reasons, however, the broad aim is to summarize existing evidence but the 
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method can be used to inform specific decisions in clinical practice. The specific 
breakdown and explanation of analysis of this meta-analysis are described in-depth 
in section 2.4.1. 
This method has been selected to investigate the presence of SBI in systemic 
vascular disease as it involves reviewing all existing literature and summarizing it 
appropriately. This process provides a systematic approach to performing the 
research synthesis whilst being able to indicate where more research in the topic is 
necessary (Stroup et al 2000). 
2.3.2 Search strategy and selection criteria 
The search strategies identified thousands of studies relating to SBI in vascular 
disease (Figures 2.4, 2.5, 2.6). Reference lists were searched of relevant studies, 
resulting in another 17 for SBI in ischaemic stroke, 12 for SBI in coronary artery 
disease and 7 in SBI in peripheral artery disease. Studies were included if they were 
on patients with symptomatic stroke, peripheral artery disease and ischaemic heart 
disease. The studies included were published in English, had imaging using either 
CT or MRI. SBI lesions were recorded in some studies and defined in size between 
3-5mm in diameter. The cardiac studies used a variety of techniques to identify CAD 
such as ECG, SPECT, troponin, echo, scintography. As with studies using troponin 
as a measure of heart disease, Jespersen et al (2008) explain that a rise in cardiac 
troponin (cTn) is not necessarily due to coronary thrombosis as seen in patients with 
severe physical or mental stress which is often the case when someone is having or 
has just suffered a stroke and may not be an indication of CAD, therefore studies 
using troponin as a measure of CAD have been excluded from the analysis. 
2.3.3 Study selection 
Study selection was performed independently by two reviewers and disagreements 
were resolved by consensus and by the opinion of a third reviewer when necessary. 
Inclusion criteria included: (1) studies in populations of acute ischaemic stroke, 
coronary artery disease and peripheral artery disease; (2) studies where the 
presence of silent brain infarction was measured using CT and/or MRI imaging; (3) 
subjects were >18 years of age. Exclusion criteria included: (1) subjects were <18 
years age; (2) studies which focussed on populations with no history of any vascular 
disease; (3) studies where cases of stroke had a background of metabolic disease or 
other non-vascular origin. Tables 2.1, 2.2 and 2.3 provide detail about the studies 
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included in the meta-analysis including author, year, sample size, mean age (where 
listed in the studies) and percentage of SBI found in patients. 
2.4 Results 
2.4.1 Data extraction and analysis 
Data for analysis were extracted independently from each study by two reviewers, 
results compared, and disagreements resolved by consensus. The following 
information was extracted from each study: first author, journal, and year of 
publication, stroke sub-type, and the number of cases and evidence of SBI for each 
subgroup. Data was analysed using Review Manager v5.0.  For each paper a pooled 
odds ratio (OR) and 95% confidence interval (CI) was calculated using a fixed 
(Mantel-Haenszel) and random effects (Mantel-Haenszel) analysis model. The 
strength of presence of SBI versus no presence of SBI was considered statistically 
significant with an OR greater than 1 and p-value of <0.05. For each meta-analysis 
an I2 test for heterogeneity was performed, with significance set at p<0.05.  Visual 
funnel plot inspection and Egger regression intercept p-value (two-tailed) were 
performed to identify probability of publication bias. 
 
The meta-analysis was performed using excel and Review manager software 
systems. Three separate analyses were performed for silent brain infarction in the 
presence of AIS, CAD and PAD.  As this was a one-sided investigation without a 
comparison group, an arcsine transformation was used for the meta-analyses 
(Kulinskaya et al 2008).  This consists of taking the arcsine of the square root of a 
number. The square-root transformation is commonly used when the variable is a 
count of something as in this study, the variable is the count of SBI found in the 
different populations examined (McDonald 2009). Full formulae used for arcsine 
formatting are outlined in Appendix 1.  For each study, the percentage proportion of 
stroke patients who were positive for silent brain infarction from the total population 
of patients was recorded.  The standardised mean difference and standard error for 
each proportion was then calculated and the results combined using the generic 
inverse variance approach in Review Manager Version 5.1.1 (Cochrane 
Collaboration 2011). Pooled data was first analysed with a fixed-effects model and if 
heterogeneity was detected by T2 tests for heterogeneity, including visual inspection 
of forest plots, a random-effects model was used.  This produced a standardised 
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mean difference (SMD) with 95% confidence interval (CI) for each study and a 
pooled effect size for all studies with 95% CI that was weighted to the size of the 
individual studies.  The results are presented representing the prevalence of SBI in 
vascular patients is interpreted as a percentage (Kulinskaya et al 2008).  
2.4.2 Silent brain infarction in the presence of acute ischaemic stroke  
Figure 2.4 shows the PRISM statement and search strategy, including  all the 
studies identified in the course of the systematic review and reasons for inclusion 
and exclusion from the meta-analysis. Initial search produced 10487 potential 
studies. The majority of papers were excluded because they were not population 
specific, there was no measurement of SBI or SBI was measured in a non-stroke 
population (p=<0.01).   
The Forest plot in figure 2.1 suggests there is a relative risk of SBI in the presence of 
acute ischaemic stroke is 23% with a standard mean deviation of 0.99 (CI 95% 0.88 
- 1.10).  
2.4.3 Silent brain infarction in the presence of coronary artery disease 
Figure 2.5 shows the search strategy and reasons for inclusion and exclusion from 
the Meta analysis for the presence of SBI in patients with CAD.  Much exclusion was 
due to studies focussing on asymptomatic CAD in stroke patients, no relevant data 
or measurement of SBI, papers identifying risk factors for CAD or SBI and non-CAD 
populations. The final 11 papers were identified for the meta-analysis out of a total of 
nearly 600 which were identified in the search.  
The Forest plot in figure 2.2 suggests there is a 35% relative risk of SBI in patients 
with CAD with a standard mean difference of 1.26 (CI 95% 0.95, 1.58).  
2.4.4 Silent brain infarction in the presence of peripheral artery disease 
Figure 2.6 shows the search strategy and reasons for inclusion and exclusion from 
the meta-analysis for the presence of SBI in patients with PAD.  Much of the 
exclusion was due to studies focussing on asymptomatic PAD in stroke patients, no 
data or measurement of SBI in patients with PAD. From 162 papers only 2 papers 
were able to provide data of patient population numbers with a diagnosis of PAD and 
a measure of the presence of SBI observed in that population.  
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The Forest plot in figure 2.3 suggests there is a 14% relative risk of a patient with 
peripheral artery disease having silent brain infarction. The standard mean difference 
is 0.48 (CI 95% 0.42, 0.54). There is significant heterogeneity in the population 
(p=0.0002). 
2.5 Discussion 
This systematic review and meta-analysis provides an up-to-date understanding of 
the burden of SBI in vascular disease, as well as highlighting independent risk 
factors associated with SBI in asymptomatic populations. SBI significantly increases 
the risk of stroke in all vascular groups examined and is particularly high in patients 
with CAD (35%). This review confirms that age and hypertension are the most 
consistent determinants for SBI (Vermeer 2007, Giele et al 2004, Ong et al 2009), 
however systemic vascular disease including CAD, CVD and PAD share similar 
cardiovascular risk factors and the risk of suffering these diseases, increases with 
age, therefore increasing the risk of SBI in all populations. 
This study provides further evidence to concur that physicians need to approach all 
manifestations of atherothrombotic vascular disease whether clinically symptomatic 
or silent, as one pathologic entity that intermittently affects different vascular 
territories (Fuster and Moreno 2005). A global and aggressive approach to vascular 
disease control and management may result in appropriate risk stratification and 
therapy, reduction in future events and a better quality of life for patients. Patients 
with vascular disease are at risk of SBI at a younger age (Giele et al 2004), this is an 
important consideration for health professionals when instigating prevention 
strategies in this population and it should be suggested that thresholds should be 
reduced for commencing therapeutic regimes for the prevention of stroke.   
It is important to mention SBI appears frequently in relation to vascular dementia. As 
recurrent stroke is a known cause of vascular dementia and disability (Ong et al 
2009) it is important to associate SBI in stroke patients with an increased risk of 
dementia and poorer outcome. Although SBI does not produce neurological 
symptoms the risk of dementia is increased in a population with multiple SBI’s 
(Masuda et al 2001). Multi-infarct dementia (MID) is the second most common cause 
of dementia after Alzheimers disease (Brewer 2007).  
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MID is caused by a series of SBI which occur over time causing a gradual increase 
in brain damage which eventually presents as a series of symptoms: 
 Difficulty performing tasks that used to come easily, such as balancing a 
chequebook, playing games (such as bridge), and learning new information or 
routines 
 Getting lost on familiar routes 
 Language problems, such as trouble finding the name of familiar objects 
 Losing interest in things you previously enjoyed, flat mood 
 Misplacing items 
 Personality changes and loss of social skills 
The symptoms can present individually and the patient may improve in between 
occurrences but then worsen again in response to another SBI or they may go on to 
suffer a larger symptomatic stroke (Brewer 2007). 
Silent brain infarction also adds to the burden of risk for patients with symptomatic 
atherosclerosis. This study highlights another aspect of vascular disease which 
expands the level of risk for patients with vascular disease in one arterial bed as they 
are at risk of having silent brain infarction also. We know that patients who suffer a 
stroke are at a high risk of going on to suffer another stroke or heart attack, with a 10 
year risk of 42.8% (Jenkinson et al 2007). These reports have been supported by the 
findings from the REACH (REduction of Atherothrombosis for Continued Health) 
registry which evaluated the long term risk of atherothrombotic events in an at risk 
population. REACH has already demonstrated that a significant proportion of people 
with PAD, CVD or IHD will have disease in more than 1 vascular location. In 1 year 
follow-up 8.29% of patients with CVD went on to have a further vascular event while 
CV event rates increased significantly with the number of symptomatic locations 
(p=0.0043) (Morrell et al 2007). 40% of patients with CVD demonstrated multi-
vascular involvement with many of these affected beds being clinically silent yet 
ultimately exposing patients to increasing risk profiles with each bed involved. This 
study supports the risk of vascular disease as a multi-organ condition. 
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SBI is an independent risk factor for stroke and heart disease which are the most 
common manifestations of vascular disease. PAD is the most commonly under-
treated vascular disease and therefore, the need to stratify the risk of SBI in these 
diseases was important for the prevention of disease progression and management. 
SBI as an independent risk factor for stroke is key to management, however, 
prevalence of SBI identified in the populations examined was varied, the percentage 
of SBI found in the stroke studies varied from 14%-24%, in healthy, asymptomatic 
populations the prevalence varied from 8%-35%, increasing markedly with age. In 
CAD prevalence varied from 10%-55% and in PAD it was between 5%-21%. The 
study sizes and populations varied greatly, increasing the heterogeneity, however, 
SBI existed in all vascular manifestations examined and is therefore a real risk for 
patients with manifest vascular disease as well as the ageing population. 
Fortunately it seems the prognosis of stroke and outcome is not influenced by the 
presence of SBI (Brainin et al 1995, Jorgensen et al 1994), however, the risk of 
stroke for people with 1 or more silent infarcts does  increase by 2-10 fold during a 
mean follow-up time of 2-4 years (Giele et al 2004, Bernick et al 2001).  Therefore, 
patients with vascular disease are at an increased risk of SBI and are therefore at 
increased risk of stroke and dementia and subsequently should be treated with 
primary prevention therapies to reduce their risk of stroke and other vascular events. 
There was substantial heterogeneity found across all meta-analyses, although not 
entirely unexpected. Not only was there variation in the methods used to detect the 
symptomatic disease e.g. in some studies computed tomography (CT) has been 
used to diagnose stroke and in other studies they have used either CT or magnetic 
resonance imaging (MRI) for diagnosis of SBI. MRI is significantly superior in 
identifying cerebral infarcts than CT and therefore the studies may not be 
comparable. The variations in the cardiac studies for identifying CAD suggest these 
cohorts may also not be comparable. Also the size and location of acute ischaemic 
stroke may be varied and was not specified in some studies and therefore may not 
be comparable. It is possible, the difference in clinical and methodological diversity 
could explain the statistical heterogeneity found between the studies. Despite this, 
the use of a random-effects model provided a pooled estimate of the average effect 
of all the included studies. In addition, besides strict inclusion and exclusion criteria, 
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there were similar mean ages and proportion of males to females across all studies, 
allowing reliable comparison. 
To conclude this study highlights the risk associated with stroke in the presence of 
SBI in all vascular diseases studied. The literature within the review has also 
highlighted the presence of SBI more than doubles the risk of subsequent dementia. 
Screening and treating high-risk patients can effectively reduce the risk of further 
infarctions, stroke and dementia (Vermeer 2007). This meta-analysis quantifies the 
risk associated with silent brain infarction in the presence of other vascular diseases 
both peripheral artery disease, coronary artery disease and symptomatic 
cerebrovascular disease and therefore we can suggest patients presenting with any 
form of vascular disease should be treated as high risk for stroke and dementia. 
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2.6 Chapter 2: Tables and Figures 
Figure 2.1: SBI in the presence of acute ischaemic stroke 
SBI in stroke
 
 
 
 
 
 90 
Figure 2.2: SBI in the presence of coronary artery disease 
SBI in CAD
 
Figure 2.3: SBI in the presence of peripheral artery disease 
 
 
SBI in PAD
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Studies retrieved for more 
detailed evaluation (n=635) 
Studies excluded, with reasons 
(n=595) overview only, divided into 
subgroups and insufficient 
information to perform a meta-
analysis. 
Potentially appropriate 
studies to be included in the 
meta-analysis (n=40) 
Potentially relevant studies 
identified and screened for retrieval 
(n=10487) 
Studies included in meta-analysis 
(n=33) 
Studies with usable information, by 
outcome (n=19) 
Studies excluded, with reasons (n=14) 
Not enough useable information to use for 
a meta-analysis 
Figure 2.4: Search strategy flow chart - silent brain infarction in stroke 
Studies excluded, with 
reasons (n=9852). Papers 
excluded as not topic specific, 
sickle cell, metabolic 
syndrome, carotid artery 
surgery, AF, children, non-
stroke population, and kidney 
disease.  
Studies excluded, with reasons (n=7) 
Studies refer to patients with silent brain 
infarction in the healthy population or 
analysis is not useable for meta-analysis 
 92 
 
Studies excluded, with 
reasons (n=15000) non-stroke 
related, cardiac surgery, 
overviews of vascular disease, 
AF, other cardiac conditions 
unrelated to stroke, non- 
stroke population. 
Studies retrieved for more 
detailed evaluation (n=579) 
Potentially relevant studies 
identified and screened for retrieval 
(n=15579) 
Potentially appropriate studies 
to be included in the meta-analysis 
(n=66) 
Studies included in meta-
analysis (n=15) 
Studies with usable information, by 
outcome (n=11) 
Studies excluded, with reasons 
(n=51) unable to extract data for 
meta-analysis, no data available for 
meta-analysis, more asymptomatic 
CAD in the presence of stroke and 
PAD.  
Studies excluded, 
with reasons (n=4) 
Unable to use data for 
Meta analysis.  
Figure 2.5: Search strategy flow chart – silent brain infarction in coronary artery 
disease (CAD) 
Studies excluded, with 
reasons (n=513) 16 duplicates, 
symptomatic coronary artery 
disease in the presence of 
stroke, CAD in healthy 
populations. 
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Potentially relevant studies 
identified and screened for retrieval 
(n=147) 
Studies excluded, with 
reasons (n=112) overviews of 
vascular disease as a risk 
factor for stroke, no figures, 
silent PAD in the presence of 
stroke 
Figure 2.6: Search strategy flow chart – silent brain infarction in peripheral artery 
disease (PAD) 
Potentially appropriate 
studies to be included in the 
meta-analysis (n=12) 
Studies included in meta-
analysis (n=11) 
Studies with usable information, 
by outcome (n=2) 
Studies excluded, with 
reasons (n=1) difficult to 
extract any data 
Studies excluded, with 
reasons (n=9) Data not 
collected for silent brain 
infarction, data collected for 
silent PAD in the presence 
of stroke. 
Studies excluded, with reasons 
(n=23) ankle brachial pressures as a 
predictor of risk, screening for risk of 
stroke but no imaging.  
Studies retrieved for more 
detailed evaluation (n=35) 
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Table 2.1.  Silent brain infarction in acute ischaemic stroke. 
Study 
 
Study population – SBI in AIS 
 
n 
Mean age 
range 
years 
 
% 
Boon A et al 
(1994) 
Silent brain infarcts in 755 consecutive patients 
with first ever supratentorial stroke 
755 71 27 
Brainin A et 
al (1995) 
Silent brain infarcts and TIA: a 3 year study of 
first ever ischemic stroke patients 
728 68±10 11 
Chodosh et 
al (1988) Silent stroke in the NINCDS stroke data bank 
1203 69.1 11 
Corea F et 
al (2001) 
Silent infarcts in stroke patients: patient 
characteristics and effect on 2 year outcome 
202 70.05 25.7 
Corea F et 
al (2002) 
Brain CT scan in acute stroke patients: silent 
infarcts and relation to outcome 
191 76 37.8 
Coutts SB et 
al (2005) 
Silent ischemia in minor stroke and TA 
patients identified on MR imaging 
143 - 9.8 
Davis PH et 
al (1996) 
Silent cerebral infarction in patients enrolled in 
the TOAST study. 
629 65 22.7 
Giele JLP et 
al (2004) 
Silent cerebral infarctions in patients with 
manifest vascular disease 
308 58 17 
Herderschee 
D et al 
(1992) 
Silent stroke in patients with TIA or minor 
ischemic stroke 
2329 - 13 
Jorgensen 
et al (1994) Silent infarction in acute stroke patients 
322 73±12 32.5 
Kang DW et 
al (2006) 
Silent ischemic lesion recurrence on MRI 
predicts subsequent clinical vascular events 104 
- 33.7 
Kase CS et 
al (1989) 
Prevalence of silent stroke in patients 
presenting with initial stroke: the Framingham 
study 
124 46 10 
Liebetrau 
(2004) 
Silent and symptomatic infarcts on cranial 
computerized tomography in relation to 
dementia and mortality 
239 85 8.6 
 
Minn UK et 
al (2005) 
Significance of silent infarcts in acute 
ischaemic stroke patients aged 80 years and 
older 
50 >=80 76 
Oh SH et al 
The prevalence and risk factor analysis of 
silent brain infarction in patients with first-ever 
395 63.8 33.4 
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Study 
 
Study population – SBI in AIS 
 
n 
Mean age 
range 
years 
 
% 
(2010) ischemic stroke 
Ong CT et al 
(2009) 
Impact of silent infarction on the outcome of 
stroke patients 
226 68±13 20 
Ricci S et al 
(1993) 
Silent brain infarctions in patients with first-ever 
stroke. A community based study in Umbria, 
Italy 
209 71 38.3 
Vermeer S 
et al (2002) 
Prevalence and risk factors of silent brain 
infarcts in the population-based Rotterdam 
Scan Study 
1077 75 24 
Vermeer et 
al (2003) 
Silent brain infarcts and white matter lesions 
increase stroke risks in the general population: 
The Rotterdam scan study 
668 71±7 14 
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Table 2.2: Silent brain infarction in coronary artery disease 
 
Study 
 
Study population  - SBI in CAD 
 
n 
Mean age 
range 
years 
 
% 
Geerlings et 
al (2010) 
Brain volumes and cerebrovascular lesions on 
MRI in patients with atherosclerotic disease. 
The SMART study.  
1044 58±10 10 
Giele et al 
(2004) 
Silent brain infarcts in patients with manifest 
vascular disease.  
308 18-79 17 
Hara et al 
(1994) 
Silent cerebral infarction associated with 
coronary artery disease.  
50 - 80 
Hoshide et al 
(2001) 
Different patterns of silent cerebral infarct in 
patients with coronary artery disease or 
hypertension.  
107 62 46 
Kozdag et al 
(2008) 
Silent cerebral infarction in chronic heart 
failure: ischemic and non-ischemic dilated 
cardiomyopathy.  
72 50-74 39 
Nadareishvili 
et al (1999) 
Cerebral micro embolism in acute myocardial 
infarction. Stroke.  
112 68±11 15 
Ozeren A et 
al (1998) 
Silent cerebral lesions on magnetic resonance 
imaging in subjects with coronary artery 
disease.  
72 - 43 
Pardo PFM 
et al (1998) 
Silent brain infarctions in patients with coronary 
heart diseases. A Spanish population survey.  
100 34-82 30 
Selvetella G 
et al (2003) 
Left ventricular hypertrophy is associated with 
asymptomatic cerebral damage in 
hypertensive patients.  
195 67±1 55 
Siachos et al 
(2005) Silent stroke in patients with heart failure.  
117 51 34 
Uekita et al 
(2003) 
Cervical and intracranial atherosclerosis and 
silent brain infarction in Japanese patients with 
coronary artery disease.  133 
- 58 
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Table 2.3: Silent brain infarction in peripheral artery disease 
Study 
 
 
Study population – SBI in PAD 
 
n 
Mean age 
range 
years 
 
% 
Geerlings et 
al 2010 
Brain volumes and cerebrovascular lesions on 
MRI in patients with atherosclerotic disease. 
The SMART-MR study. 
1044 58±10 5 
Giele et al 
2004 
Silent brain infarcts in patients with manifest 
vascular disease.  
58 18-79 21 
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Chapter three: Knowledge of stroke and risk 
perception in a stroke population. 
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3.1 Introduction 
Recurrence of stroke carries an increased risk of death, additional disability and/or 
dependence on health care (Jorgensen et al 1997). Long-term determinants of 
survival and risk of vascular events following minor ischaemic stroke or TIA have 
been studied and approximately 10 years after a first event 54% of participants had 
experienced at least 1 new vascular event (Van Wijk et al 2005). Of the 130,000 
annual new stroke occurrences in the UK this year, one third will go on to have a 
further stroke. Therefore improving secondary stroke prevention is a fundamental 
challenge for health providers. It is well known that risk factor control can reduce 
morbidity and mortality and improve survival (Chaudhry et al 2008).  However, 
studies have shown that secondary risk factor management is not optimal (Qureshi 
2001, Chaudhry et al 2008). In reality fewer than 20% of patients with cardiovascular 
disease are reaching their target lipid levels (Chaudhry et al 2008) despite clear 
recommendations that implementation and adherence to secondary risk reduction 
strategies are important for reducing the risk of recurrent stroke (RCP 2008).  At 
least 2 to 3 years of consistent LDL cholesterol lowering are needed to see 
significant reduction in CVD events and atheroma burden (Goldenberg & Glueck, 
2009). Patient non-adherence is suggested as one of the reasons for this, however, 
a greater understanding of what people understand about their stroke and how they 
perceive their risk of having a further stroke,  may provide information which can 
enable health professionals to  develop interventions to improve adherence to 
secondary prevention.   
Comprehensive approaches to the control of cardiovascular diseases have resulted 
in a 60% decline in mortality rates over a 25-year period (WHO 2002), however, 
despite the general trend in reduction in stroke occurrence globally, the ageing 
population in the West continues to challenge healthcare due to the strong 
relationship between increasing age and stroke incidence (Asplund et al 2009). 
Low knowledge of risk factors and warning signs in high risk patients and the general 
public have been well documented in large scale surveys (Pancioli et al 1998, Sug 
Yoon et al 2001, Schneider et al 2003, Kraywinkel 2007). Dearborn et al (2001) 
found knowledge of warning signs is lacking in many at-risk populations, however, 
Kraywinkel et al (2007) found knowledge of a risk factor was higher in those affected 
by it, but Dearborn and McCullough (2001) found conflicting results in their cohort as 
patients with AF and carotid stenosis did not identify those conditions as risk factors 
for stroke. They also reported there remains confusion between stroke and heart 
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attack knowledge as women identified chest pain as a warning sign for stroke, 
however stroke knowledge did not predict risk perception suggesting risk perception 
is a separate entity to knowledge and may not be affected by educational level or 
social status. A review of 15 studies of knowledge of stroke warning signs and risk 
factors in low and high risk populations (Nicol and Thrift 2005) showed a generally 
low knowledge in both populations. Using free re-call between 20%-30% could not 
name a single risk factor for stroke. Poor knowledge was associated with lower 
education level and older age, similar to other studies (Kraywinkel et al 2007, Samsa 
et al 1997).  
There is still debate that individual healthcare professionals are responsible for the 
education of patients in a format which aids understanding, pitched at a level to 
optimise the transfer of information regarding level of risk and the need for lifestyle 
behaviour changes and adherence to medical interventions (Rothwell 2007), 
however more work is needed to identify the best strategies to provide the most 
accurate and effective education and information to patients which can positively 
affect their behaviour post-stroke. Increasing our understanding of stroke survivor’s 
knowledge of stroke and perceptions of risk, may provide us with more information 
about behaviour and insight about adherence to secondary prevention strategies 
after stroke.  
The health belief model proposes that patients weigh up a health-related behaviour, 
such as adherence, by considering their perceived susceptibility to an illness and the 
seriousness of the illness, as well as the benefits of the action. The model includes 
the concept of barriers to performing an action and cues which might prompt it. The 
theory of planned behaviour, on the other hand, describes action as secondary to 
intention. In turn, intention is derived from attitude, perceived control over the 
behaviour and the views of others. The self-regulatory model is a useful model in 
assessing specific health beliefs and how they influence medication-taking behaviour 
in particular. The self-regulatory model proposes that health related behaviour is 
strongly influenced by ideas around certain themes (termed illness representations). 
There are five themes: identity, time-line, cause, consequences and cure/control. 
Beliefs about these components of illness determine coping strategies. Compliance 
is regarded as a specific problem focused coping strategy; patients weigh up 
whether the proposed treatment is in line with what they believe about their illness in 
order to decide whether or not to comply with it. Patients will also assess the 
success of their treatment and may not continue with it if they perceive it to be 
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unsuccessful. Many studies have considered one or two aspects of the model, but 
few have examined the whole picture. The production of a new questionnaire allows 
for a more complete assessment. Since the publication of the Illness Perception 
Questionnaire (IPQ-R), a number of studies have utilised it to look at a range of 
diseases. Horne and Weinman (1999) have proposed that beliefs about treatment 
are also important and can be added into this model.   
It has been suggested that there is a gradual rise in risk of recurrence after the 3 
year period following stroke and one of the suggested reasons for this has been the 
possible decline in drug compliance and reduced attention to lifestyle factors in 
follow-up (Van Wijk et al 2005). It has also been suggested that follow-up is 
markedly reduced at three years, however, further research should be performed to 
look at assessment and care patterns for secondary prevention to determine 
whether there are gaps between actual care and the evidence based 
recommendations (Vickrey et al 2002). Young stroke survivors are an interesting 
population to focus on due to their long-term risk of stroke from the perspective of an 
aging population.  They will need their risk factors modified and controlled for a 
longer period of time bearing in mind the increased risk as they age. 
This study aims to gain an understanding of stroke survivor’s knowledge of stroke 
and their perception of their risk of further stroke and heart disease and how this 
knowledge and understanding affects their behaviours post stroke, including how 
they adhere to lifestyle changes and medication taking. Studies have shown that the 
provision of information may improve knowledge but has not been found to improve 
perceived health status (Rodgers et al 2001, Forster 2001) therefore, more 
information is required to understand stroke survivor’s perception of their illness with 
particular attention to their understanding of risk. It has been suggested that patient’s 
own perspectives about stroke illness and recovery are important as they may 
influence emotional adjustment and adherence to medical recommendations 
(Townend et al 2006). Through gaining a more thorough knowledge of stroke 
survivor’s behaviours after stroke it might be useful to predict how other, future 
stroke survivors will adhere to the secondary prevention advice after stroke.  
3.2 Aims and objectives 
1. To investigate stroke survivors’ knowledge of stroke, risk factors, signs 
and symptoms and causes of stroke 
2. To identify stroke survivors’ understanding of risk and its influence on their life 
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3. To identify stroke survivors’ perceptions of their risk of future stroke and 
other vascular events. 
4. To identify if any particular finding influences stroke survivors  
behaviours post-stroke which improve their adherence to secondary stroke 
prevention. 
3.3 Methodology 
A detailed, face-validated questionnaire (Appendix 2) containing 57 questions 
divided into 4 sections was sent to members of a stroke survivor’s charity. The aim of 
the questionnaire was to gain insight and understanding into stroke survivor’s 
knowledge of stroke and risk factors and perception of their risk of future stroke and 
heart disease. With this insight it was an important aim to generate questions to  
identify the behaviours of this population to ascertain if knowledge of stroke and 
perceptions of causes and consequences affect behaviours after stroke. Theories 
from the health belief model, theory of planned behaviour and the IPQ-R were all 
used to generate items for the questionnaire. The frameworks were used to inform 
the methodology of this study and the questionnaire in order to ask the right 
questions to get the most useful answers. Perception was measured using aspects 
of the illness perception questionnaire (IPQ) (Weinman et al 1996) to identify the 
participants perceptions of the causes, consequences and a combination of time-line 
and cure-control were used to develop section 2 of the questionnaire (Appendix 2). 
The study used qualitative, quantitative and longitudinal designs to gain a breadth of 
knowledge from the cohort. A combination of styles were used in the questionnaire 
including open and closed-ended questions. Open-ended questions provide the 
resarcher with the most accurate estimation of the partiicpants knowledge, 
understanding or perception through the use of free re-call, however these questions 
produce large volumes of text which can be difficult and time-consuming to compile 
and analyse. Mulitiple choice closed-ended questions are simpler to analyse 
however the act of asking the question and providing a list of possible answers may 
influence the participants responses. Therefore a combination of the two questions 
styles was used. The questions were divided in to four main sections; (1) General 
information and demographics, (2) stroke knowledge and perception of illness, 
consequences and recovery, (3) experience of stroke and understanding of 
prevention (4) perception of risk of future stroke and heart disease. 
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The host charity took responsibility for the distribution of the questionnaires to their 
members, this secured anonymity of the participants from the researcher. The 
questionnaire contains no identifiable data. The questionnaire was delivered to 
approx. 2,000 active members on the charity database in both paper format and to 
those who were members electronically, the questionnaire (Appendix 2) was 
formatted into a pdf to enable them to complete and return the questionnaire 
electronically. The questionnaires were only sent out once and a deadline was given 
for return of completed questionnaires.  
Ethical approval was granted by Hammersmith and Queen Charlotte’s & Chelsea 
Research Ethics Committee. 
Content face validity was produced via a pilot study using 20 individual volunteers 
with a history of stroke in order to gain feedback on the design and question content. 
Relevant healthcare professionals were also consulted including medical, nursing 
and allied health professionals who were all specialists in stroke patient care. 
Subsequent validity and reliability testing took place in approximately 100 
participants Test-retest reliability was undertaken using volunteers who were given 
two questionnaires, two weeks apart and correlation between the sub-scales was 
assessed. Subscale reliability was achieved using Cronbach alpha (0 - unreliable, 1 
– perfect reliability) which was examined within each relevant section/sub-scale. 
Construct validity was achieved through a comparison of questionnaire scores using 
an alternative questionnaire successfully utilised in a previous study which explored 
the impact of social and cultural influences upon perceptions of cardiovascular risk 
and long term lifestyle changes amongst first time MI patients (Murray et al 2000).  
Discriminant validity used comparison of scores on perception and knowledge of risk 
of secondary cardiovascular events sub-scales taken between those participants 
who engaged in some degree of secondary prevention measures and those who did 
not. The data obtained from the validation study was used to identify any problems 
with the questions and was also used to test the method of analysis for the main 
data set to identify any potential problems (McGibbon 1997).     
In response to the pilot, one question was removed as it elicited the same response 
as a previous question and some terminology was altered to ensure the question 
was understandable by the respondent. The pilot group were also asked to feed 
back on the length of time the questionnaire took to complete to ensure it was not 
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too time-consuming. The feedback was that it took approximately 10-12 minutes to 
complete and this was felt an acceptable amount of time to elicit a response. 
Sample size is a particularly important consideration in population-based research 
(Nicol and Thrift 2005) as large numbers are needed to achieve adequate power. 
Therefore every effort was made to support the contribution and advertisement of 
this study to the members of the charity, however, electronic membership can be 
elusive and effective communication difficult to achieve despite support and 
enthusiasm from the administrators of the database for the charity. 
3.4 Analysis 
Over a two month period, a 31% response rate was achieved with over 600 
responses received (n=626). Once the majority of expected questionnaires had been 
received, data was entered into Excel and 10% of questionnaires (60) were checked 
by an independent researcher to evaluate inter-rater reliability. Inter-rater 
discrepancy occurred in less than 1% of data-sheet entries.  
Data generated from the closed questions was subjected to analysis using Excel and 
SPSS software. Multivariate analysis was used to identify which measures effect 
outcome. Bivariate associations between patient characteristics and behavioural risk 
factors were analyszed with chi-square tests.  
3.5 Results 
Analysis was performed on 622 responses aged 18-91 (mean age 55.4 years old; 
309 males, 313 females). The overall gender specifics of the members of the charity 
was not available and it is therefore unknown if this is representative of the 
membership, however the equal numbers of male and female participants offers an 
equal distribution for this study. Four of the responses were excluded because they 
were completed by the mothers of young children with stroke. Table 3.1 summarizes 
the demographic characteristics of the population studied. The majority of 
respondents were Caucasian, of white European descent (n=556) and educated to 
secondary school and university level (76%). Subtype of stroke was self-reported as 
mainly ischaemic (n=316) with the majority (67%) having had their event more than 5 
years previously (n=419).  
 
 
105 
3.5.1 Knowledge of stroke and heart attack 
Knowledge of stroke and heart attack was demonstrated through free text responses 
(Q2.1-Q2.5). The respondents described stroke cause as due to clots (41%), 
blockages (10%) or bleeding (29%) in the brain (72%). Heart attacks were described 
as painful (26%) and blockages (16%) in the heart (69%). Most reported receiving 
health information from a professional (77%) following their stroke. Many thought 
they had a good knowledge of their cause of stroke (65%) while 72% thought they 
had a good understanding of how to prevent a further stroke. 70% of the 
respondents feared having another stroke, although 74% of the respondent’s 
reported that they were unaware of ‘having a stroke’ at the time of the event.  
3.5.2 Self-reported vascular risk factors 
A diagnosis of hypertension was self-reported in over half (52%) of the population, 
diabetes in 11%, ischaemic heart disease in 14%, peripheral artery disease in 14% 
and renal disease in 4%. Smoking was self-reported in 9% (Table 3.2). 
3.5.3 Hypertension 
Over half of the population (52%) self-reported a diagnosis of hypertension. Of the 
hypertensive population 43% documented taking prescribed anti-hypertensive 
medications in the appropriate section. 83% of the hypertensive population 
accurately described taking antihypertensive medication as a form of stroke 
prevention; however, 17% did not associate anti-hypertensive medication with stroke 
prevention.  Interestingly, 60% of the haemorrhagic stroke survivors self-reported a 
diagnosis of hypertension.  
3.5.4 Smokers 
Of the total population 9% (n=55) continue to smoke following their stroke. When 
asked directly only 19% of the ex-smokers reported that they gave up smoking in 
response to their stroke. Almost half of the smokers (n=25) reported that giving up 
smoking should be part of a secondary stroke prevention strategy despite continuing 
to smoke. 
3.5.5 Knowledge of risk factors  
The participants were asked to name, using free re-call, the risk factors they believed 
caused stroke and 48% of the respondents named both smoking and blood pressure 
as risk factors for stroke respectively. Stress was named as the next highest risk 
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factor with 35% of the respondents. Overweight, cholesterol and diet were also 
named as risk factors, 21%, 23%, and 18% respectively. (Figure 3.1)  
Behaviours were unaffected by knowledge of stroke risk factors as opposed to 
awareness of secondary stroke risk. Analysis showed that those who named more 
than 3 risk factors for stroke (41%) were equally likely to make the same amount of 
behavioural changes as those who named 3 or less risk factors, 35% and 29% 
respectively.  
3.5.6 Knowledge of stroke signs and symptoms 
Symptom knowledge was measured using the FAST terminology (DH, 2009). One 
point being assigned each time Face, Arm or Limb or Speech was mentioned. When 
asked about their knowledge of signs and symptoms of stroke only 3.5% of the total 
population used the term FAST in relation to signs and symptoms. 34% did not 
mention any of the FAST signs or symptoms, 26% mentioned one, 26% mentioned 
two and only 14% mentioned all three of the FAST signs. There was no difference 
between gender in the use of FAST terms in describing signs and symptoms (Figure 
3.2). A variety of terms were used to describe stroke signs and symptoms, including 
some which are not commonly associated with stroke such as pain, loss of 
consciousness and nausea. 
3.5.7 Illness perception 
Illness perception was measured using a five-point (1-5) scale ranging from ‘strongly 
agree (1) to strongly disagree’ (5) in response to statements which focussed on 
causes, consequences and future recovery from their stroke. Tables 3.4, 3.5 and 3.6 
give the ‘rating of agreement’ median scores for the participant’s perceptions of their 
stroke including aspects of the illness perception questionnaire to understand more 
about aspects of the cause, consequences and future recovery from their stroke.   
Overall, the population disagreed in the majority that a germ, virus or pollution 
caused their stroke (84% and 80%, respectively) (Table 3.4). However, almost half of 
the participants (44%) agreed with the statement; “it was just by chance that I had a 
stroke”. Stress was mentioned frequently in the responses as playing a role in the 
causation of stroke, 35% identified ‘stress’ as a risk factor for stroke and another 
51% agreed with the statement, “Stress was a major factor in causing my stroke”. 
Interestingly, over half (51%) of these participants self-reported a diagnosis of 
hypertension. 30% of those who quoted stress as a risk factor for stroke were unable 
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to give one of the signs or symptoms for stroke (Face, Arm, Limb or Speech) used in 
the FAST campaign when asked to give a free text response (Figure 3.2). 
The majority went on to agree that stroke is a serious condition which has a major 
consequence (Table 3.5) on the participant’s life (90%) and that stroke has strongly 
affected the way the participant and others see them (61%). Two thirds (60%) of the 
participants agreed that their stroke had had serious economic and financial 
consequences (Table 3.5), this is significant for a younger population with the 
average age still a working age (median age 55 years). 
Overall, the responses show a positive cohort who believe their stroke will improve in 
time (44%) and there is a lot they can do to control their symptoms (53%) and the 
same agree that treatment will be effective in preventing another stroke (Table 3.6). 
However, the results are not overwhelmingly positive and almost a quarter (22%) 
believed that recovery from their stroke was largely dependent on chance or fate. 
(Table 3.6) 
When asked, 70% of the respondents said they feared having another stroke, 
however only 41% believed they were at risk of a future event, nevertheless a 
massive  74% of the respondent’s reported they were unaware that they were 
‘having a stroke’ at the time of the event.  
3.5.8 Risk Perception 
Respondents were asked if they had been diagnosed with any of the established 
vascular risk factors for stroke such as hypertension, diabetes, ischaemic heart 
disease, peripheral vascular disease and/or renal disease; over half of all 
respondents self-reported a diagnosis of hypertension (Table 3.2). Analysis was 
performed looking at whether the people who self-reported a diagnosis of a risk 
factor accurately responded positively to having a risk factor later on in the 
questionnaire, almost half (45%) denied having a recognised risk factor for stroke.  
Over half (54%) identified that they were more likely to have a further stroke or heart 
attack compared with other possibilities such as winning the lottery or getting run 
over by a bus. This question was added to ensure the majority of the population 
were able to understand a basic level of their risk of stroke. 84% of 18-75 age group 
of the population were able to correctly calculate a percentage question in order to 
assess their ability to calculate risk.   
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3.5.9 Lifestyle changes since stroke 
Personal risk awareness appears to influence life-style changes after stroke as  
those who didn’t think they were at risk were more likely to make no changes at all in 
response to their stroke (P=0.02) (Figure 3.3).  
Lifestyle changes were not influenced by education level or gender. The number of 
lifestyle changes made by each participant was disappointing with only 1% making 
all seven lifestyle changes (Figure 3.4). The participants were given a choice of 
lifestyle changes to choose from and they could select either none or all seven 
changes. However, 19% of the participants admitted making no lifestyle changes 
since their stroke. A small number of 9% (n=55) were still smoking and 18% gave up 
smoking in response to suffering a stroke. 43% have started a low fat diet since their 
stroke, 51% eat less salt, 43% eat more fruit and vegetables and 40% take more 
exercise. However 19% made no lifestyle changes at all since their stroke. Also 36% 
and 27% have taken less alcohol and lost weight since their stroke respectively.   
Behaviour was not influenced by the length of time since stroke. There were no 
differences in the type or amount of lifestyle changes made depending on whether 
the stroke had been less than 1 or more than 5 years ago. The cohort is well 
educated with 77% being educated to secondary school level and above.  
3.5.10 Medication taking 
The self-reported results for medication taking as a secondary stroke prevention 
strategy was disappointing in that only 66% of participants with ischaemic stroke 
reported they were still taking  antiplatelet therapy, 45% taking a statin and 44% 
taking antihypertensive medication. Of those who self-reported a diagnosis of 
hypertension, 83% reported taking anti-hypertensive medication as a way to prevent 
a further stroke. However, 17% of the hypertensive population did not associate 
taking antihypertensive medication with stroke prevention (Table 3.3).  
20% of the respondents when asked did not put stroke prevention medication down 
as stroke prevention drugs, most put Aspirin down but statins, anti-hypertensive and 
anti-hypoglycaemic drugs were put in the ‘other medications’ box.  This gives an 
indication that some respondents are unaware that they are taking specific stroke 
prevention medications.  
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3.6 Limitations 
This work has a number of important limitations which include the sample selection 
of members of a stroke survivor’s charity, which may not be representative of the 
entire stroke population of stroke survivors as one can presume they are well 
informed as they actively sought out information and support from this source. The 
questionnaire was only available in English language and therefore reduced the 
generalisability of results as non-English speakers and anyone with a communication 
problem would have been excluded from participating in the study unless they had 
an interpreter which was suggested as a possibility in the information section 
provided. The cohort is a young selection (mean age 55.4yrs) which is not 
representative of the ageing population.  There is a lack of ethnic diversity in the 
responses which is largely European in its representation. Reporting bias is another 
major limitation of this study as we are reliant on the population giving truthful 
responses to the questions, particularly in lifestyle and behavioural changes since 
stroke. However this is a common limitation and has been recorded in other studies 
(Silcock et al, 2007, Bushnell et al 2009).  
3.7 Discussion 
Gaining an understanding of stroke survivors’ knowledge, perceptions and 
behaviours post stroke is important for the development of strategies for improving 
adherence to secondary prevention measures. The key findings from this study 
concur with previous findings in that generally knowledge of stroke and risk factors is 
low and perceptions  of future risk is low amongst high risk stroke survivor 
populations (Samsa et al 1997, Forster et al 2001, Townend et al 2006). 
Studies have shown there is a lack of a sense of control over causes of stroke and 
many stroke survivors have fears associated with idiosyncratic and fatalistic beliefs 
(Townend et al 2006). The findings from this study support the concept that many 
stroke survivors’ fear recurrence despite the fact they didn’t realise they were having 
a stroke at the time of the event. The majority of respondents said they received their 
stroke information from a health professional, this informs us that information is 
being provided but it may not be effective in increasing knowledge of signs and 
symptoms or personal risk factors for future stroke and vascular events and 
therefore the type of information health professionals provide may need investigating 
further. 
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Low knowledge of risk factors has been recorded in other studies (Dearborn & 
McCullough 2009, Kraywinkel et al 2007) and in one study, knowledge of a risk 
factor was shown to be superior in those affected by it (Kraywinkel et al 2007). 
However, this was not seen in this population and their behaviours were unaffected 
by knowledge of stroke risk factors as those who could name more than 3 risk 
factors for stroke were equally likely to make the same amount of behavioural 
changes as those who named 3 or less risk factors.  Therefore we can conclude in 
this population of younger stroke survivors that there was no relationship between 
knowledge of risk factors and adherence to secondary prevention behaviours. 
Knowledge of stroke signs and symptoms was low in the context of a recent national 
campaign which was aimed at improving the public’s awareness of stroke and it is 
more surprising in this cohort which has already suffered a stroke. However, stroke 
knowledge has been shown to be poorest in groups at highest risk (Pancioli et al 
1998). Indeed, many patients (72%) in this study did not realise their symptoms were 
indicative of stroke, although with the proposed repetition of the media campaign this 
figure may improve.  
Aalto et al (2005) showed that patients with cardiac disease believed that 
psychosocial problems contributed to their risk of future disease and over half the 
respondents in this study who quoted stress as a risk factor, self-reported a 
diagnosis of hypertension. This may show some similarities between the two groups 
of patients. A quarter of the respondents who quoted stress as a risk factor for stroke 
also felt that there was little to be done to improve their symptoms from stroke. This 
finding may play a role in identifying patients who have a more fatalistic attitude to 
their recovery from stroke and may therefore not actively make behaviour changes in 
response to their stroke.  
These results show that perception of risk is poor in this high risk population of 
stroke survivors. Despite the poor understanding of ‘risk’ in this population, studies 
have shown that additional risk factor advice provision has shown disappointing 
results for lifestyle change after stroke (Ellis et al 2005) Therefore, it may be 
important to take into account patients personal experience, beliefs and fears when 
developing secondary prevention programmes.  
In this study 40% of the participants’ self-reported taking more exercise since their 
stroke, however, Rand et al (2009) reported levels of physical activity in adults with 
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mild motor impairment after stroke are half those of healthy older people. Although 
physical activity is encouraged post stroke, Boysen et al (2009) went on to report 
that repeated encouragement and verbal instruction did not result in a measureable 
increase in physical activity in a cohort of stroke survivors following mild ischaemic 
stroke, although professional advice and guidance with continued support 
encouraging sedentary people without previous stroke to be more physically active 
was effective in a previous trial (Foster et al 2005). Therefore ‘stroke specific’ 
rehabilitation programmes may be beneficial to stroke survivors although 
understanding how the population behaves is the key to developing such 
programmes and perception may provide insights into activities. This study 
population may perceive they are taking more exercise but may not be in reality 
therefore, joint research into perceptions of stroke survivors may provide us with 
more information regarding their beliefs about their condition and action related 
behaviours.  
Obesity is a risk factor for stroke and maintaining a stable weight and weight 
reduction are key secondary prevention behaviours. Towfighi and Ovbiagle (2009) 
assessed the independent association between body mass index (BMI) and mortality 
among stroke survivors and found that stroke survivors were more likely to be 
overweight (BMI 25 to 29 kg/m2) or obese (BMI >30 kg/m2) than those without 
stroke. They concluded that higher BMI after stroke is associated with a greater risk 
of all-cause and cardiovascular death among younger individuals. Younger stroke 
survivors may especially benefit from more vigorous efforts to monitor and treat 
obesity (Towfighi & Ovbiagle 2009). A quarter of the participants in this study self-
reported weight loss, this is difficult to validate in an unseen cohort, however, self-
reporting a positive behaviour even if it is an exaggeration indicates an awareness of 
the need for that behaviour in this context.  
The population of younger stroke survivors showed a mixed response to their stroke 
and outlook on the future. Almost equally half are positive about their future and half 
are pessimistic about what can be done to improve their symptoms and are fatalistic 
about recovery. Over half (53%) agreed that treatment will be effective in preventing 
a future stroke. It has been shown in older adults that optimism may play a protective 
role against stroke, as higher optimism was associated with a lower risk of stroke 
(Kim et al 2011) and Nabi et al (2010) identified low pessimism is linked to reduced 
risk of stroke in adults under 54 years. Kim et al (2011) recognise that optimism is 
related to other positive psychological constructs such as positive affect, positive 
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emotions and feelings of joy and happiness, however they suggest optimism is 
conceptually distinct and measures an individual’s positive perception and 
expectations. Further work in this interesting area may be effective in gaining further 
insight into reasons for behaviour in stroke survivors. 
The risk of a vascular event has been found to be at its highest shortly after the 
ischaemic event and at its lowest point at about 3 years and then gradually rises 
again afterwards (Van Wijk et al 2005). One explanation for the gradual rise of 
increased risk after the 3 year period was the possible decline in drug compliance 
and from reduced attention to lifestyle factors in follow-up. In light of the substantial 
risk of recurrence of subsequent ischaemic events and advances in therapeutic 
treatments which have demonstrated to be effective for secondary prevention, it has 
been suggested (Vickrey et al 2002) that further research should be performed to 
look at assessment and care patterns for secondary prevention to determine whether 
there are gaps between actual care and the evidence based recommendations. 
Interestingly, the majority of participants in this study had their stroke more than 5 
years ago (67%) and the results could be seen positively as they suggests these 
high risk patients are still aware of secondary prevention in the long term following 
stroke, although, Qureshi et al (2001) reported actual risk factor control in 1252 
survivors of MI and stroke from the National Health and Nutrition Examination 
Survey 3 was poor in the long-term. Qureshi et al (2001) reported risk factors were 
poorly controlled with only 35% of hypertensives BP controlled and blood glucose in 
diabetes was controlled in only about 50% and cholesterol was poorly controlled in 
46%. About 18% of individuals were also still smoking cigarettes. Health 
professionals should be mindful that secondary prevention involves monitoring 
treatments as well as prescribing them to ensure ultimate control of risk factors is 
obtained. 
In this study fewer than half of stroke patients reported taking a statin (45%), 
consistent with other studies (Jacobson et al 2004) despite widespread 
acknowledgement of the need for this. Interestingly, 66% of respondents’ reported 
taking an antiplatelet. Thus, the lack of statin therapy may be due to health 
professionals either not realising their overall benefits or under-estimating their risk 
reduction benefits to a relatively younger stroke population. This outcome is similar 
to other studies that report lower levels of control and compliance with stroke 
prevention (Hillen et al 2000, Marini et al 1999, Sappok et al 2001). However, 
younger patients are less likely to adhere to statin therapy (Goldenberg et al, 2009). 
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Notwithstanding this observation, fewer than 20% of patients with cardiovascular 
disease are known to reach their target lipid levels (D’Agostino et al 2000) despite 
clear recommendations that implementation and adherence to secondary risk 
reduction strategies are important for reducing the risk of recurrent stroke then our 
findings are an indictment against current public health strategies to improve 
cardiovascular outcome.  
Some of the population with a haemorrhagic stroke reported taking antiplatelet 
medication (37%) this is most likely due to multiple risk factors for ischaemic stroke 
in a small section of the population who are at risk of both ischaemic and 
haemorrhage stroke. This combined with the majority of stroke survivors in this 
study, who suffered their stroke more than five years ago may be the clinical reason 
for antiplatelet medication. 43% of the haemorrhagic strokes had other risk factors 
such as, diabetes (14%), ischaemic heart disease (11%), peripheral artery disease 
(14%) and renal disease (8%). 
The information obtained from this study highlights the importance for health 
professionals to understand and be aware of the poor level of risk perception in this 
high risk population, when developing secondary prevention programmes. This 
population identified ‘stress’ as a key risk factor in stroke causation and prevention, 
therefore stress should be addressed in secondary prevention discussions to ensure 
patients understanding of stress reduction as part of their secondary prevention is 
realised to avoid them concentrating on relieving the stress alone and neglecting 
other aspects of secondary prevention such as medication taking and behaviour 
modification.  It is important to ensure strategies are investigated to measure 
patient’s perception of risk to guarantee stroke prevention can be effective in the 
future.  
By allowing the participants to complete the questionnaires in their own homes and 
without any health professional contact has created a unique example of unbiased 
information about this stroke population. However, it clearly suggests day to day 
knowledge and appreciation of future risk of stroke and cardiac events is poor, and 
the lack of understanding of established and pre-existing risk factors to 
cardiovascular disease in the population of stroke survivors suggests on-going 
information provision is low. The majority of patients were unaware that their stroke 
was the consequence of their long standing risk factors. The key finding suggests 
that those who are more aware of their risk of future vascular events are more likely 
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to perform lifestyle behaviour changes in response to stroke than those who are 
unaware and regardless of their knowledge of stroke risk factors. These findings 
have important implications for those developing secondary prevention strategies as 
well as for the on-going high profile FAST campaign that aims to reduce the burden 
of stroke. 
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3.8 Chapter 3: Tables and Figures 
Table 3.1: Population demographics 
Population characteristics n=622 % 
Mean age, years 
Range 
55 
(18-91) 
 
Male 309 48 
Ethnicity   
White British 556 89 
White other 40 6 
Black British 7 1 
Asian British 2 0.3 
Marital Status   
Married 352 56 
Single/divorced 157 25 
Widowed 20 3 
Educational level   
Secondary school education 216 35 
University 260 42 
Stroke sub-type 
Ischaemic 
Haemorrhagic 
Both 
Unknown 
 
316 
189 
12 
105 
 
51 
30 
2 
17 
Time since stroke:   
< 1 year 76 12 
1-5years 111 18 
> 5 years 419 67 
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Table 3.2: Self-reported stroke risk factors 
Stroke Risk Factor n % 
Smoking 55 9 
Hypertensive 325 52 
Diabetic 67 11 
Ischaemic Heart Disease 85 14 
Peripheral Arterial 
Disease 
90 14 
Renal Disease 25 4 
 
Table 3.3: Medications 
Medications n % 
Antiplatelet therapy 414 66 
Statin therapy 279 45 
Antihypertensive 
therapy 
272 44 
Warfarin 63 10 
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Figure 3.1: Risk factors for stroke 
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Figure 3.2: Knowledge of stroke using modified FAST 
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Table 3.4: Perception of stroke: Cause 
Cause
1-525. Stress was a major factor in 
causing my stroke
1-534. It was just by chance that I 
had a stroke
1-543. My stroke was caused by 
hereditary factors, it runs in 
my family
1-552. Pollution of the environment 
caused my stroke
1-551. A germ or virus caused my 
stroke
*RangeMedianRating of agreement.
*Range: 1-strongly agree to 5-strongly disagree
 
Table 3.5: Perception of stroke: Consequence 
Consequence
1-527. My stroke has strongly affected the 
way I see myself as a person
1-526. My stroke has serious economic and 
financial consequences
1-525. My stroke has strongly affected the 
way others see me 
1-554. My stroke has had little effect on my 
life
*reverse scoring
1-523. My stroke has become easier to live 
with.
1-512. My stroke has had a major 
consequence on my life
1-5
1-strongly agree
5-strongly disagree
11. My stroke is a serious condition
*RangeMedianRating of agreement
*Range: 1-strongly agree to 5-strongly disagree
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Table 3.6: Perception of stroke: Future perspective 
Future perspectives
1-545. Recovery from my stroke is 
largely dependent on chance or fate
*reverse scoring 
1-524. My treatment will be effective in 
preventing a future stroke
1-543. There is very little that can be 
done to improve my symptoms
*reverse scoring
1-522. There is a lot which I can do to 
control  my symptoms
1-531. My stroke will improve in time
*RangeMedian
*Range: 1-strongly agree to 5-strongly disagree
 
 
Figure 3.3: Awareness of risk and effects on behaviour 
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Figure 3.4: Number of lifestyle behaviour changes 
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Chapter four: Understanding knowledge of blood 
pressure in the general public 
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4.1   Introduction 
Hypertension is the most common treatable risk factor for stroke (Volpe & Dedhiya 
2006, Bosworth et al 2006).  Multiple studies including randomized, controlled trials 
have demonstrated a reduction of between 30-40% of stroke by blood pressure 
lowering (Chalmers 2000, Yusuf et al 2000, Lawes et al 2004). In secondary stroke 
prevention only a minimal reduction of BP (10mmHg) is needed to reduce the risk of 
recurrent stroke by as much as 28% (Rodgers et al 1996).  However, it has been 
estimated that nearly half (45%) of all strokes in patients who are on treatment for 
hypertension could be attributed to poorly controlled hypertension (Li et al 2005). It 
has been estimated that for the population as a whole worldwide, 75% of strokes 
occur in 90% of individuals with a blood pressure greater than 155/95 (McMahon and 
Rogers 1994). Therefore control of BP in secondary prevention is of great 
importance and in order to achieve this goal, understanding why BP is so poorly 
controlled in the hypertensive population is key. 
Recent studies have shown that patients and public are aware of the link between 
hypertension and stroke but do not appreciate the consequences of uncontrolled 
hypertension (Volpe and Dedhiya, 2006), however it has been suggested that 
patients who recognize their increased risk for stroke are more likely to engage in 
stroke prevention practices than those who do not (Samsa et al 1997). Similar 
findings were found as a result of the questionnaire study (Chapter 3) in this thesis 
where stroke survivors who reported being ‘at risk’ of a future event were more likely 
to make behaviour changes (less alcohol, more fruit and ‘veg’, less salt) than those 
who said ‘no’, however Dedhiya (2006) found that public and hypertensive patients 
alike did not consider hypertension as a serious health problem and only a third of 
the respondents in their study knew that hypertension could be asymptomatic.  
Looking at a hypertensive population, Oliveria et al (2005) found that hypertensive 
patients had a  general understanding of ’hypertension’ but were less knowledgeable 
about specific factors related to their condition and specifically their own level of BP 
control. There is no standardized tool available to assess knowledge or awareness 
of hypertension (Oliveria 2005) however, this study aims to go some way to adding 
to the field of knowledge using a large population sample of the general population to 
gain a breadth of understanding of their perception and knowledge of BP. 
Individuals with pre-hypertensive levels of BP, as defined by 120/80 to 139/89 
mmHg, also have an increased risk of developing cardiovascular disease and stroke 
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compared with those with optimal BP <120/80 mmHg. The association is among 
blacks, those with diabetes mellitus and those with a high BMI (Kshirsagar et al 
2007). Cohort studies now indicate that in the Asia Pacific region as well as in North 
America and Western Europe, each 10 mmHg lower systolic BP is associated with a 
decrease in risk of stroke of approximately one third in subjects aged 60-79 years 
(Lawes et al 2004). The association is continuous down to levels of at least 115/75 
mmHg and is consistent across sexes, regions, and stroke subtypes and for fatal 
and nonfatal events. The proportional association is age dependent but is still strong 
and positive in those aged 80 years. Data from randomized controlled trials, in which 
mean age at event was approximately 70 years, indicate that a 10 mmHg reduction 
in systolic BP is associated with a reduction in risk of stroke of approximately one 
third. Per mmHg systolic BP reduction, the relative benefits for stroke appear similar 
between agents, by baseline BP levels, and whether or not individuals have a past 
history of CVD. There is, however, evidence of greater benefit with a larger BP 
reduction. Epidemiologically expected benefits of BP lowering for stroke risk 
reduction are broadly consistent across a range of different population subgroups 
with greater benefits from larger BP reductions (Lawes et al 2004). 
There is little knowledge or understanding of blood pressure and its role as a major 
risk factor for stroke and heart disease in the general public (Samal et al 2007, 
Celentano 2004, Volpe and Dedhiya 2006). Samal et al (2007) found that despite 
77% of the patients stated they knew that hypertension was a risk factor for stroke, 
only 30% felt at an increased risk of stroke. Other studies have shown that patients 
and public are aware of the link between hypertension and stroke but do not 
appreciate the consequences of uncontrolled hypertension (Volpe and Dedhiya, 
2006). Volpe and Dedhiya (2006) found that the public and hypertensive patients 
alike did not consider hypertension as a serious health problem and only a third of 
the respondents in their study knew that hypertension could be asymptomatic. 
4.2   Quality and outcomes framework 
The significance of achieving better BP control has increased since 2003 with the 
release of new clinical practice guidelines for the prevention, detection and treatment 
of high BP and more recently the introduction of Quality and Outcomes Framework 
(QOF 2004). Variations in the quality of healthcare have been extensively 
documented in the UK and US and continue to persist despite considerable 
investment (Crawley et al 2009). Pay for performance programmes were first 
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initiated in the UK in 2004 with the introduction of QOF. This provides financial 
rewards to G.P’s for achieving large numbers of evidence-based quality indicators 
and places considerable emphasis on the management of common cardiovascular 
conditions of which hypertension is the most treatable. The study by Crawley et al 
(2009) looked at impact of pay for performance on quality of chronic disease 
management by social class group in England. The study was performed to compare 
the 2003 and 2006 surveys which focused on cardiovascular disease risk factor 
management. They found no difference in usage of anti-hypertensive or 
achievement of BP target following the implementation of the QOF.  However, further 
QOF analysis is showing more promising results in a 2005-2007 comparison study of 
General Practitioner records (Ashworth et al 2008) 82.3% of adults in England had 
an up-to-date BP recording in 2005 and this increased to 88.3% in 2007. The 
proportion of patients reaching a target BP level ranged from 71-85% in 2005, rising 
to between 78.6-89.4% in 2007. These results show an improvement in base levels 
of one CVD risk factor, however, Wolfe et al (2010) argue QOF payments have only 
been evaluated in relation to BP control and have not been evaluated in a RCT. 
Variations still exist despite the opportunities to improve BP control and the financial 
rewards that are now available.  It appears that despite regular monitoring, BP 
control is still reported as suboptimal in the hypertensive population (Ashworth et al 
2008) in Europe, which inadvertently puts this population at increased risk of stroke 
and cardiovascular disease.  
Physicians worldwide appreciate the importance of managing hypertension to avoid 
future complications such as stroke, however Volpe & Dedhiya (2006) suggest they 
do not conform to the recommendations in various hypertension guidelines and have 
higher thresholds than guideline recommendations for defining and categorizing 
hypertension and need to engage in patient communication regarding hypertension 
(Volpe & Dedhiya 2006). A study looking at lifestyle modification knowledge among 
health professionals and students resulted in only 10% achieving the desired scores 
of 80% or higher. The majority of health professionals in this study promoted the 
theoretical concept of lifestyle modification but had difficulty in providing practical 
advice to patients. Lack of time, lack of patient adherence and language barriers 
were given as the main barriers to providing lifestyle counselling (Parker et al 2009). 
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4.3   Relation between knowledge and BP control 
It has been suggested that knowledge about hypertension and its control can 
influence blood pressure control in patients with hypertension (Samal et al 2007).  
Samal et al (2007) performed a study which looked at the relation between 
knowledge about hypertension and education in hospitalized patients with stroke in 
Vienna. They found that patients without a basic school education had a significantly 
lower frequency of blood pressure measurements than the others (P<0.05 compared 
with the reference category). Three fourths (76%) of the patients stated they owned 
a blood pressure meter, but only 63% used it. Knowledge of other possible 
consequences of hypertension, namely myocardial infarction, nephropathy, 
peripheral vascular disease, and retinopathy, were significantly associated with 
educational attainment. Knowledge about these consequences ranged from 64% for 
myocardial infarction to 11% for peripheral vascular disease. Concerning non-
pharmacologic options for lowering blood pressure, there were significant differences 
defined by educational level as well; the higher the educational level, the more 
patients were likely to know about physical activity, reduction of salt intake, reduction 
of caloric intake, and relaxation techniques. Knowledge about these options ranged 
from 17% (relaxation techniques) to 54% (reduction of salt intake). When asking 
about adherence to these lifestyle modifications, 37% to 66% affirmed to do so. 
Samal et al (2007) concluded that knowledge in their population was insufficient and 
partly associated with educational level, leaving much room for improvement by 
educational campaigns.  
The importance of education programmes has been reported and patients who are 
aware that elevated BP levels can lead to reductions in life expectancy have been 
reported to have a higher compliance level with medication use and follow up visit 
than patients without this awareness (Balazovjech  1993).  Oliveria et al (2005) found 
that many patients did not know their BP level nor could they accurately classify their 
level as elevated or normal. 41% of patients in this study reported that their BP 
values were in the normal range but in fact they were elevated. This highlights the 
need for investigation into perceptions of blood pressure in the community and 
identification of appropriate educational systems to inform people about the 
importance of adequate blood pressure control to prevent vascular events such as 
stroke and myocardial infarction. 
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4.4  Health literacy in long term conditions 
Most measures of health literacy have been developed in the US, where 
approximately 40% of the population have inadequate health literacy. In the UK 
prevalence is unknown but at least 20% of UK adults have literacy and numeracy 
skills insufficient to read simple written information, these people are therefore at risk 
of having inadequate health literacy. The prevalence of low health literacy places a 
bigger responsibility on health professionals to ensure patient comprehension and 
health information is relayed appropriately to patients (Colledge et al 2008). This is a 
major obstacle to providing high quality care, as long-term and chronic  diseases 
require self-management skills and the ability to negotiate complex treatments and 
health service needs with health professionals. Patients require sufficient knowledge 
and skills in order to handle the complex information demands of the health system, 
to communicate in order to make appropriate use of health services available to 
them and contribute to optimising the management of their own care. 
Stroke survivors are at a high risk of repeated vascular events and therefore their 
self-management is crucial to their long-term care, however, due to the complex 
communication difficulties sustained by most stroke patients, this makes health 
literacy a particular challenge in this population, but still a goal to aim for. Also 
patients with good health literacy skills can act as advisers and mentors for other 
patients with long-term diseases and thus help spread best practice and improve 
disease management. 
The United Kingdom White Paper (2004) ‘better information, better choices and 
better health’ sets out a strategy to provide improved access to high quality health 
education and information and suggests health professionals should communicate 
more effectively with patients. They also suggest a nationally coordinated process to 
deliver and produce information. There have been improvements in information 
provision via many approaches such as telephone and internet access, however, 
many patients still don’t have access to the information they need or want in the 
format they can understand. 
4.5   Adherence as a tool to controlling BP 
It is well known in population studies, higher educational level and income positively 
influences BP control (Egan et al 2003, Muntner et al 2004, Mendez et al 2003). 
Higher education influences a persons ability to become health literate and this 
factor may influence adherence to both medication taking and lifestyle modifications 
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in the context of BP control. It has been estimated only 30%-50% of patients with 
hypertension regularly take their anti-hypertensive medication (Stephenson 1999, 
cited by O’Carroll et al 2010). Improving adherence to medications prescribed for 
hypertension and secondary stroke prevention has the potential to have a major 
impact on cardiovascular disease prevention (Silcock & Standage 2007). However, 
lack of knowledge about BP or understanding of risk is associated with non-
adherence as patients do not believe the expected behaviour such as medication 
taking, may reduce their risk or they do not perceive they are at risk in the first 
instance. Dearborn and McCullough’s (2009) study found  women who were high-
risk still perceived their risk to be the same as their peers and a study of 1502 
American adults over the age of 50 (Egan et al 2003) identified 46% of the 
hypertensives did not know their own BP. This study concluded limited awareness of 
systolic BP was a barrier to control. This continued lack of perceived risk and lack of 
knowledge of risk factors has considerable consequences for health professionals 
working with first time stroke survivors to ensure high risk individuals adhere to 
stroke prevention strategies.   
Patient-centred strategies may lead to the identification of better tools to improve 
control of long-term conditions (Schedlbauer et al 2004, Silcock & Standage 2007) 
while randomized controlled trials have shown specific health behaviour modification 
interventions can be successful, such as advice to give up smoking (Law et al 1995) 
and healthy eating in nurse-led cardiovascular disease (CVD) follow-up programmes 
(Wood et al 2008). Specifically targeted programmes may be beneficial to the stroke 
population if they are individually designed. Notwithstanding these successes, 
studies to examine if improvements have been made to long-term management of 
chronic vascular diseases such as coronary heart disease, diabetes and 
hypertension with the formal introduction of pay-for-performance targets have shown 
no improvement in blood pressure control (Crawley et al 2009). Indeed, even 
improved patient knowledge has failed to guarantee higher levels of adherence 
supporting the opposite view that poor knowledge does not necessarily lead to low 
adherence (Silcock and Standage 2007). Studies investigating interventions to 
improve adherence have been unable to identify advantages in any one type of 
intervention (Schedlbauer et al 2004, Horne et al 2005). The provision of medically 
accurate information may improve knowledge but may not improve mood or 
perceived health status and therefore the patient’s own perspectives about stroke 
and their recovery. Preliminary studies of additional risk factor advice provision have 
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produced disappointing results for lifestyle change following stroke (Townend et al 
2006).  
4.6  Physician approaches to BP control 
Patient non-adherence is certainly one possible reason for low levels of BP control in 
hypertensive populations, however, some studies have investigated how physicians 
make decisions about initiating and modifying pharmacologic treatments for 
hypertension (Oliveria et al 2002, Andrade et al 2004). These studies have found 
that many physicians have a high tolerance despite guidelines stating levels at which 
treatment regimens should be commenced or altered.   
Many patients with hypertension have inadequate BP control and often BP 
thresholds for diagnosis and treatment of hypertension are substantially higher than 
recommended (Berlowitz et al 1998, Andrade et al 2004, Hyman et al 2000). This is 
despite evidence suggesting that primary care physicians are aware of the existence 
of treatment guidelines for hypertension (Oliveria et al 2002). Several studies have 
shown suboptimal BP control in specialist hypertension clinics (Andrade et al 2004, 
Berlowitz et al 1998, Knight et al 2001). In one study 40% of patients with a 
diagnosis of hypertension who visited a hypertension clinic more than six times in a 
year still had a BP of >160/90mmHg (Berlowitz et al 1998). This study focused on a 
selected population of older men, however those who received more intensive 
therapy had better controlled BP, despite this, the study showed that many 
physicians are not aggressive enough in their approach to the management and 
treatment of hypertension. Andrade et al (2004) found that physicians were 
significantly more likely to intensify the antihypertensive regimen only when the 
systolic BP reached 160mmHg or greater. 
Among the cohort examined in the 2003–2004 National Health and Nutrition 
Examination Surveys (NHANES) that gather information about health and diet from 
households in the United States, the overall prevalence of hypertension was 29.3%. 
In the 2005–2006 NHANES, the overall prevalence of hypertension was slightly less 
at 29.0%. In both studies, hypertension was defined as a blood pressure of ≥140/90 
mmHg or as taking antihypertensive medication. Interestingly in the Health Survey 
for England (2003), of those with hypertension (BP ≥140/90 mmHg) 61.7% were 
aware of their diagnosis and only 21.8% had adequate BP control (BP ≤140/90 
mmHg).  
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Ashworth et al (2008) identified from National surveys between 12-25% of the 
population of 5 European countries had a systolic BP of ≥160mmHg compared with 
7.4% in Canada and 5.2% in the US. Under-treatment with antihypertensive 
medications was identified as a probable cause for the disparity with only 41-52% of 
those in European countries being treated compared to 62% and 78% in Canada 
and the US respectively. Although the number of patients treated for hypertension 
has increased gradually over time (Ashworth et al 2008), blood pressure is not 
controlled in all patients with hypertension. In NHANES 2003–2004, hypertension 
was controlled in only 37% of all patients with hypertension and in 57% of those 
treated for it. In NHANES 2005–2006, the rate of hypertension control had improved 
to 43.5% of all patients with hypertension and to 64.0% of those patients who were 
taking medication to control it. 
4.7    Local population 
The Hammersmith and Fulham (pop 170,000) borough has a population which has a 
highly diverse culture and ethnic mix. 22.2% of the Hammersmith and Fulham 
population is made of an ethnic group other than white.  Poor blood pressure control 
remains a common problem that contributes to significant morbidity and mortality 
particularly among ethnic minority groups (Bosworth et al 2006) such as south 
Asians and Black African and Caribbean groups. 18% of adults aged between 16 
and 74 years of age have no formal qualifications in the borough. The influence of 
educational level and poorer outcomes and levels of care delivery for ethnic minority 
groups are a consideration for this local population, therefore a random study would 
include a large number of low education level and ethnic minority groups although 
this was not specifically studied as part of this project. The literature informs us that 
there is little knowledge or understanding of blood pressure and its role as a major 
risk factor for stroke and heart disease in the general public (Samal et al 2006, 
Celentano 2004, Volpe and Dedhiya 2006). In another study it was found that the 
public and hypertensive patients alike did not consider hypertension as a serious 
health problem and only a third of the respondents knew that hypertension could be 
asymptomatic (Volpe and Dedhiya 2006).  
The aim of this survey is to gain insight into the knowledge and perceptions of blood 
pressure in a convenience sample of the local population of predominantly 
Hammersmith and Fulham residents in London. This will allow us to gain further 
information regarding BP awareness in the local population and also gain some 
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insight into the knowledge of BP in an asymptomatic hypertensive section of the 
population who are at high risk of vascular disease. This information may be able to 
inform the development of primary and secondary prevention strategies to inform the 
public in a way that ensures an adequate understanding of the risk factors for stroke 
and how blood pressure prevention can play a major role in its prevention. 
4.8    Aims and Objectives 
1. To gain an understanding of the local population’s perception of blood      
pressure: 
 Perception of what is a normal blood pressure 
 Knowledge of their own blood pressure measurement 
2. Identify the level of knowledge that hypertensive patients taking               
medication have of ‘normal’ blood pressure and their own measurements.    
4.9   Methodology 
As part of an awareness campaign about stroke, members of the public were offered 
blood pressure testing and were asked relevant questions to identify their perception 
and understanding of blood pressure. Performing a BP reading is an important 
element of this study as it provides clinical data in order to compare the participants 
perception and knowledge of their own BP level and what they perceive to be a 
‘normal’ level. All BP’s in this study were undertaken by a trained health professional 
with clinical experience enough to perform the measurement and training to provide 
written and verbal information about BP, hypertension and risk factors for stroke. 
Members of the public were approached to participate from within the local borough 
at selected venues such as the Town Hall, local shopping centre, coffee shop of a 
local hospital and an exhibition hall during a careers convention. 
A joint approach to blood pressure recording was used with a combination of 
sphygmomanometry and wrist BP devices used to measure the participants BP. The 
wrist BP devices were the Omron 637IT. Individuals were asked the following 
questions: 
1. Gender 
2. Age 
3. Postcode and London borough in which they reside 
4. Whether they have ever been diagnosed with hypertension (high BP) 
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5. Whether it has been treated with medication 
6. If they had knowledge of what a ‘normal’ BP was and if so to give an 
example 
7. If they had knowledge of what their own BP was when it was last recorded  
The British Hypertension society classification (2005) of a ‘normal’ BP equates to 
that of the European Society of Hypertension (2003) and that of the World Health 
Organisation – International Society of Hypertension (1999) states that the systolic 
BP should be <130mmHg and the diastolic should be <85mmHg (Table 4.1). 
4.9.1 Study design 
 This is a quantitative study using a survey approach to obtain information of 
participant perception of blood pressure and demographic information such as Age, 
Gender and drug therapy history for hypertension and post code information.  
4.9.2 Power Calculation 
The power was calculated using an earlier study (Wizner et al 2003) which reported 
perception and knowledge of normal blood pressure among the general population. 
The reported difference among normotensive and hypertensive members of that 
population was 47%, with 95% confidence and with a 3.15 bond on error of 
estimation. Therefore a sample of 965 patients was required to gain an 
understanding of the local population’s perception of blood pressure. Allowing for a 
5% non-response rate our final sample size was 1019.  
4.9.3 Validation of the Omron 637IT 
The Omron 637IT used for this study passed according to the International Protocol 
criteria and is recommended for use in adults and obese adults. The standard 
location for BP measurement is the upper arm, however monitors that measure BP 
at the wrist are becoming increasingly popular as the monitors are smaller and 
lighter than upper arm devices and in the context of this study doing BP recordings in 
public places require less invasive removal of external clothing to reach the wrist 
rather than upper arm. Owing also to population trends of increasing body weight, 
most BP machines are sold in the market with inappropriate cuff sizes, however wrist 
diameter is little affected by obesity and therefore can be used on obese adults. 
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4.9.4 Consent 
Verbal consent to participate was obtained prior to asking any of the questions and 
performing a blood pressure recording. 
4.9.5 Professional responsibility 
Participants with a blood pressure recording of >140-90mmHg on three consecutive 
recordings on both OMRON and sphygmomanometer testing, (according to British 
Hypertension guidelines on blood pressure measurement) were advised to see their 
G.P or Practice nurse for further investigation and advice. 
4.9.6 Analysis 
The results were obtained using Excel and SPSS software in order to answer 
questions relating to a person’s knowledge and understanding of blood pressure. 
Chi-squared test was used to compare healthy and hypertensive populations and 
multiple logistic regression was used to adjust for differences in the groups 
associated with age. 
4.10 Results  
4.10.1 Population Characteristics  
Table 4.2 provides the demographic information of the 1019 participants who took 
part in the survey. The mean age for the total population was 54 years (range 16-
92). In total 194 people (19%) who participated in the survey had consistently high 
readings on the day and were advised to see their GP service or practice nurse 
within one week in accordance with the professional responsibilities set out for the 
study (Section 4.9.5).  
Of the total population, 313 participants self-reported hypertension and 299 reported 
taking medications for BP, however 334 (33%) were clinically hypertensive according 
to BHS coding from optimal to severe hypertension.  Of the 334 who had a SBP of 
≥140mmHg, 182 (54%) were from the self-reported hypertensive group and 152 
(45%) were from the ‘healthy’ group. In further analysis of those who were clinically 
hypertensive with either a SBP of ≥ 140mmHg or a DBP of ≥90mmHg, 58.7% had no 
idea and were unable to guess what a ‘normal’ BP is. 
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4.10.2 Knowledge of a ‘normal’ BP  
Of the total population, 52% of the participants had no idea what a normal blood 
pressure should be, they either guessed incorrectly outside of the normal values or 
were unable to give an answer (Table 4.3) The majority of the hypertensive 
population (77%) were unable to give a correct value for a ‘normal’ BP and 63% of 
the healthy population were also unable to give an accurate report of a ‘normal’ BP 
reading (Chi Square test P=0.03) (Figure 4.1). 
4.10.3 Knowledge of own BP 
When asked to guess their own BP, 58% of the overall population either had no idea 
or did not report their own BP correctly (Table 4.3). Of the healthy population 67% 
guessed incorrectly and 89% of the hypertensive population guessed incorrectly or 
couldn’t guess at all (Chi Squared test P=<0.001) (Figure 4.2). Only 11% of the 
hypertensive population were able to guess their own BP of ≤140/≤90mmHg, 
however, this may be due to hypertensives believing their BP to be higher than that. 
Despite this 30% (306) of the hypertensives continued to have a SBP of ≥140 
mmHg.  
4.10.4 BP recordings 
Only 31% of the total population in this survey had an optimal BP (<120/80 mmHg) 
recording on the day and 33% had mild-severe hypertension on BP recordings 
(>140/90mmHg). Mean blood pressure for the total population was 130/77 mmHg. 
The mean SBP for the hypertensive population was 150/87. Those with a SBP of 
more than 155mmHg were 334 (33%) which may put them at increased risk of stroke 
according to McMahon and Rodgers (1994). Of the people who self-reported a 
diagnosis of hypertension, 32% had a systolic BP recording of >140mmHg.  
4.10.5 Hypertensive Vs Healthy populations 
Healthy is defined as a BP of ≤139/89mmHg and hypertensive is defined as a BP of 
≥140/90mmHg (Table 4.1). Of the self-reported hypertensive population 77% 
guessed a normal BP incorrectly compared with 63% in the healthy population. 
There was no significant difference in participants understanding of systolic and 
diastolic BP as both were either guessed or both were not guessed at. Age of pre-
diagnosed hypertensives that had no idea or guessed incorrectly was significant 
higher. Independent T-Test calculated a significant difference between mean age for 
the hypertensive population as 63yrs and the healthy population 50yrs (P<0.001) 
 
 
134 
(Figure 4.1).There was a significant association between the differences between 
control of BP in the hypertensive population which corresponded with their 
knowledge of a normal BP. Chi-squared test identified the hypertensive group had 
less knowledge of a ‘normal’ BP (P=0.03) (Figure 4.1) and a highly significant 
difference in knowledge of their own BP (P=<0.001) (Figure 4.2). Independent T-Test 
calculated mean BP in participants who guessed normal correctly as SBP 147 
mmHg and those who guessed incorrectly as SBP 150 mmHg which had a 
significant p-value of p=<0.047 (Std 9.3 and 12.6 respectively) (Table 4.3). 
The results suggest that there is poor understanding of blood pressure in the general 
public and of particular importance people who are known to be hypertensive and 
who take medication for blood pressure have little knowledge of their own blood 
pressure and what is ‘normal’ blood pressure.  
4.11   Limitations 
Random selection of BP recording could be higher due to recent activities but this 
would be the same if recorded in a busy clinic environment. Possible ‘white coat’ 
phenomenon although still away from the clinical environment but nevertheless a 
health professional took the BP and therefore could have influenced a ‘white coat’ 
reaction from the participant. Ethnicity was not recorded as part of this study. Also 
the population is largely comprised of women. This may have occurred due to the 
method of using passing trade with a bias towards large numbers of females, 
however, this may also be because women are more likely to approach a health 
monitoring stand rather than men. Men generally are less likely to volunteer to get a 
health check and men are 20% less likely to go to their GP than women (WHO 
2003). However, many couples approached the stand together in this study, which 
highlights the probability that women initiate the approach and bring their partners 
with them, where men did not approach alone but accompanied their female 
companions. 
4.12   Discussion 
With the increase in stroke and heart disease worldwide it becomes critical to define 
and measure patient perceptions of blood pressure. This project has been able to 
identify the perception and knowledge of a large sample of a local population of West 
London (1019 participants). A key finding from this project is knowledge of BP in a 
hypertensive population does appear to influence control. Patient’s understanding of 
‘normal’ BP may enable them to participate in the management of their care more 
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and the process of bringing their BP under control and they may be more likely to 
make behaviour changes to reduce their BP. Approximately one third of the 
population self-reported hypertension and were taking BP medications. The 
presumption could therefore be made that this group which made up 29% of the 
population studied, would have seen a health professional at one time to discuss 
their BP. Disappointing then that only 23% of the hypertensive group were able to 
guess a ‘normal’ BP correctly compared with 37% of the healthy group. One reason 
for this may have been because the hypertensive group were more familiar with 
higher BP readings and didn’t recognise what a ‘normal’ BP should be. However, 
when asked about their own BP, only 13% were able to guess correctly and 30% of 
this population’s BP was uncontrolled with a SBP of ≥ 140mmHg. This highlights the 
lack of BP management in this population despite QOF and is similar in outcome to 
results from the Health Survey for England (2003) where only 21.8% of 
hypertensives had adequate BP control. Increasing age has however, been a strong 
indicator for poorer knowledge and affected perceptions of BP in this survey. The 
hypertensive population were significantly older than the healthy population which 
may account for the poorer understanding however this issue should be highlighted 
to health professionals to ensure information is adequately tailored towards older 
people as they are the population most likely to have hypertension.  
The lack of public and patient awareness of the importance of hypertension control 
for general good health and stroke prevention is well documented (Volpe & Dedhiya 
2006, Oliveria et al 2005, Samsa et al 1997). The data from this project supports 
these findings and concurs with Egan et al (2003) who found nearly half (46%) their 
hypertensive population did not know their own BP. This therefore, highlights the 
need to investigate further how the provision of information by health professionals in 
both primary and secondary care is given to patients. It is vital that educational and 
awareness programs are developed to inform both patients and the general  public 
of the importance of routine blood pressure monitoring and reducing high blood 
pressure effectively when it has been diagnosed.  These results show there is a 
significant lack of understanding of blood pressure in the general public population 
and people have little knowledge of what a normal blood pressure should be and 
even less understanding of what their own blood pressure is. There is an identified 
need for greater information provision and education for the general public 
surrounding blood pressure with specific interest in understanding what blood 
pressure is in terms of defining systolic and diastolic differences. This is with the aim 
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to empower people to take responsibility for their own health needs and to 
encourage members of the public to understand the significance of blood pressure 
on their own health. More importantly health professionals should be aware that 
those members of the general public diagnosed with hypertension also show little 
knowledge of normal BP and this has shown to effect control of their hypertension. 
Therefore health professionals should not presume that patients with diagnosed 
hypertension on treatment have any knowledge of their condition and information 
and education should be repeated at every opportunity when in consultation with 
patients. 
Although there is a large female sample in this population it is interesting that many 
couples had their BP checked at the same time and frequently if one partner didn’t 
know what ‘normal’ was then the other also didn’t know and vice versa if they did 
have an understanding. Therefore it could be suggested that if awareness can be 
raised in one person then this information and knowledge is likely to be passed on to 
their spouse and therefore improve the health and wellbeing of two people with one 
interaction.  
The hypertensive population within this study demonstrated less knowledge of what 
a normal BP should be than that of the healthy population, this is associated with 
age, however age itself is the highest non-modifiable risk factor for stroke and 
hypertension is the highest modifiable risk factor for stroke, therefore health 
professionals should be made aware with a sense of urgency that older people with 
hypertension may benefit from extra time and education at consultation, regarding 
BP control. This study reinforces the concept that hypertensives within the general 
population are not well controlled as one third of the hypertensive population 
continued to have a SBP of ≥140mmHg. Knowledge of normal BP values may be a 
reflection of an individual’s appreciation of the importance of BP control and the need 
to treat it and may therefore result in adherence to medication and behaviours which 
may improve control. 
It could be argued that knowledge of one’s own BP may reflect the frequency with 
which BP is taken (by self or doctor) as a result of poor BP control, however that was 
not an issue in this study as the hypertensives had poor knowledge of their own BP 
(77%). This is similar to Egan et al (2003) who found 46% of hypertensive adults 
over the age of 50 years did not know their own BP.  
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The results of this study have identified a significant lack of understanding and 
knowledge about blood pressure and a survey to explore the population in greater 
depth or by surveying a larger population may give valuable insight into public 
perceptions of health. This information can be developed and used in London-wide 
and national educational programmes and advertising campaigns in order to improve 
the overall public health and prevention of cardiovascular disease. To conclude this 
study has identified that those who guessed correctly had a lower BP, those who 
guessed incorrectly were significantly older and the healthy were more likely to 
guess correctly compared to the hypertensive groups. Therefore we can target 
information and education about BP control to older hypertensives within the 
community, however time should be spent to ensure the format of the information is 
targeted in such a way as to be effective in improving knowledge of BP and its 
relationship to stroke risk and awareness of individual risk to improve adherence to 
prevention strategies. 
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4.13  Chapter 4: Tables and figures  
Table 4.1: British Hypertension Society Guidelines for Hypertension 
Management (2004) 
Grades of hypertension 
Bp Category Systolic Bp mmHg Diastolic Bp 
mmHg 
Lifestyle Drug 
therapy 
Optimal <120 <80   
Normal ≥120 + <130 ≥80 + <85 - - 
High normal ≥130 + <139 ≥85 + <89 Yes Consider * 
Mild 
hypertension 
(grade 1) 
 
140-159 
 
90-99 
 
Yes 
 
Consider + 
Moderate 
hypertension 
(grade 2) 
 
160-179 
 
100-109 
 
Yes 
 
Yes 
Severe 
hypertension 
(grade 3) 
 
>180 
 
>110 
 
Yes 
 
Yes 
*Drug therapy may be indicated for people with established cardiovascular disease,  
chronic renal disease or diabetes with complications at BP levels >130/80mmHg. 
+ Drug therapy is recommended for people with established cardiovascular disease 
and Diabetes or evidence of target organ damage or a 10 year CVD risk > 20%. 
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Table 4.2: Population characteristics 
Population characteristics n=1019 % 
Age 
Range 
54 years 
16-92 
 
Female 724 74 
Self-reported hypertension 313 31 
Self-reported taking medications for BP 299 29 
No idea of normal BP or guessed 
incorrectly 
259 52 
No idea of own BP or guessed incorrectly 592 58 
Total clinically hypertensive 334 33 
 
 
 
Table 4.3: Blood pressure knowledge 
 
Question 
 
No idea or guessed incorrectly  
n=1019 
 
% 
What do you think is a 
‘normal’ BP 
529 52 
What do you think 
your own BP   reading 
is? 
592 58 
GP referrals 194 19 
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Table 4.4: Hypertensive coding results for study population 
Code n=1019 % 
Optimal  316 31 
Normal  167 16 
High normal 202 20 
Mild hypertension 256 25 
Moderate 
hypertension 
64 6 
Severe hypertension 14 1 
 
Figure 4.1: Knowledge of ‘normal’ BP  
 
Knowledge of ‘normal’ BP
23%
77%
correct
incorrect
Hypertensive
37%
63%
correct
incorrect
Healthy
Chi Square test P = 0.03
Mean age 63 years Mean age 50 years
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Figure 4.2: Knowledge of own BP  
Knowledge of own BP
11%
89%
correct
incorrect
33%
67%
correct
incorrect
Hypertensive Healthy
P = < 0.001
 
Figure 4.3: Knowledge of ‘normal’ BP in hypertensive group associated with 
lower BP readings 
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Chapter five: Individual risk awareness intervention 
in stroke (IRAIS) study 
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5.1 Introduction 
Recurrent stroke occurs in up to 20% of patients (Talelli & Greenwood 2008) and is 
more likely to be fatal than first stroke and survivors are more likely to be left with 
major disability (Rothwell 2007). Secondary stroke prevention strategies and risk 
factor management as well as advances in medical care have been shown to reduce 
stroke recurrence (Chaudhry et al 2008) and improve survival following an acute 
vascular event, however, studies observing behaviours post stroke have identified 
sustained behaviour change is low.  
From over 2,000 patients with ischaemic stroke followed up at 3 months, one quarter 
reported discontinuing 1 or more of their prescribed secondary prevention 
medications (Bushnell et al 2010). Redfern et al (2000) studied patients at one year 
post-stroke and reported 22% smoking, 36% obese and 4% drinking excessively. 
They suggest different behavioural risk factors are associated with specific socio-
demographic groups within the stroke population, for example they found younger, 
white males were more likely to smoke and non-white women more likely to be 
obese. Wang et al (2006) evaluated adherence to secondary prevention strategies 
within one year following ischaemic stroke and 69% were taking some sort of 
antithrombotic medication, however, only 36.4% were still taking the same 
antithrombotic therapy they had been discharged with. They concluded that 
adherence to secondary prevention was poor and identified income levels, 
categories of thrombotic agents and personal living ability as closely related to 
compliance. They suggested doctors should pay more attention to secondary stroke 
prevention and suggested providing patients with detailed medications instructions 
as a way of increasing the potential effectiveness of prevention treatments. In CAD, 
illness beliefs have been shown to contribute, as perceptions of more serious 
consequences have predicted better adherence (Stafford et al 2008).  
Studies to identify characteristics of adherence and non-adherence are important in 
recognising strategies to improve lifestyle behaviours post-stroke, and there are 
more studies investigating behaviours in cardiac patients than stroke. To our 
knowledge no study to date has investigated if risk awareness has any influence on 
stroke survivors’ behaviour.  
It has been suggested, stroke survivors are less likely to adhere to secondary 
prevention strategies than patients following myocardial infarction (MI) (Lewis et al 
2008 & Qureshi 2001). Pain at onset associated with MI has been suggested as one 
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factor which may contribute to adherence in cardiovascular patients, as an incentive 
to reduce the risk of experiencing the pain again (Agyeman et al 2006). Stroke is 
usually painless and often multi-factorial in its onset which is suggested as one of the 
possible reasons for the delay in presentation and poor knowledge of signs and 
symptoms in stroke patients. International studies have shown that patients are 
unlikely to call for urgent attention if they or a family member suffer a stroke (Segura 
et al 2003, Samsa et al 1997, Sug Yoon et al 2001, Pancioli et al 1998). This may go 
some way to explaining the disparity between behaviours in the two populations, 
however, studies have shown that attendance at cardiac rehabilitation programmes 
(French et al 2006) can be poor and long term adherence to medication in chronic 
disease groups is estimated as low as 50% (WHO 2003). Therefore, identifying the 
influences and causes of non-adherence are key questions which if answered may 
improve outcomes. However, diagnosis and management of  cardiovascular disease  
is improving in response to the national targets set for GP’s (QOF) and this may be 
one reason  for reductions seen in cardiovascular events in the UK, despite reports 
of low levels of adherence.  
The cognitive effects of stroke may be one cause of both delayed presentation to 
hospital and poor adherence. Stroke can severely affect a patient’s memory 
sufficiently to result in ‘unintentional non-adherence’ (Silcock & Standage 2007, 
Croquelois & Bogousslavsky 2006) which is often due to physical and /or cognitive 
problems. Cognitive impairment has been associated with non-adherence (O’Carroll 
et al 2010), however physical disability and social isolation can cause barriers to 
adherence such as having no one to collect a prescription or due to physical 
disability which affects getting to a pharmacy to collect a prescription or lack of 
financial support to afford regular prescriptions (under 65 years) for what could easily 
be three or more medications. The complexities which influence adherence are all 
important issues which should be discussed during interactions with health providers 
in order to identify potential barriers as soon as possible. 
5.2 Risk awareness 
Studies addressing knowledge of future event risk have mainly focussed on the 
general public (and then predominantly the white population) but one study showed 
that only 42% of patients with a history of previous stroke were aware of their future 
stroke risk and only 27% recalled being informed of their risk by a physician (Samsa 
et al 1997). Chapters 3 and 4 of this thesis have identified low levels of risk 
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awareness in a high risk stroke population with only 41% reporting being at risk of a 
future event (Chapter 3) and low levels BP awareness in a general population where 
knowledge of a ‘normal’ BP also appears to influence control (Chapter 4). Failure by 
physicians to control cardiovascular risk factors following stroke is an on-going 
problem but signs of improvement are being seen, since 2004 and the introduction of 
QOF BP monitoring and control have shown signs of significantly improving 
(Ashworth et al 2008), however, other studies have suggested CVD risk factor 
management remains inadequate (Girot et al 2005, Wang et al 2006, Raine et al 
2009, Wolfe et al 2010). The explanation for this may be related to poor patient 
awareness and knowledge (with older patients and those who have made an 
excellent recovery being at particular risk of poor awareness) and sub-optimal 
adherence to risk modifications (Crosquelois and Bogousslavsky 2006). Conversely, 
providing information about atherosclerosis may improve adherence to intervention 
protocols such as medications and lifestyle modifications (Kraywinkel et al 2007). 
Increases in public awareness of the signs and symptoms of stroke have improved 
early recognition and allowed new treatment advances such as thrombolysis for 
acute ischaemic stroke (RCP 2008).  
Charitable organisations such as the Stroke Association have been responsible for 
improvements in public awareness with recent surveys suggesting an increase in 
knowledge of stroke signs and symptoms from 45% to 85% (Stroke Association 
2010) mainly due to media campaigns such as F.A.S.T. (Face, Arm, Speech and 
Time). However, stroke patients are still slower than cardiac patients at attending 
hospital urgently with their symptoms and stroke patients may not recognise future 
signs and symptoms of stroke which differ from their original symptoms. However, an 
increase in general public awareness is useful for future generations of stroke 
sufferers. 
5.3 Barriers to risk factor awareness and control 
Barriers to risk factor control have been identified in various studies and include 
inadequate follow-up and monitoring of stroke survivors by health care professionals, 
inadequate prescribing of secondary prevention therapies, poor information provision 
and inadequate self-management of risk factors by patients (Jorgensen et al 1997, 
Rigler et al 2001, Bak et al 2002, Rudd et al 2004, Girot et al 2005, Kaplan et al 
2005, Wang et al 2006). Raine et al (2009) studied general practice records between 
1995-2005 and found only 25.6% of men and 20.8% of women received secondary 
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prevention. Wolfe et al (2010) suggest barriers to risk factor control include 
inadequate follow-up and monitoring by health care professionals, inadequate 
prescribing of secondary prevention medications, poor information provision and 
inadequate self-management of risk factors by patients. Therefore a multi-factorial 
approach is required to improve secondary prevention in this highly complex 
population. It is also important to consider an individual is not likely to initiate, change 
or maintain health behaviour in the face of barriers, unless they have a core belief 
they have the personal resources to do so (e.g. making the decision to stop smoking 
by not buying cigarettes, but sustaining smoking cessation when faced with the usual 
‘smoking-break’ with work colleagues). Thus consideration of self-efficacy, an 
individual’s motivational and self-regulatory skills, is imperative in any behaviour 
change intervention; such self-regulation will involve monitoring own behaviour, 
setting realistic goals to motivate and guide behaviour and enlisting social support to 
sustain behaviour (Bandura 2007). 
Increased knowledge of stroke risk factors is significantly associated with younger 
age, a higher educational level and not living alone (Muller-Nordham at al 2006). 
Well educated patients from high social classes are known to be more 
knowledgeable and compliant with healthcare advice than those from less privileged 
backgrounds (Nutbeam 2000). Indeed, even knowledge about hypertension and its 
aetiological role as a risk factor for stroke is not only poorly realised but partly 
associated with educational background (Samal et al 2007).  Therefore the challenge 
for health professionals is how to educate members of the public and patients about 
risk factors and other health messages, however, this challenge has been on-going 
for decades and is linked to health literacy. More research on patient behaviours 
post stroke will inform future campaigns to improve the effectiveness of health 
messages to all members of society particularly those at high risk from vascular 
disease. 
5.4 Risk management 
‘Risk management’ has been described in a number of ways, including a way of 
controlling future uncertainty (Giddens 1991, Beck 1992) and for allocation or 
apportioning of blame (Sachs 1996). However both the Department of Health (DH 
2001) and The Royal College of Physicians (RCP 2004) have taken risk 
management to mean a specific clinical construct defined in health policy by the 
National Service Framework for Older people (2001) and the National Clinical 
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Guidelines for stroke (2008). Risk management in this context is used to design 
strategies to prevent both primary and secondary stroke. These strategies have 
largely relied upon health professionals providing information, support and 
monitoring of patients conditions and control of individual risk factors for stroke such 
as BP, cholesterol, diabetes and smoking status. However, Redfern et al (2006) 
remind us that studies have identified failures in putting these strategies into 
practice. They suggest this failure is due to conflict between providing a patient 
centred approach and the goals of public health, but go on to offer social influences 
as key to risk factor management. Social influences impact on patient beliefs, 
adherence to medication and lifestyle advice as well as the socio-economic 
challenges of low economic status and educational levels as well as ethnicity and 
cultural disparities. 
5.5 Ethnicity 
Studies to identify specific risk differences in varying ethnic populations are useful to 
understand which groups are at high risk from certain vascular risk factors, for 
example, it has been suggested that men born in South Asia are 50% more likely to 
have an MI or Angina and Bangladeshi’s have the highest rates. In contrast men 
born in the Caribbean are 50% more likely to die of a stroke than the general 
population (POST 2007). Despite the biological differences, ethnicity also involves 
cultural and religious variables which effect behaviour of patients and it appears 
health professionals. Recent evidence implicates racial origin as a determinant of the 
type and level of healthcare received, suggesting that inequalities exist as a function 
of ethnic or social background (Bourke et al 2006). It is well known that patient’s 
values and beliefs influence behaviour (Smedley et al 2002, Hunt el al 2005) and this 
is of particular importance to Black Minority Ethnic (BME) groups when in 
consultation with health professionals from different ethnic backgrounds and should 
be taken into consideration during every interaction. Bentley et al (2008) found large 
variations in cultural diversity training for health care professionals across the 
country depending on profession and region. They called for National Guidelines to 
incorporate cultural competency training for all UK health care professional training 
bodies. 
5.6 Raising risk awareness to change behaviour 
Provision of information alone is rarely sufficient to affect health behaviour change 
(there are few, if any, smokers who are unaware of the message ‘smoking kills’), 
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however it remains a crucial element of health education. Due to the challenge this 
presents and the rise in the need for communication of risk to patients and the 
general public in order to increase self-management of chronic health conditions, the 
communication of risk information has recently received increased attention (NICE 
2010, WHO 2011). Research in the field of health psychology has demonstrated that 
individuals are more responsive to information about relative risk than absolute risk, 
and the former has greater influence over decision making (Edwards et al 2000). It 
has also been suggested that an individual’s perceptions of severity of the targeted 
health threat are as influential as perceptions of risk in relation to motivating 
behaviour change (Milne et al 2000, Witte & Allen 2000). Provision of risk 
information should also be accompanied by a personally tailored action plan of 
where and how the risk reducing behaviour may be implemented within the context 
of that individual’s current lifestyle (Sheeran 2002). Explicit in any risk 
communication should be an explanation of the process whereby the risk leads to 
the disease and the process through which that risk is reduced when health 
behaviour is altered or undertaken.  
Studies have shown that the provision of information may improve knowledge but 
has not been found to improve perceived health status (Forster et al 2001). It has 
been suggested that patient’s own perspectives about stroke illness and recovery 
are important as they may influence emotional adjustment and adherence to medical 
recommendations (Townend et al 2006). Wolf et al (1991) suggested that 
information about ones’ risk of stroke may provide the impetus for risk factor 
modification. The dissemination of risk information is indeed necessary if reductions 
in risk are to be achieved (Edwards et al 2000) and studies which include 
interventions to communicate risk, are useful to identify if risk awareness can 
improve adherence to secondary prevention strategies or the likelihood that patients 
will participate in behaviour changes to reduce risk.    
A review of the literature was performed in order to identify other relevant studies 
performed in order to improve adherence to secondary prevention and no directly 
specific risk awareness interventional studies were identified. However, other studies 
have been performed using strategies such as, enhanced educational programmes 
to impact on behaviour and improve adherence to secondary prevention strategies 
following stroke specifically (Gillham et al 2009, McManus et al 2009, Wolfe et al 
2010). From other reviews of interventions to improve adherence or alter behaviours, 
few have had significant results and of the 5 randomised controlled trials performed 
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specifically in stroke the most effective study used an integrated care model of 
multiple components and an integrated management system to demonstrate 
improved effects on risk factor management (Joubert et al 2009). This whole team 
commitment is an example of a ‘gold standard’ of stroke care, however, the multiple 
intervention components would be costly and difficult to coordinate in the long term 
and would require excellent communications between secondary and primary care. 
Although these elements should be expected, it would be challenging to implement 
these strategies across every stroke service in the country. Nevertheless, in-hospital 
initiation of secondary prevention therapies yielded high rates of adherence in the 
stroke PROTECT (Preventing Recurrence of Thrombo-embolic Events Through Co-
ordinated Treatment) program. This project delivered 8 medication/behavioural 
secondary prevention measures known to improve outcomes in patients with 
cerebrovascular disease (Ovbiagele et al 2004). The 4 medication goals were: 
 Antithrombotic 
 Statin 
 ACE 
 Thiazide Diuretic 
 The 4 Behavioural goals were: 
 Smoking cessation counselling 
 Exercise counselling 
 Diet counselling 
 Education about personal risk factors 
They found high rates of adherence to the measures at 3 months and suggest the 
inpatient setting provides a unique window of opportunity for the initiation of 
secondary prevention measures. The initiation of secondary prevention measures as 
an inpatient have been shown to be effective in other diseases such as coronary 
heart disease where good outcomes were demonstrated and led to a revision of 
national guidelines to endorse the approach as a national standard of care in 
patients with cardiac disease (Fonarow et al 2001). Currently stroke care guidelines 
provide evidence based treatment targets but do not suggest how secondary 
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prevention should be initiated or managed, however as the risk of stroke in the early 
days and weeks following initial event is so high the guidelines suggest prevention is 
initiated as soon as possible after the event (RCP 2008). Rothwell et al (2007) 
concluded urgent use of existing preventive treatments was associated with an 80% 
reduction in risk of early recurrent stroke following a prospective study with the 
primary outcome as risk of stroke within 90 days of first seeking medical attention 
following stroke. The urgent preventive treatments used in this study were: 
 Antiplatelet therapy 
 BP lowering medications (existing medications or Perindopril) 
 BP lowering plus or minus Indapamide (Thiazide Diuretic) 
 Anticoagulation as required 
Further studies are required to identify if there is a long-term effect, however, this 
study clearly suggests the positive effect of acute, urgent preventive medical 
treatment for stroke and TIA. 
Changing illness perceptions could improve behaviours. Petrie et al (2002) examined 
whether a brief hospital intervention designed to alter patients perceptions about 
their myocardial infarction (MI) would result in better recovery and reduced disability. 
The intervention caused significant positive changes in patient views of their 
recovery from their MI. It has also been suggested illness perception can influence 
attendance to the cardiac rehabilitation programmes (French et al 2006). French et 
al (2006) identified patients who viewed their condition as controllable, symptomatic 
and with severe consequences and who felt they understood their condition were 
more likely to attend than those who did not. This offers insight into how perceptions 
can influence behaviour following MI and may be useful in understanding how stroke 
survivors may react following their event.  
Communicating risk information is a key element of the intervention of this study and 
Edwards et al (2000) offer strategies to improve the effectiveness of risk 
communications through including individual risk estimates rather than general risk 
information during a risk consultation. Edwards et al (2000) found that patients 
appeared to be more amenable to make behaviour changes with risk estimates 
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given during a discussion between the health professional and patient rather than 
attending screening sessions. 
Leventhals model of common-sense self-regulation (Diefenbach and Leventhal 
1996) is used as a premise that patients develop their own cognitive representation 
to make more sense of the threat to their health which therefore determines their 
behaviour in response to the threat. Theoretically the hypothesis for this study is, 
increasing individuals’ awareness of future vascular risk including secondary stroke, 
will influence their appreciation of the threat to their health and therefore increase the 
likelihood of behaviour change and adherence to secondary preventions strategies 
which will reduce the threat or in this situation risk of future vascular events. 
5.7 Aims and objectives 
1. To study the characteristics, knowledge of stroke and perception of risk in a 
stroke population. 
2. To investigate if a risk awareness intervention increases risk awareness in a 
stroke population using a RCT. 
3. To identify if an increased risk awareness improves adherence to secondary 
prevention strategies such as medication taking and behaviour modification in 
the 3 months following discharge from hospital. 
5.8 Methodology  
This study will use a variety of methods to measure adherence including 
physiological measurement and patient self-reporting.  
The MRC presents a step-wise approach to the implementation of complex 
interventions and suggests a randomised controlled trial is the optimal study design 
to minimise bias and provide the most accurate estimate of a complex intervention’s 
benefits (MRC 2000). This study was developed using the MRC approach to 
complex interventions as a framework for the design and evaluation of the RCT. 
The first step of the framework used was to establish the theoretical basis that 
suggests that the intervention should have the expected outcome. The literature 
review informed and identified stroke recurrence as a real risk and secondary 
prevention of stroke using strategies such as medication taking and lifestyle 
modification as key. The second step in evaluating a complex intervention is to 
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develop an understanding of the intervention and its possible effects. This involves 
delineating an intervention’ components and how they inter-relate and how active 
components of a complex package may be related to either surrogate or final 
outcomes. ‘Modelling’ refers to the possibility that this phase is paper-based for 
example computer simulations or economic modelling. It may also include qualitative 
testing through focus groups, preliminary surveys case studies or small 
observational studies. The results from chapters 3 and 4 have been used to assume 
increased knowledge and awareness of personal risk improve control of 
hypertension and behaviours post stroke and have informed the development of the 
intervention to be tested. The third step in is the crucial stage prior to the main RCT. 
Evidence can be obtained to support the theoretically expected treatment effect, to 
identify an appropriate control group, outcome measures, estimates of recruitment 
for a main trial and other requirements of such a trial. The fourth phase and central 
step in the evaluation of a complex intervention is the main RCT and required 
attention to standard issues of adequate power, adequate randomisation and 
blinding appropriate outcomes measures, informed consent of participants and other 
standard features of well designed trials. 
 
It has been suggested that a multiple assessment approach to the measurement of 
adherence is the most accurate way to measure all the aspects of secondary 
prevention advice. Using a mix of physiological and psychological measurements 
can provide a more robust understanding. Cummings et al (1981) employed a multi-
method design to assess the construct validity of 3 commonly used methods for 
assessing compliance, physiological assessment such as blood chemistry, ratings by 
health professionals and patient self-reports. They concluded multiple assessments 
are the best way to ensure accuracy in gauging levels of patient adherence and 
behaviour to medical instructions and therefore this study will aim to use similar 
methods of assessment.   
5.8.1 Trial design 
A pre and post open labelled RCT intervention trial design was used to measure 
stroke risk factor control and patients perception of their risk of future stroke and 
heart disease as well as measuring their understanding of stroke risk factors, likely 
cause and intended behaviour modifications at baseline and at follow-up. Following 
the Medical Research Council Framework for the development and evaluation of 
complex health service interventions (Craig et al 2008) work was performed to inform 
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the development of this novel intervention to improve adherence to secondary 
prevention strategies and influence risk factor control in a stroke population. This 
work is detailed in chapters 2-4. The results from the studies performed as part of 
this PhD have informed the researcher in order to identify the intervention and the 
variables to be measured as part of the RCT. Awareness of BP improved control in 
hypertensive members of the public and awareness of risk resulted in more stroke 
survivors making behaviour changes in response to their stroke even up to 5 years 
after the event. Clear, transparent and detailed reporting of RCT’s are important 
aspects and this study uses the CONSORT convention (Hopewell et al 2008) as a 
guide to maintain a clear and transparent report of the design, methodology and 
results obtained from this study. 
The study was registered as the Individual Risk Awareness Intervention in Stroke   
study with the International Standard Randomised Controlled Trial Number register 
(ISRCTN67999605) as part of the quality standard process for this study. Figure 5.1 
is a flow chart of the process of the study including number of participants 
approached about the study, those recruited and randomised, the intervention and 
controls and the final numbers at follow-up for endpoint data collection.  
5.8.2 Risk modelling for secondary stroke risk 
The Framingham study risk models have been used to identify cross-risk for IHD, 
stroke and diabetes (D’Agostino et al 2000 and Wolf et al 1991). This  and other 
models have been found to be useful tools to gain a better understanding of the 
relationship between risk factors and the occurrences of cardiovascular events in 
subjects who are free of systemic vascular disease, as well as individuals who have 
had a prior event or are at particularly high risk of an event (D’Agostino et al 2000). 
Risk assessment is now a well-established tool for health professionals to identify 
patients at a higher risk of stroke, however the concept of risk has not been broadly 
taught to patients following a first vascular event to control factors affecting the risk 
of further events.  
Logistic regression (Appendix 3) was used in the development of a risk modelling 
tool to produce a risk score for secondary stroke. The regression was used to create 
a predictive model based on the development dataset which included 300 subjects 
from the British Repository of DNA in Stroke (BRAINS) database. BRAINS is a 
platform for several arms for collecting DNA in patients with different 
cerebrovascular diseases including TIA, Arterio Venous Malformations (AVM), 
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ischaemic and haemorrhagic stroke. Using uni-variate analysis, we evaluated a 
range of covariates as potential determinants of secondary score risk including age, 
gender, history of hypertension, diabetes, ischemic heart disease, peripheral artery 
disease (PAD), atrial fibrillation, smoking history and any drug history 
(statin/antiplatelets/antihypertensive). Baseline parameters significant on uni-variate 
analysis (p<0.25) were used in step-wise multi-variable logistic regression analysis to 
determine independent predictors of secondary stroke. Once the final model had 
been defined, an equation (listed below) was constructed using beta co-efficients of 
variables significant in multivariable logistic regression analysis to derive a score 
which would predict risk of secondary stroke (Appendix 3).  
5.8.3 Independent variables 
Independent variables were identified to measure adherence and effectiveness of 
the intervention to control risk factors and influence patient's lifestyle modification. 
The independent variables measured were: 
 Blood Pressure 
 Blood sugar 
 HbA1c 
 Weight 
 Waist 
 Cholesterol 
 National Institute of Health Stroke Scale (NIHSS) 
 C - reactive protein (CRP) 
In stroke patients with hypertension the absolute risk reduction is 2.2% after 2 years 
of treatment for an average diastolic BP reduction of 5-6mmHg and for an average 
systolic BP reduction of 10-12 mmHg (Collins et al 1990). Treatments to produce a 
BP lowering effect are numerous, the HOPE trial (2000) showed that Ramipril, an 
Angiotensin Converting Enzyme (ACE) inhibitor reduced the risk of vascular events 
and PROGRESS (2001) showed that a combination of an ACE and a diuretic 
(Indapamide) reduced the risk of a new vascular event after an ischemic or 
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haemorrhagic stroke. For patients with a history of ischaemic heart disease or 
hypercholesterolaemia, treatment with a statin leads to approximately 25% relative 
risk reduction in stroke (Di Mascio et al 2000) and the Heart Protection Study (2002) 
showed a benefit for patients with previous ischemic stroke if treated with statins 
regardless of their cholesterol levels. Both blood glucose and HbA1c were measured 
to reflect current diabetes control, the HbA1c measurement was particularly useful in 
that it measures glycaemic control over the 3 month period. 
Few weight loss studies have been powered to detect differences in mortality and 
morbidity or followed patients up for sufficient time, however low fat diets in the 
overweight and obese have been shown to reduce type 2 diabetes, improve blood 
pressure control and reduce hypertension medication for up to 3 years. However, it 
is important to consider dietary change should be feasible financially and should fit 
within the patient’s lifestyle as well as appealing to ones tastes in order to be 
sustainable over time (Singh et al 2002). Waist was measured in order to identify 
weight loss but also as a way of measuring potential cardiovascular risk reduction as 
waist measurement is an indicator for cardiovascular risk (Zhu et al 2002). Janssen 
et al (2002) reported that increased visceral fat, as measured by magnetic 
resonance imaging (MRI) in 341 whites, had a stronger correlation with waist 
circumference than with body mass index (BMI; in kg/m2). Using the third National 
Health and Nutrition Examination Survey data in 9019 Europeans, Zhu et al (2002) 
reported that waist circumference is more closely linked to cardiovascular disease 
risk factors than BMI. Cholesterol was measured to indicate effective secondary 
prevention with medication and to support self-reports of medication taking.  Severity 
of stroke was assessed using the National Institute of Health Stroke Scale (NIHSS) 
(Brott et al 1989). This NIHSS is a standardized method used by physicians and 
other health care professionals to measure the level of impairment caused by a 
stroke. The scale serves several purposes, but its main use in recent years is during 
the assessment of whether or not the degree of disability caused by a given stroke 
merits treatment with thrombolysis (Bradley et al 2004). The NIHSS is also 
commonly used in research, where it allows for the objective comparison of efficacy 
across different stroke treatments and interventions. 
The NIHSS (Brott et al 1989) measures several aspects of brain function, including 
consciousness, vision, sensation, movement, speech, and language. A certain 
number of points are given for each impairment identified during a focused 
neurological examination. A maximal score of 42 represents the most severe and 
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devastating stroke and a score of 0 reflects no measureable impairment. Current 
guidelines as of 2008 (RCP) allow thrombolysis to be given to patient with a 
diagnosis of stroke with scores of greater than 4 points (Bradley et al 2004). 
C - reactive protein (CRP) was measured in order to provide a scientific control of 
the study as CRP is a critical component of the immune system, a complex set of 
proteins that are made when faced with a major infection or trauma. CRP is an 
‘acute-phase reactant’ and goes up during the acute period and then goes down 
again, however it has also been recognised as a risk for cardiovascular disease 
(Ridker 2003). Studies have demonstrated that baseline levels of CRP in apparently 
healthy men and women are highly predictive of future risk of heart attack, stroke, 
and the development of peripheral arterial disease (Libby et al 2002). CRP levels 
predict recurrent coronary events among patients who already suffer from heart 
disease and that the prognosis of patients in the acute phase of a heart attack is 
tightly linked to CRP levels. Individuals with elevated levels of CRP have a risk of 
stroke, about 2 to 3 times higher than the risk of those with low levels (Ridker 2003). 
Self-reported behaviours measured at follow-up were: 
 Smoking cessation 
 More exercise 
 Less alcohol 
 Weight loss 
 Low fat diet 
 Less salt 
 Taken medications 
 Smoking cessation was self-reported as well as alcohol intake. 
Weight loss was self-reported in conjunction with weight and waist measurements. 
Low fat diet as a secondary prevention strategy was included in the intervention and 
therefore measured as a behaviour change at follow-up. High salt intake is 
associated with significantly increased risk of stroke and total cardiovascular disease 
(Strazzullo et al 2009). Reducing sodium intake is also known to reduce BP (Sacn 
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2003) and a small reduction from 9g to 6g (teaspoon) per day is significant to 
produce an effect. Moderate levels of activity (30 mins per day) have been 
associated with a significant reduction in stroke risk of 20% (Wendel-Vos et al 2004). 
It has also been suggested the addition of exercise to diet can reduce the risk of 
metabolic syndrome in men (Brown et al 2009). However, Brooke et al (2009) found 
only half of the stroke survivors in their study were participating in physical activity at 
12 months post stroke and were less likely to perform physical activity to lose weight.  
5.8.4 Power calculation 
Group sample sizes of 48 in group one and 48 in group two achieve 80% power to 
detect a difference between the group proportions of 0.28. The proportion in group 
one (the treatment group) is assumed to be 0.4 under the null hypothesis and 0.68 
under the alternative hypothesis. The proportion in group two (the control group) is 
0.4. The test statistic used is the two-sided Z test with pooled variance. The 
significance level of the test was targeted at 0.05. The significance level actually 
achieved by this design is 0.05. 
5.8.5 Inclusion criteria 
 All patients with a diagnosis of ischaemic stroke who are being treated as 
inpatients at Imperial College Healthcare NHS Trust.  
 All patients who are able to participate in a one to one risk awareness 
intervention session or who have a spouse willing to engage and 
participate in the study. 
 Patients who are able to consent both verbally and sign a written consent 
form.  
5.8.6 Exclusion criteria 
 Patients who are unlikely to live as a consequence of the stroke 
 Patients who are unlikely to be able to attend follow-up consultation at 3 
months. 
 Patients who are unable to participate in the intervention due to cognition 
and memory difficulties following their stroke or pre-morbidly. 
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5.8.7 Randomisation and blinding 
Subjects were randomised using computer-generated random codes. The 
researcher was blind to randomisation until after recruitment of each participant to 
avoid selection bias. The trial is an open-labelled design with blinding of the 
researcher only at randomisation. This was achieved through sealing each random 
code in an envelope prior to commencing the trial, which was only selected after the 
participant had been recruited.    
5.8.8 Intervention 
Early initiation of prevention strategies has been shown to improve sustained 
adherence and good outcomes in stroke patients (Ovbiagele et al 2004) therefore 
the intervention was given whilst the patient was still an inpatient, however with a 
discharge date set. 
Those patients randomised to receive the intervention underwent a 30 minute risk 
awareness intervention session with the researcher. An intervention proforma 
(Appendix 5) was used to ensure all intervention participants received similar 
information regarding specific risk factors. The proforma was divided into sections: 
1. Smoking 
2. Exercise and Activity 
3. Medications 
4. Blood pressure 
5. Cholesterol 
6. Diet 
7. Alcohol 
8. Salt 
9. Follow-up 
The participant was informed with medication information specific to their individual 
risk factors to ensure they were given an understanding of which medications were 
for which risk factor and how the medication affects and controls each risk factor in 
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order to reduce overall stroke risk. This has been shown to be successful where a 
relationship was found between regimen persistence of stroke prevention 
medications in those with an understanding of why prevention medications were 
prescribed and how to refill the prescriptions (Bushnell et al 2010). The intervention 
group received enhanced risk factor awareness information, comprising further 
information about stroke pathology specific to their current condition and diagnosis, 
explanation of their individual stroke risk factors with particular focus on how lifestyle 
change and medication could influence modification of risk factors for future stroke 
and vascular disease (Appendix 5). Relatives were invited to be present during the 
intervention sessions. The intervention group were also given a percentage risk 
score for future stroke stratified by current smoking status which was developed 
using logistic regression modelling. The risk score was presented to the participants 
in a percentage format to provide them with an element of numerical understanding 
of their personal risk of future stroke (Appendix 3).  
The control group received usual practice and no further risk awareness information 
and were followed up for data endpoint collection at 3 months. All participants 
completed the study proforma (Appendix 4) prior to randomisation to obtain baseline 
data such as age, gender, ethnicity, educational level and marital status and 
baseline dichotomised risk perceptions were also recorded for both study arms prior 
to the intervention. 
All the stroke survivors invited to participate in the study had suffered an acute 
ischaemic stroke confirmed on imaging. This subgroup of stroke was chosen as the 
risk factors for ischaemic stroke are most affected by control, management and 
behaviour change, however BP is a risk factor for both ischaemic and haemorrhagic 
stroke and reduction and management benefits both equally. 
A favourable ethical opinion was given to the study by the East London Research 
Ethics Committee (REC 10/H0701/9) on 8th April 2010.  
5.8.9 Analysis 
Data collected from the proforma completed for each participant was double-entered 
into Epidata and exported to STATA-11.1 for statistical analysis (StataCorp 2007).  
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5.9 Results 
Population characteristics and demographics are found in Table 5.1. The study 
reached power with 96 participants recruited. Of the 96 participants, 47 were 
randomised to the intervention and 49 randomised to control group. Two participants 
were lost to follow-up from the control group, therefore 94 patients data were 
analysed with 47 in both arms of the study. No one suffered a further ischaemic 
stroke event during the 3 month study period. Mean age was 65 years in the 
intervention group and 66 years in the control group (95% CI 12.1-12.7, P=0.56). 
There was an equal gender split in both groups (Male n= 30 in intervention arm and 
n=26 in control arm). The majority of participants were white in both groups with 29 
(61.7%) in the intervention group and 33 (67.3%) in the control group.  Black Ethnic 
Minority (BME) groups made up 13% of the total cohort. The majority of participants 
were married in both groups with 27 (57.4%) and 27 (55.1%) respectively. All the 
participants had at least a secondary school education and 19 (40.4%) had a 
university education in the intervention group and 9 (18.3%) in the control group 
(P=0.06). NIHSS showed minimal deficit at discharge for both groups with a mean 
score of 1.2 and .73 (P=0.42) respectively which was not significantly different. 
Length of stay on the stroke unit was longer in the intervention group with 14 days 
compared to 5 days in the control group however this was statistically insignificant 
(P=0.06) and can be explained by the inclusion of a single outlier in the intervention 
group of 67 days, this is further demonstrated by the Median length of stay which for 
the intervention group was 3 days compared to 2 for the control.  Results for 
perception and knowledge questions asked at discharge were prior to the 
intervention and therefore any impact of the intervention will be seen in the analysis 
of the responses given at follow-up to ensure any significance is related specifically 
to the intervention. Mean length of follow-up was 89 days. 
Interventions during admission were recorded to identify if a medical intervention had 
any effect on behaviour, however medical interventions for the entire group were low 
with 5 patients undergoing a carotid endarterectomy (Intervention arm n=2, control 
arm n=3), only one patient underwent a hemi-craniectomy from the intervention arm, 
none from  the control arm. Eight patients from the intervention arm received 
thrombolysis compared to two patients in the control arm. The majority of patients in 
the study received no advanced medical interventions beyond usual care 
(intervention arm n = 36, control arm n = 44) (Figure 5.2). 
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5.9.1 Past medical history 
Hypertension was self-reported as the most common risk factor in both groups (n=39 
intervention group and n=26 in the control group, P=0.09), followed by 
hypercholesterolaemia with 19 (40%) and 12 (25%) respectively. A previous stroke 
was reported in 16 (34%) of participants in the intervention group and 13 (28%) of 
the control group (Table 5.2). 
5.9.2 Medication taking  
Medications on admission were recorded and only cardiovascular disease related 
medications were recorded for the purpose of this study. The medications were 
divided into groups for, 1) any antiplatelet, 2) any statins, 3) any hypertensive 
medications, 4) anticoagulation (Warfarin), and 5) any diabetes medication. The 
discharge medications were recorded and follow-up medications were then recorded 
at the 3 month consultation. On admission a moderate amount of the participants 
were admitted to hospital taking no medication (intervention n=12, control n=17), 
however at discharge all patients were taking either antiplatelet or anticoagulation 
medication in both groups, and nearly all were taking statins (intervention n=47, 
control n=43).  Of the intervention group at baseline 94% (n=44) were discharged 
with an antiplatelet and 96% (n=45) of the control group, 6% (n=3) and 4% (n=2) 
were discharged with warfarin medication respectively and 51% (n=24) of the 
intervention group were taking anti-hypertensive medication and 68% (n=32) of the 
control group. At discharge 98% (n=46) of the intervention group and 91% (n=43) of 
the control group were prescribed a statin. At follow-up 89% (n=42) in the 
intervention and 94% (n=44) in the control group self-reported they were prescribed 
and were taking an antiplatelet medication. At follow-up 91% (n=43) of the 
intervention group and 87% (n=41) of the control group self-reported being 
prescribed and taking a statin, 47% (n=22) reported taking hypertensive medication 
in the intervention group compared to 64% (n=30) in the control group and 13% 
(n=7) and 17% (n=8) respectively reported taking medications for diabetes (Table 
5.3). 
5.9.3 Pre-stroke behaviours 
Smoking frequency was measured as never, past or current/recently quit. Alcohol 
intake was measured recording none, recommended (21units for men, 14 units for 
women) or more than recommended. Both smoking and alcohol history was self-
reported. Current or recent smoking was found in 16 participants at discharge in the 
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intervention group and 8 of the control arm (P=0.17). At follow-up 9 participants from 
the intervention arm self-reported quitting and 2 from the control arm reported the 
same. Alcohol intake at discharge was high in both groups but especially the 
intervention arm with 13 participants drinking more than the recommended amount 
of alcohol per week and 8 in the control group reporting the same, at follow-up 11 
from the intervention group self-reported drinking less alcohol compared to only 3 in 
the control arm (P=0.06). 
5.9.4 Risk awareness and perception 
Risk perception was measured by asking patients at baseline and then follow-up, 
whether they perceived themselves to be at risk of a future stroke. They had the 
opportunity to answer either, yes, no or don’t know. At discharge both groups 
answered similarly, 30% of the intervention arm and 31% of the control arm 
answered yes, 19% of the intervention arm and 18% of the control arm answered no 
and the majority in both groups answered don’t know (51% intervention group and 
51% in control group). However at follow-up 51% of the intervention group compared 
to 33% of the control group answered yes to being at risk, 23% and 15% respectively 
answered no and 25% and 51% respectively answered don’t know (P=0.041) 
showing a significant difference in perception of risk in the intervention group. There 
was a similar result when asked about their risk of a heart attack with a significant 
difference in perception between the two groups at follow-up (P=0.039).  
5.9.5 Knowledge of cause and type of stroke  
Overall knowledge of the cause of stroke was poor with 82% of the total population 
unable to name in free-text any cause of their stroke at baseline and 70% unable to 
name a cause of their stroke at follow-up. As part of the inclusion criteria all patients 
recruited into the study had a diagnosis of ischaemic stroke and knowledge of stroke 
type was seen in both groups with 60% (28) of the intervention group responding to 
the question with either clot or ischaemia and 41% (20) in the control arm (P=0.141) 
at discharge, however at follow-up the intervention group showed significantly higher 
knowledge of stroke type with 80% (28) able to answer clot or ischaemia compared 
with 47% (17) from the control group at follow-up (P=0.001) (Figure 5.3). 
5.9.6 Knowledge of risk factors 
At baseline and then at follow-up participants were asked if they had any risk factors 
for stroke, they were given the option to answer yes and provide information about 
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their risk factors or to answer no. At baseline 49% (23) of the intervention arm 
answered yes to having risk factors compared to 61% (30) of the control arm. At 
follow-up 70% (33) of the intervention arm answered positively to having risk factors 
for stroke compared to 51% (23) of the control arm which suggests a trend (P=0.061) 
towards greater awareness in the intervention group. Risk factors identified at 
discharge included Blood Pressure (Intervention 36%, control 50%), previous stroke 
(intervention16%, control 16%), stress (intervention 8%, control 0) and smoking 
(intervention 12%, control 8%). At follow-up more participants generally cited 
appropriate risk factors and in the intervention group BP was cited as a risk factor by 
48% compared to 47% in the control arm.  
5.9.7 Behaviour changes after stroke 
The participants were asked if they planned to make any lifestyle or behaviour 
changes in response to their stroke at the initial interview prior to the intervention and 
were asked if they made any of those changes at the follow-up interview. The 
number of behaviour changes self-reported at follow-up was divided into three 
groups for the analysis, none, 1-2 changes or 3 or more changes. The results (figure 
5.5) for the intervention group showed 8% (n=4) made no lifestyle changes, 56% 
(n=26) made 1-2 changes and 36% (n=17) made 3 or more changes. For the control 
group 46% n=21) made no changes, 46% (n=22) made 1-2 changes and only 8% 
(n=4) made 3 or more changes.  This suggests a highly significant difference in the 
number of lifestyle changes made between the two groups (P<0.001) (Figure 5.4). 
 
Analysis of the types of behaviour change made identified medication taking as the 
most frequent behaviour change in both groups. The intervention group made more 
lifestyle changes in all categories and the most reported changes following 
medication (70%) taking were more exercise (34%), less alcohol (23%), followed by 
low fat diet (21%), smoking cessation (19%), weight loss (15%) and less salt (4%) in 
the intervention group, however in the control group only 29% self-reported taking 
medications, 11%  reported taking more exercise, 8% a low fat diet, 6% less alcohol 
and 2% reported weight loss. No one reported taking less salt in their diet and only 
4% stopped smoking in response to their stroke (Figure 5.5). T-test analysis 
identified the intervention group made overall more lifestyle changes in all categories 
of behaviour compared to the control group (P=0.03) (Figure 5.5).   
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5.9.8 Risk factor control 
Risk factors were measured at baseline and again at follow-up. Data was collected 
and analysed for Blood pressure, cholesterol, weight, waist, blood glucose and CRP. 
Mean measurements were calculated and entered into STATA for analysis. There 
was no statistical difference between blood glucose at discharge for the intervention 
group (6.2mmols; 2.0Std dev, P=0.12) versus the control group (6.9mmols; 2.6Std 
dev) with a P=0.12 and follow-up for the intervention group (5.8mmols; 1.5Std dev) 
and controls (6.3mmols; 1.67Std dev) and a P=0.23, weight at discharge and follow-
up didn’t significantly alter for both groups (intervention at discharge 79.3kgs; std dev 
18.5 and control 78.7kgs;std dev 11.92), waist at discharge was lower in the control 
group but not significantly (intervention 37.1 inches and 36.5 inches for the control) 
or cholesterol in both the intervention and control groups at discharge (4.7mmols 
intervention; 4.3mmols control) going down to 4.1mmols in the intervention group 
and 4.06 in the control, however CRP measurement at discharge and follow-up for 
the intervention group was significantly different P=0.05 and systolic BP at follow-up 
was shown to be significantly different for the intervention group compared with the 
control group (P=0.01). The reduction of SBP was shown to be 3 mmHg in the 
intervention group but this was not significant (P=0.25) (Table 5.4). 
5.10 Limitations 
The control group received conventional treatment, however it might be possible that 
by being involved in the study awareness of risk was inadvertently raised and may 
have influenced their behaviours and improved adherence and lifestyle behaviours. 
This is known as the Hawthorne effect, by potentially tainting the ‘control’ status 
though involvement in the study information sheet. 
The researcher conducted all the assessment and interventions as well as the 
follow-up assessments therefore it is important to discuss the limitation of lack of 
blinding of the researcher throughout the totality of the project, however it is 
important to highlight that blinding at the time of recruitment was upheld rigorously 
with randomisation numbers (1=intervention, 2=control) sealed in envelopes until 
recruitment had been made. 
5.11 Discussion 
The results suggest the intervention was successful in increasing risk awareness in 
this population of stroke survivors. It also suggests that increasing risk awareness 
has an impact on knowledge and behaviour during the first 90 days after stroke. The 
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majority of both participants in both groups were married, which suggests a level of 
support after discharge, however spouse input was not measured at follow-up but 
approximately 25% of participants had a family member present during the 
intervention. Social support has been documented as a valuable resource affecting 
health and health behaviours (Conn 1991) and low NIHSS scores describe a 
population with minimal to mild disability and deficits following their stroke. The acute 
medical interventions were minimal and did not affect behaviour, however, the 
thrombolysis rate was 12.5% which is representative of current thrombolysis rates in 
London (RCP 2010) which supports the reliability of the cohort and is representative 
of current stroke practices in London. Researcher bias is avoided through using 
independent variables and data collection was specifically chosen to avoid any 
subjective elements, however this may have been introduced at the time of endpoint 
data collection because the researcher was not blinded to the intervention group. 
The evidence for medication taking in this population provides an example of good 
clinical prescribing of secondary prevention medications at discharge and generally 
suggests high levels of adherence at 3 months, however, on further analysis it was 
noted that despite the high numbers of self-reported medication taking in both 
groups at follow-up across the five secondary prevention drug groups (antiplatelet, 
warfarin, statins, hypertensive and diabetes medications), at follow-up four out of the 
five medication groups showed a small reduction. The intervention group taking 
antiplatelet therapy went from 94% at discharge to 89% at follow-up, this is a small 
reduction of 5%, however it occurred over a short period of time. This reduction in 
medication taking may be the result of non-adherence or poor repeat prescribing 
over time but could end up in a significant loss of risk factor management for 
secondary prevention. The reduction of antihypertensive medication taking at 
discharge compared to admission (Table 5.3) may be due to specialist knowledge of 
drug treatment regimens which enable a reduction in the overall amount of 
antihypertensive medications through the introduction of a more effective drug. The 
only drug which saw an increase over the 3 month period was warfarin which may 
have indicated the slight drop in participants taking antiplatelet medications, however 
the reduction in statin therapy went from 98% to 91% in the intervention group and 
91% to 87% in the control group. This result suggests there is a need for medication 
focussed follow-up to ensure patients continue to take prescribed medications, it is 
understandable for medication prescriptions to change if there are side-effects, 
however, the long-term risk reduction benefits of these medications should be 
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explained at discharge to ensure patients are aware of the need to take them for the 
foreseeable future and health professionals in the specialist areas should ensure 
other health care colleagues are aware of the long-term needs of patients to be 
prescribed the medications.  
The number of BME participants in this study was low (13%), however, the results 
are representative of the ethnic diversity across the country, despite this the 
importance of risk and ethnicity should be discussed with regard to how health 
professionals manage secondary stroke prevention strategies. Few studies have 
focussed on knowledge of stroke risk factors in BME populations in the UK. Due to 
the low uptake of BME groups in this study knowledge of behaviour and risk 
awareness remains low. Studies from overseas looking at knowledge of high risk 
populations have shown knowledge of risk factors for cardiovascular disease is low 
(Khan MS et al 2006), this raises concerns regarding populations living in the UK 
and how health information messages are shared to ensure knowledge of risk is 
increased in all sectors of society and ethnicities. Further studies of BME groups in 
stroke are needed to increase the body of knowledge regarding knowledge and 
behaviour.  
Perception of risk was poor at baseline, prior to the intervention. Interestingly both 
cohorts answered similarly at discharge with only one third in each group perceiving 
they were at risk of a further stroke and half of both groups answered they did not 
know about their risk. The results remained the same for the control group at follow-
up but an increase was seen in the intervention group response at follow-up of 21%. 
The number of participants in the intervention group who went from ‘don’t know’ at 
discharge to ‘at risk’ at follow-up went from 51% down to 20% which suggests a shift 
in perception of risk. These results mirror similar studies which found risk perception 
low (42%) in a cohort of patients who have a history of stroke (Samsa et al 1997).  
Interestingly, the REACT study (Erhardt & Hobbs 2002), of attitudes and behaviours 
of the general public in 5 major European Countries, found that risk awareness and 
knowledge was poor in all groups studied and the presence of cardiovascular risk 
factors had no influence on risk perception when compared with members of the 
public with no risk factors. Similar results were found in the level of knowledge of 
stroke risk factors in this study, with a trend (P=0.069) for the intervention group as, 
half (49%) believed they had risk factors for stroke and this went up to 69% at follow-
up whereas in the control group the figure went down at follow-up from 61% to 47% 
who believed they had risk factors for stroke. This suggests an improvement in 
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knowledge of stroke risk factors in the intervention group and the retention of 
information throughout the 3 months after the intervention. 
Stock (2009) found a perceived lack of consistent secondary prevention advice from 
health professionals was a cause of stroke survivors being uncertain about 
implementing guidance in their daily lives. However, both groups answered highly to 
receiving enough information about their stroke, with only 2 participants answering 
no to the question. However, a future study might involve asking patients about how 
they perceive the information they are provided to understand if they believe they 
receive consistent information and if they understand what the information is trying to 
convey. 
The results show low levels of knowledge overall relating to the cause of stroke, 
however, knowledge of stroke sub-type was good in both cohorts but significantly 
better in the intervention group at follow-up (P=0.001) (Figure 5.3). This result is 
interesting as the initial data at discharge showed the intervention group had less 
knowledge of the type of stroke than the controls, therefore indicating the 
intervention significantly increased their knowledge of the type of stroke and they 
retained that information at 3 months. It would be interesting to understand why the 
results for knowledge of stroke cause were low compared with knowledge of stroke 
subtype, however this may be a direct reflection on the information provided 
regarding cause of stroke as an inpatient in hospital as it can be difficult to find the 
cause of stroke in as many as 25% of patients during the acute phase of their 
admission. The identification of the subtype of stroke is done early as part of the 
urgent treatment and this is communicated to patients as part of routine practice. 
However, the results at the time of discharge were actually low for knowledge of 
stroke sub-type and they remained quite low in the control arm of the study, 
therefore this result might suggest that communication of stroke subtype may not be 
effective during the acute phase or it may not be highlighted as an important factor 
for secondary prevention for patients unless it is communicated in the form of a risk 
awareness intervention. As during the intervention the reasons for medications to 
prevent clot formation were discussed and reinforced to the participants as part of 
the intervention. 
This may also be a reflection of the individualisation of the intervention, through 
personalising their stroke, they were more likely to retain the information at follow-up. 
They showed a significant learning and retention of information through the 
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intervention as they had less knowledge than the control group at discharge, 
however at follow up the intervention group showed a significant difference in their 
awareness of having vascular risk factors. However, it is also important to suggest 
the simple increase in attention and professional interaction may have been enough 
to increase learning and retention of information in the intervention group.    
Knowledge of risk factors was significantly higher in the intervention group who were 
more aware of their risk of future stroke at follow-up than the control group. They 
were also more aware of their individual risk factors for stroke as 60% compared to 
47% of the control group, at follow-up answered yes to having a risk factor for stroke. 
An increase in their risk awareness and having risk factors was hypothesised as 
likely to influence behaviour and increase participant’s reaction to the threat of 
suffering a recurrent stroke and may be the reason for the intervention group’s 
significant increase in behaviour changes at follow-up. 
Behaviour modification overall was poor in the control group with only 29% reporting 
taking medications as a modified behaviour at follow-up in response to their stroke. 
The intervention group made significantly more lifestyle changes than the control 
group, however the changes reported were generally most common in the difficult to 
measure behaviours such as exercise, less alcohol and a low fat diet. Weight loss 
was reported in 13% of the cohort however, there was no significant difference in 
weight loss in the analysis (P=0.9). Studies have been performed to measure 
psychological reaction to information about increased risk of coronary heart disease 
in general practice (Christensen 2004) which showed no difference was found 
between any of the groups at baseline or at 1 or 5 year follow-up whether they were 
receiving information about being a low, moderate or high risk of CVD. Cooper 
(2007) alternatively offers the potential response to a false reassurance when 
receiving a low/minimal risk feedback, however, in this population of stroke survivors 
the risk is already moderate. 
Smoking results were disappointing in this study as 13 of 24 smokers were still 
smoking (54%) at follow-up overall. In the intervention group 7 of 16 were still 
smoking (43%) and only 2 of the 8 participants in the control group reported smoking 
cessation. This suggests smoking at 3 months is still a problem for stroke survivors 
who smoke, however the intervention group does appear to have been more likely to 
stop smoking, however this was not statistically significant.  
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Drinking excessive alcohol was high in the overall stroke population with 19% 
drinking more than the recommended levels of alcohol for men and women, however 
there was a significant response to reducing alcohol intake at follow-up for the 
intervention group which indicates an influence on behaviour change for lifestyle 
changes. However, drinking alcohol is high across the country, in England in 2008, 
71 per cent of men and 56 per cent of women reported drinking an alcoholic drink on 
at least one day in the week and eleven per cent of men and 6 per cent of women 
reported drinking every day (DH 2010), however 40% of the total population of this 
study didn’t drink at all according to self-reports which is reassuring. 
The overall results suggest behaviour was influenced by the intervention, however, 
the exact details of how behaviour was influenced is still unclear as just increased 
time and attention may have been equally responsible for the greater number of 
behaviour changes in the intervention group. However, one could responsibly report 
that an intervention involving increased risk perception is a useful tool to changing 
health behaviour in stroke survivors. The intervention group made significantly more 
self-reported behaviour changes than the control group and this may be related to 
participant bias in self-reporting, however in the presence of the other positive 
findings throughout the study this is unlikely. Increased risk awareness may be the 
factor which encourages patients to participate in lifestyle changes in response to 
their stroke and their perceived health threat. Therefore early initiation of a risk 
awareness intervention tool effects health behaviours at 3 month follow-up, however, 
whether this has any long-term impact is still unknown, however, as risk is highest 
during the first 90 days following stroke, these health behaviours to reduce risk are 
exciting outcomes for this study. 
The significance of a physiological impact on systolic blood pressure management is 
an exciting outcome of this study as any reduction in BP has an impact on reducing 
stroke recurrence. The reduction of 3mmHg does have significance for secondary 
stroke prevention as studies have shown even a small decrease in BP can reduce 
stroke risk by as much as 25-40%. This reduction may be the result of better 
adherence to medication taking but also as a result of the increase in behaviour 
changes made by the intervention group. They reported making more changes which 
would influence BP, such as weight loss, less alcohol, low fat diet and more 
exercise. These behaviours together with better adherence to medication taking may 
be the reason for the significant improvement in this most important part of risk factor 
management with BP being the highest modifiable risk factor for stroke.  
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Certainly the positive results from this study for medication taking is of interest as 
there was high self-reported results for all medications, the majority of participants in 
both groups were taking similar drugs to what they were discharged with at 3 
months. It has been reported that adherence is improved by regular follow-up and 
this is probably reflected in this cohort with such an early follow-up from discharge 
which reflects the high levels of adherence, also being part of a research study 
improved adherence (Benner 2004) and as the researcher ensured patients received 
contact at 3 months where possible, this may have positivity influenced both groups 
as they were guaranteed a follow-up consultation with a health professional by being 
part of a research study. Therefore as a recommendation it would be reasonable to 
suggest that it would be useful for all patients admitted to stroke units across the 
country to be invited to participate in research studies as a way of increasing 
adherence and improving long-term care and follow-up of these high risk patients. It 
was encouraging to see that all patients were discharged home with anti-platelet and 
statin therapy. However, 3 months may not have been long enough to impact 
cholesterol levels, but it is disappointing not to have seen a larger reduction in 
cholesterol levels considering the high self-reporting for taking medications at follow-
up, this may be a sign that in-fact self-reporting of medication adherence is not as 
reliable as one would like. Studies have suggested adherence to statins is as low as 
50% (Jacobson 2004) so it would be unrealistic to expect the high levels of self-
reported adherence to be completely accurate in this study. However, longer-term 
follow-up may allow a better opportunity to identify reductions in cholesterol levels 
and adherence to medication taking. Longer-term follow-up would also be useful as 
some studies have suggested although early initiation of secondary prevention 
strategies have been successful, long-term persistence may not occur (Bushnell et al 
2009). 
Stroke is a chronic condition, symptoms are usually physical and on-going 
rehabilitation is actively encouraged. However, from a secondary prevention 
perspective, many risk factors for secondary stroke remain silent or asymptomatic, 
making control and management more complex. Patients require high levels of 
health literacy to understand new medications to take and choose behaviours which 
might reduce their risk of stroke recurrence. Prior to discharge from hospital is the 
ideal opportunity to communicate important information while the perception and the 
disease consequences are high in this group, may be the most opportune time to 
communicate a long-lasting message of risk awareness for secondary prevention. 
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In conclusion, this study has resulted in enhanced patient care, and increased risk 
factor awareness for the stroke patient population studied. The intervention is simple 
and inexpensive to implement but looks at information and education provision in a 
more useful, patient centred way that seems to be effective in communicating the 
accurate risk information to the most high risk patients. In light of these findings it 
would be reasonable to suggest National Guidelines may be modified to include 
more specific directions regarding the provision of individualised patient information 
about secondary prevention strategies and risk of future events in order to improve 
adherence rates. The communication of appropriate risk information was a key 
element of the intervention of this study and increasing risk awareness is an effective 
strategy to increase patient knowledge of risk which improved lifestyle behaviours 
after stroke to reduce risk and improved adherence to secondary prevention 
strategies at 3 month follow-up after discharge from hospital after stroke.  
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5.12 Chapter 5: Tables and Figures 
 Figure 5.1: IRAIS Study design flow chart 
 
 
           
            
             
 
 
 
 
 
 
 
Approached with verbal and written 
information about the study n=133 
  
Reasons not 
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Too ill n= 9 
Unable to attend 
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Recruited to study, consent form 
signed 
Randomised n=96 
Control 
n=49 
Usual care 
Patient diagnosed with ischaemic stroke  
Assessed for eligibility n= 145 
  
Opportunity 
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Intervention 
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Usual care plus risk 
awareness 
intervention 
Endpoint data collection at 3 month 
follow-up 
 
N=47 followed-up N=47 followed-up 
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Table 5.1: Population characteristics for IRAIS 
Characteristic Intervention 
n=47 (%) 
Control 
n=47 (%) 
P Value 
T-test 
Age 
Mean (SD) 
65 
(12.1) 
66 
(12.7) 
0.56 
Male 30 (63.8) 26 (53.1) 0.29 
European ethnicity 39 (61.7) 43 (67.3) 0.56 
Married 27 (57.4) 27 (55.1) 0.96 
University 
education 
19 (40.4) 9 (18.3) 0.06 
Length of stay on 
stroke unit 
Range 
Median 
                                
14 days 
1-67 
3 
                                 
5 days 
1-7 
2 
                             
0.06 
Mean NIHSS at D/C 1.2 .73 0.42 
Mean NIHSS at 
follow-up 
0.92 0.61 0.36 
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Figure 5.2: Medical interventions performed 
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Table 5.2: Past medical history 
Risk Factor Intervention 
n=47 
Control 
n=47 
P Value 
All Risk Factors   T-test 0.09 
No Past Medical 
History 
5 12  
Stroke 16 13  
IHD 12 10  
DM 14 8  
PAD 1 1  
AF 7 8  
HTN 39 26  
Carotid stenosis 0 1  
High Cholesterol 19 12  
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Figure 5.3: Knowledge of stroke sub-type at follow-up 
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Table 5.3: Medication taking behaviours 
Medications on admission Intervention 
n=47 (%) 
Control 
n=47 (%) 
P Value 
Medications   T-test 0.10 
None 12 (25) 17 (36)  
Antiplatelet 22 (47) 19 (40)  
Warfarin 0 0  
Statin 24 (51) 21 (45)  
Hypertensive  treatment 29 (62) 19 (40)  
Diabetes treatment 12 (25) 6 (13)  
At baseline n=47 (%) n=47 (%)  
Medications   0.60 
None 0 0  
Antiplatelet 44 (94) 45 (96)  
Warfarin 3 (6) 2 (4)  
Statin 46 (98) 43 (91)  
Hypertensive treatment 24 (51) 32 (68)  
Diabetes treatment 8 (17) 10 (21)  
At Follow-up n=47 (%) n=47 (%)  
Medications   0.35 
None 0 0  
Antiplatelet 42 (89) 44 (94)  
Warfarin 5 (11) 4 (8)  
Statin 43 (91) 41 (87)  
Hypertensive treatment 22 (47) 30 (64)  
Diabetes treatment 7 (15) 8 (17)  
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Figure 5.4: Number of behaviour changes made at 3 months 
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Figure 5.5: Breakdown of behaviour changes at 3 months 
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Table 5.4: Risk factor control 
Variable Intervention 
Mean (SD) 
Control 
Mean (SD) 
P value 
CRP mg/l 
Discharge 
Follow up 
 
7.93 (16.05) 
3.33  (4.06) 
17.5 (27.1) 
6.66 (10.9) 
0.04 
0.07 
Weight Kg 
Discharge 
Follow up 
79.3 (18.5) 
78.8 (18.7) 
78.7 (11.9) 
78.4 (12.4) 
0.84 
0.90 
Waist inches 
Discharge 
Follow up 
37.1 (5.55) 
36.8 (5.35) 
36.5 (4.4) 
36.3 (4.5) 
0.57 
0.59 
Cholesterol mmol/l 
Discharge 
Follow up 
4.7(1.35) 
4.1 (0.75) 
4.4 (0.99) 
4.0 (0.79) 
0.22 
0.85 
Blood glucose 
mmol/l 
Discharge 
Follow up 
6.2 (2) 
5.8 (1.5) 
6.9 (2.6) 
6.3 (1.6) 
0.12 
0.23 
Systolic BP mmHg  
Discharge 
Follow up 
131 (17.8) 
128 (12.1) 
136 (14.7) 
134 (10.4) 
0.158 
0.01 
Diastolic BP mmHg 
Discharge 
Follow up 
77 (10.4) 
74 (11) 
78 (7.7) 
73 (12.6) 
0.78 
0.91 
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Chapter six: Conclusions and Discussion 
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6.1 Introduction 
Advances in stroke medicine such as thrombolysis are seeing more people surviving 
their first stroke and with less disability. Effective secondary prevention is the 
ultimate goal to reduce recurrence and this will become more evident in the future as 
stroke services continue to expand and require further investment and investigation 
to ensure evidence based high quality care is sufficiently applied to clinical practice. 
Vascular disease is the number one cause of death and disability on a global scale. 
Stroke alone is responsible for approximately 5.7 million global deaths worldwide 
(WHO 2011).  Therefore, the impact of vascular disease on health care in the UK is 
devastating. The Health Survey for England (2005) stated in that year, 40% of 
deaths in the UK were caused by vascular diseases (CAD, IHD, PAD, CV disease). 
Currently more than 4 million people in the UK are affected by CVD and it costs the 
UK alone £30 billion annually (Pennant et al 2008). Rates of cardiovascular disease 
and many cancers are heavily influenced by lifestyles and behaviours which in turn 
are influenced by a variety of social, economic and demographic structures (NICE 
2010). Pennant et al (2008) concur and suggest variations in incidence of CVD 
related illness in the UK are caused by geographical, ethnic and social aspects, 
however they go on to suggest CVD death rates are 3 times higher among lower 
socioeconomic groups than among more affluent groups. Nevertheless, Bunker 
(2001) suggests the provision of medical care, the development of healthier personal 
habits and the creation of a more just social environment each contribute to the 
potential to improve health. Just as vascular disease is a multi-factorial physiological 
syndrome which needs a whole systems approach, improving overall health through 
a variety of systems is a concept of health care for the future. Stroke alone costs the 
NHS £7 billion per year on direct and indirect health costs for acute care, on-going 
rehabilitation as well as informal carer costs and loss of earnings and productivity. 
13% of strokes occur in people of working age which impacts further on the economy 
as well as devastating the lives of individuals and their families. The cost and loss of 
productivity is one reason for recent Government legislative interest in primary and 
secondary stroke prevention. Stroke and vascular disease has many complex 
components including genetic and physiological causes, however the severity of 
disease progression can be affected by healthy lifestyle behaviours and we know 
stroke mortality and morbidity can be reduced through risk factor modification 
(Chaudhry and McDermott 2008). The need for risk factor management is important 
as individual risk factors alone increase the risk of CVD, however patients with 
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multiple risk factors are three to five times more likely to die or suffer a major 
vascular event such as a heart attack or stroke than those without such risk factors 
(Cooper 2007).  
Risk factors identified for CVD highlight the lifestyle behaviours which influence 
disease progression such as smoking, alcohol, poor diet and inactivity and it has 
been suggested half the deaths and disability caused by CVD could be reduced 
through the minimisation of major risk factors (WHO 2002). NICE (2009) discuss 
producing guidance on public health interventions and programmes based on fit-for-
purpose, high quality evidence from research and practice concerned with changing 
behaviours of individuals, communities and populations in order to improve health. It 
has been suggested the cost of treating disease that could be prevented through 
lifestyle or behaviour change represents a considerable burden on Western budgets 
(NICE 2009) and this is one of the precursors to producing national guidance for 
public health interventions and programmes to improve overall health of the nation 
as well as specific population targeted guidance such as the RCP national clinical 
stroke guidelines (updated 2008). The need to improve services is also reflected in 
national frameworks to monitor and measure care, with the implementation of the 
RCP Sentinel Stroke Audit in 2004 a framework to measure equity of care was 
produced and this is now embedded in stroke care services to ensure treatment, 
care and prevention is of the highest standard across the country. 
6.2  Risk of recurrence 
Stroke recurrence adds significantly to stroke-related disability, increasing the 
disease burden on individuals and health care systems. Mohan et al (2011) identified 
the disparity in reported stroke recurrence and suggested real differences in the 
populations as one possible cause, as well as differences in stroke management and 
secondary prevention techniques. It has been identified that different ethnic groups 
have higher incidences of risk factors for CVD which might reflect in the recurrence 
figures, however despite the variations, stroke recurrence is a genuine health risk 
and secondary prevention studies are important for the success of long-term 
management of risk factors. National and International guidelines are in place to 
provide evidence for effective secondary prevention to reduce recurrence (RCP 
2004, NICE 2008, EUSI 2003) and the Quality and Outcomes Framework (QOF) 
information is providing encouraging data for the UK, which suggests risk factor 
control in general practice is improving with rates of target BP control being achieved 
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and levels increasing from 71%-85% in 2005 to 78.6%-89.4% in 2007 (Ashworth et 
al 2008). 
6.3 Risk factors 
Established risk factors for stroke and CVD have been identified as well as other 
consequences of vascular disease which add to the relative risk of stroke. The main 
risk factors identified and discussed are: 
 Age 
 SBI 
 Hypertension 
 Diabetes 
 AF 
 Smoking 
 Alcohol 
 Poor diet 
 Inactivity 
 Obesity 
 Hypercholesterolaemia 
 Ethnicity 
 Carotid stenosis 
The review of the literature of stroke risk factors provides an up-to-date overview and 
clear understanding of stroke risk in the presence of individual risk factors as well as 
quantifying the risk benefits and risk reductions possible with modifications such as 
healthy lifestyle behaviour changes.  Other risk factors which are consequences of 
vascular disease have been discussed and are of importance when discussing CVD 
as a global physiological syndrome. Both renal artery disease and retinal artery 
disease are less common forms of vascular disease and are often the results of 
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multiple vascular conditions and result in the same physiological process of 
inflammation which increases stroke risk, so should be treated aggressively with the 
same preventative measures.  
Risk factors which are less common include PFO and genetic factors and research 
continues to identify the absolute risk of stroke and how if treated the risk can be 
reduced. With regard to genetic factors, high risk genes cannot be removed or 
treated, however, knowledge of genetic risk can inform us who is at greatest risk so 
that medical treatments and lifestyle modifications can be targeted specifically at 
high risk groups and may be useful to reduce risk from environmental and social 
factors. As part of this research SBI, an established vascular risk factor has been 
quantified to identify stroke risk in the presence of the two other members of the 
vascular disease family, CAD and PAD.  
The systematic review and Meta-analysis provided an up-to-date review of the 
literature surrounding SBI and the risk of stroke and highlighted the risk of multi-
infarct dementia in patients with SBI as a key finding. SBI  as an independent risk 
factor for stroke is key to management, however, prevalence of SBI identified in the 
populations examined was varied, the percentage of SBI found in the stroke studies 
varied from 14%-24%, in healthy, asymptomatic populations the prevalence varied 
from 8%-35%, increasing markedly with age. In CAD prevalence varied from 10%-
55% and in PAD it was between 5%-21%. However, the studies clearly identified that 
patients with systemic vascular disease are at increased risk of stroke and MI and 
treatment should be initiated swiftly if prevention is to be effective.  
6.4 Stroke and risk factor knowledge 
Individual studies performed throughout this project have highlighted poor knowledge 
of primary stroke risk factors and secondary stroke risk and stroke signs and 
symptoms.  BP awareness in a low risk general population was poor as well as 
among high risk stroke survivors. Stroke survivors had poor risk awareness and 
were unaffected by large scale, media information campaigns to improve knowledge 
of stroke signs and symptoms. Although surveys suggest the campaigns are 
effective for members of the general public, impact on current presentation to 
emergency department figures still suggests stroke patients are slow to present to 
hospital despite decades of research and public awareness campaigns (Moser et al 
2006). The delay for stroke patients is 2-3 times longer than for patients with acute 
coronary syndromes (Libman et al 2001) and of the stroke deaths that occur each 
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year almost half occur before the patient reaches hospital (Ayala et al 2003). 
Therefore knowledge of signs and symptoms influence stroke occurrence at every 
stage and the need to improve public awareness is of paramount importance.  
 
Low levels of knowledge of stroke warning signs and risk factor awareness have 
been identified for decades (Samsa et al 1997, Nicol and Thrift 2005, Dearborn et al 
2009). Many patients described symptoms they themselves had been affected by but 
which are not commonly associated with stroke such as pain at onset and loss of 
consciousness, this does not suggest the patient was not affected by those 
symptoms but does inform us that patients knowledge of general, well known signs 
and symptoms of stroke is poor in this context. The observational study identified low 
knowledge of risk factors for stroke similar to the Nicol and Thrift study (2005) when 
a third of patients could not name a single risk factor using free-recall in both high 
and low risk populations, the observational study found 45% of patients self-reported 
a well-known stroke risk factor and then later in the questionnaire denied having any 
risk factors for stroke, this highlights a lack of awareness of established stroke risk 
factors. The same results were found initially in the RCT, as at baseline prior to any 
intervention, risk factor knowledge was poor and increased in the intervention group 
at follow-up but nevertheless it suggests generally knowledge of risk factors for 
stroke specifically, is poor in the stroke population.  
6.5 Risk perception 
Risk perception is a subjective judgement made on a background of previous 
personal, social, geographic, ethnic and cultural experiences (Slovic 1987). Theory 
of risk perception has been identified and categorised into 3 main domains as the 
degree to which risk is understood, the degree to which the risk evokes a feeling of 
dread and the number of people exposed to the risk (Slovic 1987). Risk interventions 
to influence behaviour can be directed by knowledge of the relevant risk (the 
disease), what constitutes a ‘risky’ behaviour (smoking in the presence of a stroke), 
how the patient responds to the risk information (whether they think they should stop 
smoking since suffering a stroke) and having an understanding of what happens 
when they respond to the risk information (giving up smoking reduces the risk of 
stroke recurrence) (Slovic 1987). Therefore perception of risk clearly influences 
decision making regarding health behaviour and patient’s responses to the 
consequences of their decisions.  
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The Social Amplification of Risk Framework’s (SARF) theory states that risk events 
interact with individual’s psychological, social and cultural factors to either increase 
or decrease a populations perception of risk (Kasperson 1988). According to the 
theory, different groups may react differently to a single risk event. As health 
professionals, knowledge of this theory is useful when trying to influence reactions at 
the initial stages of communication during transfer of information about risk. The 
response mechanism of the patients has already been influenced by that individual’s 
psychological, social and cultural make-up and background, however by 
individualising risk at the time of the acute, often life-changing event, may be useful 
for influencing the patient’s response to their risk. 
Risk perception is key to understanding how a person becomes motivated to change 
health behaviours. Studies have shown high risk groups perceive to be at the same 
level of risk as their low risk peers (Dearborn et al 2009) and that has been mirrored 
in the control group of the IRAIS study. However, the risk awareness intervention in 
this study effectively increased risk perception which in turn increased the amount of 
health behaviour changes made. 
The Health Belief Model (HBM) (Lewin 1951, Glanz 2002), the theory of planned 
behaviour (Azjen and Fishbein 1980), the theory of social behaviour (Bandura 1986) 
and the transtheoretical model of behaviour change (Prochaska and Velicer 1997) 
emphasise the perceived value of a patients’ response to a consequence. The 
transtheoretical model (Pochaska and Velicer 1997) with its “stages of change” is 
another model in which interpretation of the likelihood of behaviour change is 
understood in terms of an individual’s readiness to change, and interventions may be 
targeted accordingly. Readiness to change (Pochaska et al 1983) was not measured 
throughout this project, however it would be a useful tool to understand and interpret 
a patients likelihood of change in response to their stroke in order to plan further 
programmes of education. These theoretical models have been discussed 
extensively throughout this project and were used as the basis of the theoretical 
framework for planning the risk communication intervention. In general, the models 
seek to provide an understanding of how individuals perceive risk and how this 
influences their behaviour and may go some way to developing a way of predicting 
behaviour change. These models frequently attribute consequences in behaviour 
change to two underlying dimensions: an individual’s perception of the value of an 
outcome presented in a health recommendation and the perceived threat presented 
by the outcomes in the recommendation. This was understood for the development 
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of the risk awareness intervention as a way of increasing a patients understanding of 
the threat to their health so that the health recommendation had an increased value 
by reducing the risk of a recurrence of the unwanted event i.e. another stroke. The 
observational study identified stroke survivor’s strong sense of consequence 
following their stroke (90%) and two thirds said they felt their stroke had had a major 
consequence on their life, this may certainly impact on perception, however this 
study also highlighted many of the participants believed their stroke happened by 
chance and suggests a lack of control over their condition which compared with 
cardiac studies suggesting patients who feel in control have better adherence 
(Townend 2006) this may be one reason for the differences in stroke and cardiac 
patient behaviours.  
6.6  Risk awareness 
Important factors which reflect individual risk awareness have been identified as 
adherence, behaviour and lifestyle modification. The theoretical models of 
understanding risk perception and influences on health behaviours have been 
investigated to identify how the intervention in the RCT could improve health 
behaviours to reduce risks that have been discussed. Improving adherence to 
secondary prevention strategies by increasing both health literacy and self-efficacy in 
targeted patient populations are recognised in the literature, however interventions to 
achieve this have been lacking in stroke.  
Understanding the concept of ‘risk’ has been key to developing the theoretical 
frameworks required to develop the risk awareness intervention and the potential 
impact on patient’s perception and behaviours. ‘Risk’ has many definitions which 
mainly consist of the concept of a potential loss or undesirable outcome. The notion 
implies, a choice can have an influence on the outcome and this is true of risk in 
health care and secondary stroke prevention as the patient makes a choice or a 
decision to perform a health behaviour action to reduce risk. Patients with an 
awareness of risk have behaved differently compared to controls as part of this 
thesis, an observational study of stroke survivors up to 5 years later identified those 
with a greater understanding of their risk being more likely to make more healthy 
lifestyle choices compared to those who had no risk awareness. In the RCT study in 
the first 3 months following discharge from hospital, those who had greater risk 
awareness made more lifestyle changes in direct response to their stroke compared 
with those with a low risk awareness.  
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6.7 Medication taking 
Results from the two studies investigating behaviours of stroke survivors identified 
differences in medication taking. Adherence for secondary stroke prevention was 
poor in the observational study with only 66% taking antiplatelet appropriately and 
45% taking statins. These results differed from the RCT data where medication 
taking was very well reported with 89% taking an antiplatelet and 87% taking a statin 
appropriately. The major difference between the two populations is length of time 
since stroke. Therefore these results support the concept of adherence dropping off 
over time and should be an argument for long-term follow-up with a focus on 
medication taking. Interestingly behaviour was not influenced by time since stroke in 
the observational study which would suggest once health behaviour is in place, it 
remains so in the long-term, however, a possible explanation might be changes in 
medication prescriptions’ disrupt a pattern of adherence as a change in routine might 
interrupt lifestyle behaviour. Also the identification of a small reduction in medication 
taking at follow-up in the RCT is noteworthy as the reduction was seen in all four of 
the major secondary prevention medications prescribed at discharge. It would be 
very interesting to investigate if this group continued to reduce medication taking 
over time and a follow-up at one year would be most useful.  
It is also important to highlight, it has been documented that patient compliance with 
treatment is usually substantially better in closely monitored and motivated research 
trial populations than in routine clinical practice (Sappok 2001), this suggests either 
all patients participate in a clinical research trial, which is unrealistic, or all patients 
receive better, more closely monitored follow-up at discharge from hospital. 
6.8 Methodology challenges 
A variety of study designs were used throughout this thesis including, a systematic 
review and Meta-analysis, observational study, population survey and a RCT. 
Several qualitative and quantitative methods were used to obtain and analyse the 
data including thematic analysis and statistical software packages such as SPSS 
and STATA.  The challenges were in learning new techniques of data collection and 
analysis for every new study. The observational study involved the development and 
implementation of a questionnaire which was sent out to stroke survivors both in 
paper form and electronically so there were practical barriers to overcome regarding 
delivery of and collection of the completed questionnaires, however these were 
overcome through networking with the charity organisation which eventually took 
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responsibility for the entire distribution of questionnaires to their members. Analysis 
of the questionnaires was challenging as so much data was generated in a variety of 
formats which required both thematic analysis and data entry into excel for statistical 
analysis.  
The population survey consisted of a straightforward design format however, more 
data could have been obtained. This was a response to the volumes of data 
obtained during the observational study so the population survey was made as 
simple as possible to aid analysis. However, thought went in to what data information 
should be collected and the aim of the survey was that it would be quick and non-
intrusive to enhance recruitment numbers. However, ethnicity and educational level 
would have been really useful variables to include in the survey to identify if those 
factors had an impact on awareness of BP in the general public and it would have 
also been useful epidemiological information about the local population. 
The RCT used a proforma to obtain demographic information and risk perception at 
the time of recruitment and then again at follow-up. The risk perception questions 
were developed in a short form from the observational questionnaire, however it 
would have been useful to include similar illness perception questions to identify in 
further depth the participant’s perceptions of the consequences and causes of their 
stroke, however, it was clear at the time of developing the proforma that due to the 
time constraints of the academic process there would be limited time for in-depth 
analysis, however considering the interesting results of the intervention RCT further 
analysis of perception would be really useful. 
The lack of ethnic diversity in all studies was disappointing considering the 
multiplicity of the populations London and the UK. Despite approaching patients from 
all cultures and ethnicities to participate in the studies, uptake was limited except 
from those of European descent. We therefore, have little knowledge of the impact of 
the risk awareness intervention on BME groups as a result of the low uptake and 
further work to identify effective interventions in this group would be useful.  
6.9  Overall significance 
The initial systematic review identified stroke and SBI as part of the family of 
vascular diseases and clarified the risk posed by stroke and the impact it has on 
individuals and populations at local, national and globally was important to put the 
thesis in to context. The observational study of stroke survivors understanding of risk 
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produced initial data suggesting risk awareness may play a role in lifestyle and risk 
factor modification behaviours. Stroke survivors who still thought they were at risk of 
another stroke, up to five years later, self-reported more health behaviours than 
those who did not think they were at risk. This finding informed the development of 
the RCT to investigate if through increasing risk awareness during the acute stages 
of stroke, influences health behaviours up to 3 months following discharge from 
hospital. Another interesting finding from the initial studies prior to the RCT were that 
hypertensive members of the general public who were aware of what a ‘normal’ BP 
should be had a significantly lower and therefore better controlled BP than those who 
had no knowledge. This result had the potential to impact on risk factor control and 
management and was based on information provision and knowledge improvements 
which require high levels of health literacy throughout a population.  
 
The results from the BP study concurred with other studies of awareness in the 
general population with low levels of knowledge of BP in the overall population 
surveyed and even more so in the hypertensive population. Surprisingly it was 
hypothesised that knowledge of BP would be greater in the hypertensive population 
as it was expected they would have had interactions with health professionals 
directly related to BP. This result suggests a poor general impact from the provision 
of information about BP to hypertensive populations. In the BP survey the 
hypertensive population were significantly older than the healthy population, this 
finding is useful for health professionals to understand that elderly patients with 
hypertension may not have the cognitive ability to retain the information or the 
information needs to be configured in a way which communicates the risk effectively 
to this population in a way which influences their behaviours in regard to BP control. 
 
The studies within this thesis have added to the body of knowledge through the 
examination of patient perceptions of their illness and information has been gathered 
in order to investigate further, patients decision making and coping processes related 
to long-term disease management within the field of stroke as a member of the CVD 
family, adding to the work performed around CAD and IHD. 
6.9.1 Clinical significance and changes to practice 
The RCT identified several areas where a focussed risk awareness intervention may 
influence knowledge of risk factors and behaviours post stroke. However, it is 
important to mention that it is unclear whether the intervention itself resulted in 
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increased knowledge and behaviour change or whether simply the increased 
interaction with participants resulted in the changes. However, the results do suggest 
significant differences between the two groups and risk awareness may be a way 
forward to improve patient’s perceptions of risk and attitudes to health care 
recommendations. Focussed attention at discharge to inform patients of the 
importance of risk reduction for secondary prevention and systematic education 
about risk factors is suggested with attention geared towards how medication taking 
and lifestyle modification can reduce risk may be effective. Information aimed at 
increasing health literacy for this patient population should be the ultimate goal, to 
enable patients and their families to participate in the management of their condition 
in the long term and understand the importance of risk factor control through 
adherence to medications and improved health behaviours to reduce risk of 
secondary stroke is the strongest recommendation from this thesis. 
6.10 Future research 
As an academic study the RCT follow-up data endpoint collection had to take place 
at 3 months, however, on-going investigation of behaviour in the months and years 
beyond 3 month follow-up would be useful to identify if behaviour change is 
sustained in this high risk population as studies have suggested long-term 
adherence to change is low in chronic conditions and it might be as follow-up 
becomes less regular and therefore discussion regarding risk factors less frequent 
which effects behaviour and risk awareness particularly if discussion of lifestyle 
continues to be low as it was recorded in only 37% of consultations in the Royal 
Colleague of Physicians sentinel audit for stroke (RCP 2004).  Future work should 
concentrate on ways to increase risk awareness effectively in all high risk groups. 
The intervention could also be examined when applied in different settings such as in 
TIA/minor stroke and outpatient settings. 
 
The development of a RCT to investigate the effectiveness of a stroke rehabilitation 
programme to increase risk awareness and health behaviour change in order to 
reduce recurrence and improve risk factor control would be a potential post-doctoral 
research plan. There are few structured stroke rehabilitation programmes despite the 
evidence from cardiac rehabilitation programmes which suggest good outcomes 
(Devereaux et al 2005). The Transtheoretical Model of Health Behaviour Change 
would be a useful tool to structure the study, using the six measures of readiness to 
change as framework to collect data at recruitment and the processes of change as 
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the theoretical basis for the interventions throughout the rehabilitation programme. 
The goal of the initial study would be to develop a programme based on the 
processes of change: 
1. Consciousness raising 
2. Dramatic relief 
3. Self-re-evaluation 
4. Environmental re-evaluation 
5. Self-liberation 
6. Social liberation 
7. Counter conditioning 
8. Stimulus control 
9. Contingency management 
10. Helping relationships 
 
The Transtheoretical model has been used in cardiac rehabilitation with positive 
outcomes, Devereaux et al (2005) found the framework improved readiness to 
change outcomes in the short term with 84% in the action stage at completion of the 
programme. The model has also been used to investigate stroke patient behaviours, 
Gillham (2010) most recently used the framework to study readiness to change in 
minor stroke and TIA patients, however no differences were seen in readiness to 
change but some behaviours were improved significantly in the intervention group. A 
study of mainly African Americans (Miller & Spilker 2003) were recruited from a 
family practice clinic, each with multiple risk factors and were assigned to one of 3 
interventions: 1. Control, 2. Simple advice, 3. Brief intervention. Findings showed 
significant differences in the number of newly initiated health behaviours and stroke 
knowledge among the 3 groups with the best outcomes from the intervention group. 
Although a small pilot study, the results support the effectiveness of the brief 
intervention. However these studies have all been performed in outpatient settings 
on participants with minor stroke, TIA or asymptomatic community dwelling 
populations. It would be interesting to investigate if this framework would be useful 
during an inpatient hospital stay or on patients recently discharged from hospital. 
The main goals of the project would be to investigate if the framework is effective for 
the development of a stroke rehabilitation programme and whether the programme 
itself is effective in reducing recurrence of stroke and improving health behaviours to 
improve secondary stroke prevention. 
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Finally further research to identify how risk factor information is communicated to and 
received by ethnic minorities and in patients and families where English is not the 
first language would be useful. Health inequalities for ethnic minority groups have 
been identified, however specific interventions to improve health literacy in these 
minority groups is limited which may impact on their ability to participate fully in their 
health care which may be one of the reasons for their worse outcomes compared to 
Europeans in the West. Also further research into recruitment into research trials 
would be interesting in ethnic minority groups, as a European researcher the majority 
of patients recruited into the RCT were of European decent also and it would be very 
interesting to investigate further if ethnic background of researchers influences the 
type of ethnic groups recruited into research trials.  
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Appendix 1: Arcsine transformation formulae 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arcsine transformation formulae & methodology (Kulinskaya et al 2008, 
Cochrane Collaboration 2011) 
n = number of patients with positive silent brain infarction in the presence of 
1. AIS 
2. CAD 
3. PAD 
Calculate: Proportion (P) = number of positive events / n 
Transform data:  Standardised Mean Difference (SMD) = 2 x arcsin (√P) 
Standard Error (SE) = 1 / √n 
Enter SMD and SE into Review Manager using Generic Inverse Variance data 
type and statistical method, with random-effects analysis model (DerSimonian 
and Laird) to produce pooled effect measure SMD = (A) 
Transform data back to original scale to give pooled percentage prevalence. 
% Prevalence = (Sin x (A/2)2) x 100 
 
 
229 
Appendix 2: Population-based study questionnaire 
1.1 Age  
1.2 Gender 1.Male □ 2.Female □ 
1.3 Your ethnic 
background 
1. White British                      
2. White Irish  
3. White Other 
 
 
□ 
□ 
□ 
4. Caribbean  
5. African      
6. Indian 
7. Pakistani                                      
8. Bangladeshi                               
 
□ 
□ 
□ 
□
□
9. Any other Asian        
10. Other ethnic group 
please state…………… 
□ 
□ 
1.4 Your educational background  
1. No basic school education                
2. Secondary school education            
3. Apprenticeship                                  
□ 
□ 
□ 
4. Upper secondary school education  
5. University or college graduation 
□ 
□ 
1.5 Marital status: 
 please circle  
Single/Married/Divorced/ Co-habiting/Civil partnership 
Separated/Widowed 
1.6 Do you smoke? 1. Yes     □ 2. No  □ 
1.6a If you have given up smoking, how long ago? Months                    Years 
1.7 Have you been diagnosed with high blood pressure? 1. Yes     □ 2. No  □ 
1.8 Have you ever been diagnosed with diabetes?                                                                                                                                                                                                             1. Yes   □ 2. No □ 
1.9 Have you ever been diagnosed with heart disease? 1. Yes     □ 2. No  □ 
1.10 Have you ever been diagnosed with circulation 
problems in your legs? 
1. Yes     □ 2. No  □ 
1.11 Have you ever been diagnosed with kidney disease? 1. Yes     □ 2. No  □ 
2.1 In your own words what do you think is 
a stroke? 
 
 
 
 
2.2 In your own words what do you think is 
a heart attack? 
 
 
 
 
2.3 What do you think are the risk factors 
for stroke? 
 
 
 
 
2.4 What do you think are the signs and 
symptoms of stroke? 
 
 
 
 
2.5 What ways do you think you can 
prevent a further stroke? 
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Illness perception: Cause 
 
 
Strongly 
agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
disagree 
A germ or virus caused my stroke      
Pollution of the environment 
caused my stroke 
     
My stroke was caused by 
hereditary factors, it runs in my 
family 
     
It was just by chance that I had a 
stroke 
     
Stress was a major factor in 
causing my stroke 
     
 
Illness perception: Consequence      
My stroke is a serious condition 
 
     
My stroke has had a major 
consequence on my life 
     
My stroke has become easier to live 
with  
     
My stroke has had little effect on 
my life 
     
My stroke has strongly affected the 
way others see me 
     
My stroke has serious economic 
and financial consequences 
     
My stroke has strongly affected the 
way I see myself as a person. 
     
 
Illness perception: Future 
 
     
My stroke will improve in time      
There is a lot which I can do to 
control my symptoms 
     
There is very little that can be done 
to improve my symptoms 
     
My treatment will be effective in 
preventing a future stroke 
     
Recovery from my stroke is largely 
dependent on chance or fate 
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3.1 What type of stroke did you have? 1. Bleed 
 
2. clot 
□ 
 
□ 
3. Small /TIA □ 4. Don’t know □ 
 
3.2 How long ago did you have your 
stroke? 
1. < 1 year □ 2. 1-5 years □ 3. > 5 years □ 
3.3 At the time do you think you knew 
you were having a stroke? 
1. Yes           □                              2. No                         □ 
3.4 Do you fear having another stroke? 1. Yes           □                              2. No                         □ 
3.5 Do you take any medication to 
prevent a further stroke? 
1. Yes □                                                                2. No □ 
please list below:  
 
 
 
 
 
 
 
3.5a Please list all other medications.  
 
 
 
 
 
 
 
3.6 Do you think you have any risk 
factors for stroke? 
1. Yes                      □                              2. No           □                                 
3.7 Do you have your blood pressure 
monitored?     If yes please state where:                                              
1. Yes     
a.) Home  
b.) G.P                      
c.) Hospital  
□ 
□
□ 
□ 
2. No  □ 
3.8 Besides medication have you 
undertaken any lifestyle changes 
following your stroke? Please tick all 
that apply. 
1. None 
2. Stopped 
smoking             
3. More exercise                   
4. Less alcohol               
 
□ 
 
□ 
□
□ 
5. Weight loss                        
6. Eat 5 fruit/veg per day  
7. Reduced salt intake    
8. Low fat diet               
□
□ 
□ 
□ 
3.9 Do you think you have a good 
knowledge of the cause of your 
stroke? 
1. Yes 
 
□ 2. No □ 
3.10 Do you think you have a good 
understanding of how to prevent a 
further stroke? 
1. Yes 
 
□ 2. No □ 
3.11 Where did you get your stroke 
information from? Please tick all that 
apply. 
1. Media  
2. Health 
professional  
□ 
□ 
3. Family and friends 
4. None received  
□ 
□ 
3.12 What format was the information 
in? 
1. Internet 
2. Written booklet 
 
□ 
□ 
3. Verbal face to face 
4. None received  
5. Telephone 
□ 
□ 
□ 
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4.1 Do you think you are at risk of 
having another stroke? 
1. Yes □ 2. No □ 3. Don’t know □ 
4.2 Are you still employed?                                          
                                              
  
1. Yes– what do 
you do? 
□   2. No                                □ 
3. Retired before stroke   □ 
4. Retired due to stroke   □                    
4.3 To help us assess your ability to 
calculate risk please answer this 
question 
A restaurant bill is £25, what 
amount is a 10% tip? 
£ 
4.4 Please rank the following in order 
of the most likely to happen to you.  
Please rank the suggestions 1-4 in the 
boxes, 1 being the most likely thing to 
happen and 4 being the least likely. 
 
Survive a plane crash 
 
Have a heart attack 
 
Win the lottery 
 
Get struck by lightening 
  
 
 
 
 
 
4.5 Please rank the following in order 
of the most likely to happen to you.  
Please rank the suggestions 1-4 in the 
boxes, 1 being the most likely thing to 
happen and 4 being the least likely. 
 
Get a hole-in-one in a Golf game 
 
Have another stroke 
 
Get run over by a bus 
 
Get struck by a falling plane 
 
 
 
 
 
 
 
4.6 Do you think that having heart disease would 
increase your risk of having a heart attack? 
 
 
Least  1  2   3   4   5    6    7   8   9   10 Most 
4.7 Do you think that having diabetes would 
increase your risk of having a heart attack? 
 
 
Least  1  2   3   4   5    6    7   8   9   10 Most 
4.8 Do you think having kidney disease would 
increase your risk of having a heart attack? 
 
 
Least  1  2   3   4   5    6    7   8   9   10 Most 
4.9 Do you think that having circulation problems 
in your legs would increase your risk of having a 
heart attack? 
 
 
Least  1  2   3   4   5    6    7   8   9   10 Most 
4.10 Do you think that having a stroke would 
increase your risk of having a heart attack? 
 
Least  1  2   3   4   5    6    7   8   9   10 Most 
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Appendix 3: Model formula for Logistic Regression Modelling for RCT 
design 
 
 
 
 
 
 
xi:logisticoutcome age gender  antiplats statin  antiplatsdis  
antihtndish  statdish htn dm ihd  i.smoking pvd sbpadm af 
 
adjust age=XX gender=XX antiplats=XX statin=XX  antiplatsdis=XX  
antihtndish=XX statdish=XX htn=XX dm=XX ihd=XX pvd=XX 
sbpadm=XX af=XX, by(smoking)pr 
 
Example ID 036 
adjust age=50 gender=1 antiplats=0 statin=1  antiplatsdis=1  
antihtndish=1 statdish=1 htn=1 dm=1 ihd=0 pvd=0 sbpadm=143 af=0, 
by(smoking)pr 
Smoking pr 
Never .133104 (13%) 
Ex-smoker .144045 (14%) 
Current smoker .22331 (22%) 
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 Appendix 4:IRAIS Measurement Tool 
ID STUDY NUMBER:  Consent form signed:  
1. Participant                                      2. Consultee   
Name: Date recruited: 
GENDER: 1.MALE  
 
2. FEMALE AGE: Date of Birth: Hospital Number: 
MARITAL STATUS: 1. Single  
 
2. Married/Civil partnership 
 
3. Divorced/separated   
 
4.    Widowed 
ETHNIC 
BACKGROUND:   
Corresponding 
number: 
    
1. White British                               7. Black other – please specify  
2. White other – please specify      8. Mixed race British 
3. Asian British                               9. Mixed race other – please specify 
4. Asian other – please specify     10 Black  British 
5.Chinese British                           11.Chinese other – please specify 
6.Other ethnic background – please specify  
EDUCATIONAL LEVEL: 1. No basic education 
2. secondary school 
3. Apprenticeship 
4. University 
NIHSS ON DISCHARGE:  NIHSS AT 3 MONTHS:  
LENGTH OF TIME ON 
STROKE UNIT 
                                                               Days Dysphasia:  1. yes 2. no 
DRUGS ON ADMISSION 1. 2. 3. 
4. 5. 6. 
7. 8. 9. 
DRUGS ON DISCHARGE 1. 2. 3. 
4. 5. 6. 
7. 8. 9. 
TYPE OF STROKE 1. Ischaemic 
 
2. Haemorrhagic 3. Cardio – embolic 
INTERVENTIONS DURING 
ADMISSION 
1. Carotid Endarterectomy            Neurosurgery – Hemi-craniectomy     Thrombolysis 
PAST MEDICAL HISTORY  1. Stroke 2. Ischaemic heart disease/angina/coronary artery 
disease/MI 
3. Diabetes mellitus 
 
 4. Peripheral arterial disease 5. AF 6. Hypertension 7. Carotid stenosis 
ALCOHOL 1.More than recommended units for 
gender per week 
 
2. Recommended units per 
week for gender 
3. No alcohol at all. 
SMOKING STATUS 1. Never 2. Past 3. Current/quit recently Carbon dioxide at discharge: 
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 Carbon dioxide at follow-up: 
Knowledge of stroke and perception of risk of future vascular events at RECRUITMENT 
 
Do you think you are at risk of a future stroke? 1. yes 2. no 3. don’t know 
 
Do you think you are at risk of a future heart attack? 1. yes 2. no 3. don’t know 
 
Do you think you have any risk factors for future stroke or 
heart disease?  
1. Yes            If yes what are they? 2. no 
 
 
What caused your stroke? 1. 2. don’t know  
 
What type of stroke did you 
have? 
1. infarct/clot 2. bleed 3. don’t know 4. other 
 
Do you think you have 
received adequate information 
about your stroke? 
1. yes 2. no 
What lifestyle changes if any 
do you plan to make? Choose 
from this list. 
1. None 
 
2. stop smoking 3. more exercise 4. less alcohol 
5. lose weight 6. low fat diet 7. less salt 8. take medications 
 
Knowledge of stroke and perception of risk of future vascular events at 3 MONTH FOLLOW-UP 
 
Do you think you are at risk of a future stroke? 1. yes 2. no 3. don’t know 
 
Do you think you are at risk of a future hear attack? 1. yes 2. no 3. don’t know 
 
Do you think you have any risk factors for future stroke or 
heart disease? 
 1. Yes,         if yes what are they? 2. no 
What caused your stroke? 1. 
 
 
2. don’t know 
What type of stroke did you 
have? 
1. infarct/clot 2. bleed 3. don’t know 4. other 
Do you think you have 
received adequate information 
about your stroke? 
1. yes 2. no 
What lifestyle changes, if any, 
have you made since your 
stroke? Choose from this list. 
1. none 
 
2. stopped smoking 3. more exercise 4. less alcohol 
5. lost weight  6. low fat diet 7. less salt 8. taken medications 
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Physiological monitoring 
 
BP Discharge Follow-up WEIGHT  Discharge Follow-up Hip/Waist Discharge Follow-up 
BM  Discharge Follow-up HbA1c Discharge Follow-up Total 
Cholesterol 
Discharge Follow-up 
CRP Discharge Follow-up Creatinine Discharge Follow-up Homocysteine Discharge Follow-up 
SBP on admission  Cognition/ 
MMSE 
Discharge Follow-up New event in 3 
months 
Yes No  
Drugs at follow-up 1. 
 
2. 3. 
4. 
 
5. 6. 
DESTINATION AT 
DISCHARGE 
 Follow-up date: 
CVD risk score at 
discharge: 
 CVD risk score at follow-up:  
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Appendix 5: Intervention Proforma 
Secondary stroke 
risk score: 
 
 
 
Lifestyle 
Modifications 
Intervention Initial when 
completed 
Smoking 
 
1. Smoking cessation advice re: 
NHS systems to aid quitting. 
 
 2. Contact numbers for H&F 
smoking cessation team. 
 
 3. Written information on smoking 
cessation 
 
 4. Risk reduction score for smoking 
cessation: 20% 
 
Medication 
taking 
1. Verbal information about 
individual drugs prescribed 
 
 2. Relate individual drug prescribed 
to risk factors for stroke and 
secondary prevention 
 
 3. Written information on 
medication taking 
 
 4. Aspirin reduces risk of further 
ischaemic stroke by 25%  
 
 5. Discuss specific secondary 
stroke prevention medications 
 
  Blood pressure medications 
 
 
  Statins 
 
 
  Antiplatelets/Anticoagulants 
 
 
  Diabetes medicines 
 
 
Low salt diet 1. Information about how salt 
affects health and BP 
 
 2. Provide written information on 
salt and the benefits of salt 
reduction 
 
 3. Salt reduction in the diet may 
help reduce BP which will reduce 
the risk of future stroke and 
vascular events. 
 
Low fat diet 1. Low fat diet may help weight loss 
and reduce cholesterol levels 
 
 2. Provide written information on 
low fat diet 
 
 3. Provide with a low fat , low 
cholesterol diet sheet 
 
 4. Explain how low fat healthy diet 
can reduce the risk of future 
stroke and vascular events  
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Cholesterol  
Target =  
5. Cholesterol reduction reduces 
the risk of future stroke and 
vascular events by %. 
 
Exercise 1. Exercise can aid weight loss  
 2. Exercise can help the heart 
muscle to gain strength 
 
 3. Provide written information on 
exercise 
 
 
 
Blood pressure 
Target = 
1. By reducing your BP by 5-
10mmgh you will reduce your risk 
of future stroke and vascular 
events by up to 23%. 
2. Give written information on BP 
and stroke prevention. 
 
Alcohol 1. Reduce alcohol intake to the 
correct units for gender in order 
to reduce risk 
2. Alcohol affects BP and with 
extreme alcohol intake it can 
affect the thickness of the blood 
3. Give written information on 
alcohol in stroke. 
 
 
Follow-up after 
stroke 
Reiterate the importance of seeing the 
specialist in follow-up to ensure 
secondary prevention measures are 
working to reduce the risk of future 
stroke and other vascular events. 
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